Production of Recombinant Rubella Virus Antigens. by Almu'Min, Sabah Hassan.
PRODUCTION OF RECOMBINANT 
RUBELLA VIRUS ANTIGENS
A thesis submitted to the University of Surrey 
for the degree of Doctor of Philosophy
by
SABAH HASSAN ALMU'MIN
School of Biological Sciences 
University of Surrey 
Guildford 
Surrey
1991
ProQuest Number: 27558325
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27558325
Published by ProQuest LLO (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
T O  M A M A  A N D  B A B A
SUMMARY
The 24S subgenomic mRNA of rubella virus (RV) specifies a 
polyprotein which is post-translationally processed to three structural 
proteins capsid , E2 and E l . El and E2 are membrane glycoproteins forming 
the virion spikes. In the polyprotein, El and E2 are both preceded by 
stretches of uncharged hydrophobic amino acids which were identified as 
putative signal peptides mediating the translocation of the proteins into the 
endoplasmic reticulum. The translocation of the glycoprotein is halted by 
other hydrophobic regions at the carboxy-terminus of both proteins which 
functions as an anchor.
cDNA clones encoding El glycoprotein coding region were produced 
by reverse transcriptase of rubella enhanced mRNA from virus containing 
supernatant of BHK cells infected with Thomas strain of RV. The nucleotide 
sequences of both E2 and El cDNAs were determined and compared to 
published sequences from other RV strains. Sequences coding for all or part 
of the El and E2 proteins were inserted into plasmids PUEX1, 2 and 3 for 
expression in E. coHto produce fusion proteins with where the CDNA fused 
to the 3' end of the lacZ gene to produce the whole of the El protein with 
subfragments were produced in E. coli in large amounts, (more than 20%  
of the total cell protein), and proved to be antigenic when reacted with 
human antisera. The fusion proteins were produced in inclusion bodies. The 
recombinant antigen R-gal-E1 was used in ELISA and MACRIA diagnosis 
techniques to detect RV-infected sera, significant results were obtained 
when IgM anti-rubella antibody was detected.
Expression of cDNA fragments coding for all of E2 and subfragments 
in E. co// had a severe effect on the inhibition of cell growth. Results suggest 
that the lethal effect could be due to the presence of hydrophobic domains
I
in the protein.
The antigens produced in E. coli are unglycosylated and may therefore 
not be the most appropriate substrates for recombinant vaccine 
development. Therefore, another approach was pursued for the production 
of glycosylated products of rubella antigens El and E2 by expression in 
mammalian COS cells.
Attempts were made to produce secreted proteins from both El and 
E2. As the putative signal peptide of El is not defined, a truncated 
hydrophobic amino terminal domain (signal peptide) was used to study if the 
remaining portion could translocate a truncated El glycoprotein through the 
endoplasmic reticulum (ER). El was secreted into the media, but not 
efficiently.
The E2 cDNA clone was expressed intracellularly and the removal of 
half its anchor region at the carboxy-terminus did not result in a secreted 
protein and had no effect on the protein translation efficiency.
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ABBREVIATIONS
ATP Adeno sine tri phosphate
bp Base pairs
R-gal R-galactosidase
BHK Baby hamster kidney cells
cDNA Complementary Deoxyribonucleic Acid
C Capsid protein
CHO Chinese hamster ovary
DMSG Dimethyl sulphoxide
DNase Deoxyribonuclease
DTT Ditiothreitol
El Envelope protein 1
E2 Envelope protein 2
EDTA Ethylene Diamine Tetra Acetic Acid
ELISA Enzyme-linked Immunosorbent Assay
ER Endoplasmic reticulum
HI Haemagglutination inhibition
IPTG Isopropyl-beta-D-thiogalactopyranoside
i.u. Infectious units
Kb Kilobase pairs
kD Kilodalton
MAb Monoclonal Antibody
MACRIA M-Antibody Capture Radioimmunoassay
rMwt Relative molecular weight
CD Optical density
PC Personal communication
PCR Polymerase chain reaction
RNA Ribonucleic acid
RNase Ribonuclease
RV Rubella virus
SDS Sodium dodecyl sulphate
SP Signal peptide
SRH Single radial haemolysis
SSC Standard saline citrate
TCID50 Tissue culture infectious dosesgo
uv Ultra violet
X-gal 5-Bromo-4-chloro-3-indolyl-beta-D-galactoside
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CHAPTER 1
CHAPTER 1
INTRODUCTION
1.1. TOGAVIRIDAE.
Togavirus virions consist of a lipid containing envelope, the "toga'' 
(Fenner, 1976) surrounding a nucleocapsid with icosahedral symmetry. 
Projecting from the lipid bilayer and embedded in it are the viral-encoded 
glycoproteins El and E2 anchored through hydrophobic transmembrane 
segments (Schlesinger, 1980). The genome consists of one molecule of 
positive-sense, infectious, single-stranded RNA that is encapsidated in the 
nucleocapsid.
Until recently the togaviridae were divided into three genera based on 
serology (Shope, 1985; Wesselhoeft, 1947). The family includes the genera 
Alphavirus which is arthropod-borne viruses (Arboviruses) and Rubivirus 
which are non arboviruses (Schlesinger, 1980; International congress of 
virology, 1990, PC).
The Alphavirus genus is the largest of the togaviridae and consists of 
more than two dozen distinct arthropod-transmitted viruses that cause 
diseases in humans ranging from fever, rash, and arthritis to encephalitis 
(Peters and Dalrymple, 1990). Ross River, Semliki Forest, and Venezuelan 
equine encephalitis viruses are notable in that they can produce 
demyelinating diseases in laboratory models (Chew-Lim et al, 1978; Dal 
Canto et al, 1984; Seay and Wolinsky, 1983).
The genus contains only rubella virus.
1.2. RUBIVIRUS.
Rubella virus (RV) is the only member of the genus Rubivirus, with 
man being the only known natural host for the virus. It has been reported 
that the virus can infect monkeys, chimpanzees, baboons, suckling mice, 
hamsters and rabbits (Herrmann, 1979). Monkeys usually develop a 
subclinical infection with viraemia, virus excretion and an immune response 
similar to that found in humans. Persistent infection has been established in 
suckling mice, hamsters, and rabbits. Attempts to reproduce the teratogenic 
effects of RV in animals have given inconsistent results (Best and Banatvala,
1990).
Rubella is a medium-sized ether-sensitive virus which has an outer 
envelope and a core containing a single strand of infectious RNA (Fig. 1.1). 
The virus particle is 58jf7nm  in diameter, while the nucleocapsid is 
33jf1nm  in diameter and has an icosahedral symmetry (Horzinek, 1971; 
Bakshi, 1990) (Fig. 1.2). The envelope haemagglutinin antigen, and the 
complement fixation antigen derived from the envelope, form the basis for 
the commonly used serologic reactions, haemagglutination inhibition (HI) and 
complement fixation (CF) (Stewart et al., 1967; Liebhaber, 1970).
The disease caused by RV was initially recognised as being a distinct 
disease in the early 1800s in Germany and was known by the name Rothein 
(Maton, 1815), later in England it was called rubella by Veale, 1866. In 
1941 Gregg, an australian ophthalmologist, reported an epidemic of 
congenital cataracts in children whose mothers had histories of rubella in 
early pregnancy. Many of the children also had additional serious congenital 
defects. The epidemic of deformities was suggested to be a consequence 
of natural rubella infection as almost all cases were directly preceded by a 
large rubella outbreak (Gregg, 1941).
ss +RNA
Fig. 1.1. Schematic figure of RV showing the single stranded RNA genome 
encapsidated in the nucleocapsid. The El and E2 glycoproteins are embeded 
into the lipid bilayer envelop{Mauracher et al., 1991).
Fig. 1.2. Negatively stained preparation of RV. Insert is an enlarged particle 
showing the spikes of the virus (Wilson et al., 1984).
1.3. GROWTH IN CELL CULTURE.
The virus grows in tissue culture in a number of cell lines including RK13 
(Rabbit kidney), SIRC (Rabbit cornea), and Vero (monkey kidney) cells 
(Herrmanet al., 1979). Vero cells and BHK-21 has been used extensively for 
virus isolation as it replicates to high titre in these cells 10^-10® TCIDgo/ml.
RV was first isolated in culture in 1962 which facilitated successful 
vaccine development. Although it produces a subtle cytopathic effect in 
primary human amnion cells (Weller et al., 1962), the more commonly used 
method for demonstrating RV is by culture in primary African green monkey 
cells and by demonstrating that its presence interferes with the growth of 
an easily cultivated virus, Echovirus type-11 (Parkman, 1962).
RV can be assayed in cell culture tubes employing RK13, SIRC, or 
primary VMK cells. RK13 and Vero cell cultures have been employed for 
plaque assays with variable results (Schmidt et al., 1969; Gould et al., 
1972; Best et al., 1989).
Plaque assays have been described based on (a) the failure to 
incorporate vital dyes (Liebhaber et al., 1967), (b) interference with the 
growth of paramyxoviruses which results in haemadsorption-negative 
plaques (Toms et al., 1973), (c) direct haemadsorption of pigeon red blood 
cells (Schmidt et al.,1969), and (d) immunocytochemical identification of 
foci (Fukuda et al., 1987); none of the assays have proven universally 
satisfactory.
1.4. THE DISEASE.
Prior to the introduction of vaccines, rubella epidemics occurred at 
intervals of 6-9 years. In 1940, 1963, and 1965 a high incidence was 
reported in the USA, the UK and the Australia. Later in the UK, the Royal 
College of General Practitioners reported outbreaks of rubella in 1978-79 
and 1982-83. In 1978, over 1800 cases were reported in Manchester, and 
in 1979 over 1000 cases in Newcastle.
The last major epidemic of rubella in the United States was in 1964/5 
when 20,000 infants suffered permanent damage from in utero exposure to 
rubella, (NCDC report, 1969). The vaccine introduced in 1969 was very 
successful in reducing rubella incidence and its consequences (Section 1.6) 
(Fig. 1.3).
1.4.1. POST NATALLY ACQUIRED INFECTION.
Rubella has a worldwide distribution and is endemic in temperate 
climates, with seasonal peaks occurring during spring and early summer. 
Infection is uncommon in preschool children, but outbreaks involving school 
children and young adults living in institutions are common (Best et al., 
1989).
In tropical countries, such as Africa, India, and China infection occurs
at an earlier age than in Europe or North America (Burke et al., 1985). In
Gambia, Ghana, Nigeria, and Tonga 25-50% of women of child bearing age
who attend school
are still susceptible to rubella even though most childrenTare immune by 
school age. Immigrants to the UK from these countries might miss 
vaccination and could be at risk of acquiring rubella during pregnancy.
Vaccine licensed
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Figure 13. Declining incidence of postnatally acquired and congenitally 
acquired rubella (CRS) in the USA, 1966-1983. (Burke et al., 1985.)
1.4.1.a. VIRAL DISSEMINATION.
Acquisition of rubella occurs through aerosolation (nasopharyngeal 
secretion). Although the initial events have not been elucidated, it is 
presumed that after the infection viral replication occurs in the 
nasopharyngeal mucosa, causing transient viraemia (Green et al, 1965). 
Viraemia results in wide spread dissemination of the virus which can be 
isolated from the blood, nasopharynx, urine, stool, synovial fluid, skin, 
cervix, and lymph nodes (Heggie et al., 1969 and 1978).
1.4.1.b. INFECTION AND PATHOLOGY.
RV has a 14-21 day incubation period, after which the characteristic 
features of rash may appear (Green et al., 1965; Chantier et al., 1982; 
Davis et al., 1971 ). Rubella-specific serum IgM, IgG, and IgA develop rapidly 
after the onset of rash (Fig. 1.4) (Meegan et al., 1983; Enders et al., 1985; 
O'Shea et al., 1985). Joint pains and inflammation develop very frequently 
following natural rubella virus infections (Heggie and Robins, 1969; Graham 
et al., 1983). In some patients arthritis may persist or recur over several 
years (Chantier et al., 1981 ; Tingle et al., 1986). A similar set of symptoms 
occur 9-27 days following vaccination but is encountered at a reduced 
frequency compared to that after natural rubella infection.
The most serious complication of natural rubella infection is 
postinfectious encephalopathy or encephalomyelitis which is estimated to 
occur in one of 6000 cases of natural rubella (Bechar et al., 1982; Sherman 
et al., 1965; Waxham and Wolinsky, 1984). The symptoms include 
headache, vomiting, stiff neck and generalized convulsions. The virus 
appears to have the capacity to invade the mature central nervous system 
(CNS) as the virus have been isolated from youngsters with typical rubella 
encephalopathy (Squadrini et al., 1977).
80% of patients with rubella postinfectious encephalopathy require 
only supportive treatment and the symptoms pass in a few days. However, 
20% of patients die after suffering coma, respiratory distress and then 
death; this is seen more in young adults than in children. Patients who 
survive rubella encephalopathy usually experience complete recovery (Kenny 
et al., 1965; Waxham et al., 1984).
Reinfection is likely to occur in individuals with low level of anti- 
rubella virus antibody and when immunity is vaccine induced rather than due 
to wild type infection (Horstmann et al., 1970; Davis et al., 1971 ; Farquhar, 
1972; Fogel et al., 1978; Harcourt et al., 1980). Reinfection in pregnancy 
would be hazardous only if viraemia occurred and very rarely results in fetal 
damage.
1.4.2. CONGENITALLY ACQUIRED INFECTION.
During 1970-1987, 17 years after the introduction of rubella vaccination 
the number of reported congenital rubella cases dropped from 2.3/100,000  
to 0.1/100,000 in the United States, representing a 96% decline (MMWR, 
1989). Before the introduction of vaccination in 1970 in the U.K. 200-300  
children were born each year with congenital defects due to rubella infection 
(Peckhan, 1985). Subsequently there has been a significant decline in the 
number of cases (Anderson and Grenfell, 1984)f
Maternal rubella infection contracted in the first trimester almost 
invariably results in fetal infection leading to fetal death and spontaneous 
abortion; or delivery of a severely malformed infant. The clinical features of 
congenital rubella syndrome (CRS) include fetal deafness, cataract, 
congenital heart disease and mental retardation (Banatvala et ai., 1984) (Fig. 
1.4). In the rubella pandemic of 1964-1965 in the USA, 20,000 infants
Fig. 1.4. (A) Purpuric rash in newborn infant with congenitally acquired 
rubella, who was subsequently found to have congenital heart disease and 
cataract. (B) Congenital rubella cataract in a 9-month-old infant. Cataract 
was also present in the left-eye but was removed surgically (Wilson et al., 
1984).
were born with CRS (Bart et al., 1985). Up to 80% of the infected fetuses 
were abnormal with sporadic foci of cellular damage in the heart, inner ear, 
lens, and skeletal muscles.
Serological studies show that a high proportion of infants are also 
infected following maternal infection after the first trimester, rubella-specific 
IgM being detected in 25-33% of infants whose mothers had rubella 
between the sixteenth and twentieth weeks of pregnancy (Cradock-Watson 
et al., 1980) (Fig. 1.5). As organogenesis is complete by 12 weeks, and in 
the more mature fetuses immune responses may limit or terminate infection, 
such infants rarely have severe or multiple anomalies. The only abnormalities 
associated with post-first trimester rubella are deafness and retinopathy 
(Best and Banatvala, 1990) (Fig 1.6).
Cell cultures derived from in utero infected fetal or new born tissues 
readily develop into chronically infected carrier cultures that can not be 
cured in vitro with rubella antisera (Rawls et al., 1968). These cultures 
showed slow growth rates and reduced survival. It has been recently shown 
that human embryonic cells persistently infected in vitro with rubella virus 
display an altered responsiveness to the growth promoting properties of 
epidermal growth factor, as well as a decreased capacity of collagen 
synthesis (Yoneda et al., 1986). Thus, it is probable that noncytopathic RV 
infection of selected embryonic cell types //? utero upsets the normal delicate 
balance of cellular growth and differentiation and has profound effects on 
organogenesis. If this happen during the critical phase of organogenesis it 
is likely that the organ will contain fewer cells than normal which will lead 
to multiple developmental defects.
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Figure 1.5 . Immune responses In congenitally 
acquired rubella. ( Herrmann, 1979.)
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1.5. SCREENING AND DIAGNOSIS TECHNIQUES.
The prevention of congenital abnormalities due to rubella infection 
depends partially on correct diagnosis of the disease. Diagnosis of rubella 
virus infection is accomplished by means of virus isolation (Weller et al., 
1962; Parkman et al., 1962; McCarthy et al., 1963; Cradock-Watson,
1991). In acquired rubella, the virus is most readily Isolated from swabs of 
the pharynx or nasopharyngeal secretions and reliably recovered from these 
sites for 6 days before and after appearance of the rash (Davis et al., 1971). 
Specimens should be transported immediately to laboratories in balanced salt 
solutions containing 1 % bovine serum albumin and antibiotics on wet ice, 
or they should be shipped frozen on dry ice (Rawls, 1974). Virus isolation 
techniques have been replaced by serological methods which are quicker, 
more reliable and not limited to the brief period of virus excretion.
Antigens for use in diagnosis techniques are mainly prepared in 
BHK21 cells, and a titre of 10®-10® TCIDgo/ml can be obtained using roller 
bottles or suspension culture (Best and Banatvala, 1990). Clinical diagnosis 
is often inaccurate and rubella is easily confused with measles, scarlet fever, 
or rash caused by enterovirus, parvovirus, adenovirus, cytomegalovirus, and 
Epstein-Barr virus infections as well as drug reactions or mycoplasma 
infection (Bakshi, 1990).
Recently, nucleic acid hybridization techniques have been applied with 
chorionic villus biopsy for the diagnosis of intrauterine rubella virus infection. 
Although this technique is sensitive under stringent hybridization conditions, 
false negative results do occur in experimentally rubella-infected monkeys. 
Therefore negative results by this method can not yet be taken as a sole 
criterion for ruling out fetal rubella infection (Terry et al., 1988; Eggerding 
et al., 1991).
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1.5.1 SEROLOGICAL TECHNIQUES.
Serological techniques are the main techniques for the diagnosis of 
rubella infection. The neutralization test is used to determine a rise in 
antibody titre but this technique is time consuming and has been replaced 
by haemagglutination inhibition (HI) and single radial haemolysis (SRH) which 
are more rapid and reliable (Best et al., 1990). The highly sensitive enzyme- 
linked immunoassays (ELISA) and radioimmunoassays (RIA) have superceded 
the above mentioned serological tests (Wittenburg et al., 1985).
1.5.1.a. HAEMAGGLUTINATION INHIBITION (HI).
The HI test is routinely used in the USA, however negative results can
be obtained when the patients have a low titre of antibody in neutralization
tests and ELISA. To detect a significant rise in the titre the serum should be
obtained within 3-4 days of illness. The HI test is technically more 
and
demanding ^ .expensive. It is also unreliable due to incomplete removal of 
beta-lipoprotein inhibitors, which are nonspecific inhibitors found in the test 
sera and the serum used in the production of haemagglutinin antigen (HA) 
(Kawano et al., 1987).
I.S .I.b . SINGLE RADIAL HAEMOLYSIS (SRH).
Single radial haemolysis (SRH) is a widely used technique for rubella 
antibody screening of adult women in order to determine their immune 
status, and to see if vaccination is required. SRH plates are commercially 
available but have a short shelf live. The plates contain rubella antigen, 
erythrocytes, complement and agarose. The size of the haemolysis zone
compared to the zone surrounding a standard serum (15 iu/ml) determines 
if the person is immune and whether or not there is a need for vaccination. 
A control plate without antigens should be employed to check for false 
positives. This technique is employed in the UK and Scandinavian 
laboratories where it has proved to be sensitive, specific and reliable. SRH 
has largely replaced HI test since the latter is both labour and time 
consuming and can give false positives due to failure to remove all inhibitory 
serum lipoprotein (Morgan-Capner, 1983; Kawano et al., 1987).
I.5.1.C. M-ANTIBODY CAPTURE RADIOIMMUNOASSAY (MACRIA).
Most laboratories in the UK now use MACRIA for the detection of 
rubella-specific IgM. This test is commercially available. The technique 
employs a soiid-phase coated with anti-human IgM which is sequentially 
incubated with the test serum, RV antigen and antirubella antibody labelled 
with iodine-125. This technique is used to test large number of sera and is 
less labour intensive than HI and SRH tests.
1.5.1.d. ENZYME-LINKED IMMUNOASSAY (ELISA).
ELISA is a sensitive test which will detect low titres of IgG antibody 
(Voiler and Bidwell, 1975). IgG antibody levels in test serum can be titrated 
by testing dilutions of the serum bound to constant levels of antigen. ELISA 
is commercially available and is similar to MACRIA except that the 
antirubella antibody is detected with enzyme conjugated antihuman IgG or 
IgM. Expertise, careful timing and stringent quality controls are necessary. 
However this test may not give reproducible results when sera contain low 
levels of antibody (Best and Banatvala, 1990).
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1.5.2. MOLECULAR BIOLOGY TECHNIQUES.
In 1986 Terry and colleagues isolated a virus from a chorionic villus 
biopsy taken at twelve weeks gestation following RV infection in very early 
pregnancy. They detected the presence of virus by nucleic acid hybridization 
to a rubella cDNA probe. Even though this method is very sensitive false 
negative results did occur (Terry et al., 1988). Higher sensitivity was 
obtained when the target nucleic acid was amplified by polymerase chain 
reaction (PCR) (Ho-Terry et al., 1990). A nested PCR technique was 
developed by Eggerding et al, 1991, which reduced background 
amplification. This test is of great sensitivity as samples used contained as 
little as 5fg of total cytoplasmic RNA from RV-infected cells.
1.5.3. DIAGNOSIS OF FETAL INFECTION.
Pregnancy is terminated after rubella infection because of the 
probability, rather than certainty, of fetal damage. Prenatal diagnosis of fetal 
infection, if it could be done early and quickly, would prevent unnecessary 
abortions. Fetal infection could be confirmed by IgM assays which are 
detectable in fetal serum after about 15 weeks of gestation. However fetal 
blood can only be safely obtained from the umbilical vein to determine if the 
fetus is infected or not after the 21st week of pregnancy (Daffos et al., 
1984; Morgan-Capner et al., 1985). Unfortunately, the presence or absence 
of rubella-virus-specific IgM does not reflect if the infant will be born with 
or without congenital rubella syndrome (Grangeot-Keros et al., 1988). 
Furthermore this approach is not suitable for diagnosing first trimester 
infections when the risk of fetal deformities is highest (Miller et al., 1982).
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1.6. VACCINES.
1.6.1. VACCINATION POLICIES.
Vaccines were successfully developed in 1965-67 after the 1964/5 
major outbreak of rubella In the United States and Europe, which resulted in 
more than of 6250 cases of spontaneous abortion and 5000 therapeutic 
abortions (Serdula et al., 1984). Since the introduction of the vaccines, the 
incidence of congenital rubella has declined remarkably in the United States 
and the United Kingdom.
In 1969, the US Public Health Service adopted a policy of universal 
rubella immunization for all children. Three live attenuated vaccines were 
licensed for use: HPV77-DE5 and HPV77-DK12 strains attenuated by high 
passage inAfricangreen monkey kidney (AGMK) cells followed by 5 passages 
in duck embryo and 12 in dog kidney cells respectively; and Cendehill, which 
was attenuated by 51 passages in rabbit kidney cells (Huygelen, 1969). In 
the United States, HPV-DE5 was used most extensively until its replacement 
in 1979 by RA 27/3 (rubella abortus 27, explant 3), which was grown in 
human diploid fibroblasts (table. 1.1) (Best et al., 1990; Plotkin et al., 
1965).
The rationale of the US policy was that such a strategy would reduce the 
circulation of virus in the community and prevent the periodic widespread 
epidemics which posed major risks to pregnant women. Vaccine acceptance 
In children was high, and an infrastructure for vaccine distribution was 
already in place. Universal vaccination of young children was supplemented 
with immunization of prepubescent girls (10-13 years old) and young 
women, after determination of their immunity status and appropriate 
discussion of contraception. This cautious approach was dictated by the
1 2
TABLE 1.1 CONSEQUENCES OF RUBELLA VACCINATION DURING PREGNANCY OR WITHIN THE 
THREE MONTHS BEFORE CONCEPTION, USA, 1971-1983: PREGNANCY OUTCOME IN 
SUSCEPTIBLES GOING TO TERM
Vaccine No. going to term
No. vaccinated between 1 week 
before to 4 weeks after 
conception/No. with date of 
conception known
Evidence of® 
infection Abnormalities^
HPV77.DE5/
Cendehill
94 33/86 (38.4%) 8/188° o'
RA27/3 119 44/119(37%) 0/104® 0
Total 213 77/205(37.6%) 8/292 (2.7%) 0
a IgM present, IgG persisting beyond 6 months or isolation of rubella virus, 
b Compatible with congenital rubella.
0 143 infants whose mothers were susceptible at the time of vaccination and 45 whose mothers were of unknown immune 
status, 
d Now aged 2 -8 .5  years.
e Of 150 infants bom to mothers of unknown immune status, 2 had serological evidence of infection, but no defects 
compatible with CHS.
(Centers for Disease Control, 1984; and reviewed in Burke et al., 1985).
undetermined teratogenicity of the vaccine in women with unsuspected 
pregnancies who might be accidentally inoculated. In contrast, selective 
vaccination of prepubescent girls was the sole approach adopted by health 
authorities in Great Britain.
The success of rubella immunization in the United States has been 
dramatic. There has been a 99% reduction in the total number of reported 
cases per year to less than 1000 (Fig. 1.3). CRS cases have dropped to 
fewer than 10 reported cases per year (Bakshi et al., 1990), although this 
number may represent considerable under-reporting (Coshi et al, 1989).
Outbreaks of rubella have in the past occurred on college campuses, 
at military establishments, and in work places. An expanded initiative was 
launched as part of an overall immunization effort in 1977. This included 
requiring proof of vaccination or proof of immunity to rubella at school entry. 
Emphasis was placed on vaccination in schools (through to grade 12), at 
college entry, in the work place, in health maintenance clinics, and at every 
contact with health care professional.
The RA27/3 vaccine strain was in use in europe for about ten years 
before it was licensed in the United States and it is now the most widely 
used vaccine throughout the world (Perkins et al., 1985). Its greater 
immunogenicity was attributed to its attenuation at a relatively low passage 
by cold adaptation. The attenuated virus induces protective antibodies in 
95% of vaccinated individuals (Halstead et al.,1971).
Following vaccination there is a sequential appearance of IgM and IgG 
and a variable appearance of IgA, depending upon the type of vaccine used 
and the route of vaccination. The level of antibody is four to eight times 
lower than that which follows rubella infection with wild type virus. RA27/3 
produces local and circulating IgA when given intranasally, and to a lesser
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extent when given subcutaneousiy, a property similar to natural infection 
(Ogra et al.,1971). In 1980s the USA vaccination policy was revised and a 
combined measles, mumps and rubella (MMR) triple vaccine was given to 
all children at 15 months and again at 6 or 12 years of age (Peltola et al., 
1986; Taranger et al., 1982). The immunity induced by the triple vaccine 
is comparable to that induced by each vaccine given separately.
Rubella vaccination is not recommended for patients whose 
immunological response is impaired, as a result of disease or treatment with 
immunosuppressive drugs or within 3 weeks of another live vaccine. 
Pregnancy is an absolute contraindication to immunization, since the vaccine 
strains may be transmitted transplacentally. In the UK it is recommended 
that pregnancy should be avoided for 1 month after rubella immunization, 
while in the USA an interval of 3 months is recommended (Best, 1991).
1.6.2. PERSISTENCE OF ANTI-RUBELLA ANTIBODIES.
Antibodies to RV have been shown to persist at levels > 15 ,000  iu/l 
in the majority of vaccinees for at least 18 years (Herrmann et al., 1982; 
O'Shea et al., 1982; Just et al., 1985; Orenstein, 1986). However, these 
studies have also shown that in approximately 10% of vaccinees the levels 
of rubella antibody decline to below 15,000 iu/l within 5-8 years and some 
may become completely seronegative (O'Shea et al., 1982 and 1984; 
Balfour et al., 1978; Enders, 1985).
1.6.3. REINFECTION.
The significance of low levels of antibody several years after 
seroconversion, in relation to the risk of reinfection, viraemia, and fetal
14
infection is a highly debated issue. Although HI levels may become 
undetectable, antibody may be detected by more sensitive measures such 
as ELISA (Horstmann, 1985; O'Shea, 1982). Viral challenge in such patients 
with attenuated virus administered subcutaneousiy or intranasally produced 
a secondary response with accelerated IgG production without IgM or 
viraemia (Davis, 1971). In a study of individuals with low or undetectable 
antibody several years after virus was administered intranasally, viraemia 
and IgM production were well documented (O'Shea et al., 1983; Koplan et 
al., 1982).
As noted previously, reinfection is extremely rare following natural 
infection and is more likely to occur in those whose immunity is vaccine- 
induced. The incidence of reinfection is higher among those vaccinated with 
Cendehill and HPV77-derived vaccines, than among those given the RA27/3 
vaccine (Banatvala, 1989; Eilard et al., 1974; Enders et al., 1984; Miller et 
al.,1982; Strannegard et al., 1970; Wilkins et al., 1972). Concerns exists 
that a large cohort of women vaccinated many years ago, having grown up 
in an environment where virus circulation has been virtually eliminated, may 
experience viraemia and fetal infection when exposed to wild-type virus 
during pregnancy. This issue will be clarified only by ongoing surveillance.
1.6.4. VACCINE STORAGE.
RV is very stable in a freeze-dried form. At +4°C , no detectable loss 
of viral potency was observed after 5 years. At room temperature, a gradual 
decrease was observed over several months, while at 37°C, a similar loss 
was observed over a period of a few weeks (Huygelen, 1978). Therefore, 
storage of vaccines at low temperature is essential (2°-8°C) or the labile 
virus will become inactivated and the vaccinees will fail to seroconvert (Best 
et al., 1989). This issue presents a problem of vaccination outside of the 
”cold chain" countries.
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1.6.5. SIDE EFFECTS.
Rubella vaccine has been remarkably safe and relatively free of side 
effects. Occasional fever, rash, and lymphadenopathy (disease of lymph 
nodes) may simulate mild clinical rubella. Side effects noted early on in 
community trials of vaccine prior to licensure in 1969 including a 
characteristic, transient polyneuropathy (disease involve a number of 
peripheral nerves) manifested by paraesthesia (numbness) especially in the 
hands mimicking carpal tunnel syndrome (wrist pain) from other causes and 
a peculiar bent knee gait called the "catcher's crouch syndrome".
A comparative analysis in women given HPV-DK, HPV-DE, Cendehill, 
and RA27/3 strains of rubella vaccine reported joint complaints in 49, 30, 
9, and 14%, respectively, of the vaccinees (Polk et al., 1982). HPV-77DK 
vaccine, the most arthritogenic preparation, was voluntarily removed from 
the market in 1973.
In typical patients, the pains are transient, lasting only a few days. 
Other patients seem to have recurring symptoms which over a period of time 
occur with decreasing severity and longer asymptomic intervals.
The role of rubella vaccine has not been clarified as a cause of chronic , 
persistent arthritis. A small number of women have been described as 
experiencing such complaints over a number of years. One group of 
investigators has succeeded in isolating rubella virus from such patients long 
after vaccination (Chantier et al., 1985).
A registry was maintained of all women accidentally vaccinated during 
the period from 3 months before to 3 months after onset of pregnancy, 
including a subset of pregnancies at highest risk because of vaccination 1
16
week before to 3 weeks after conception. In none of the children followed 
was there evidence of CRS. Thus the actual risk was zero, but based on the 
binomial distribution, the overall maximum theoretical risk was 3% with HPV 
vaccination and Cendehill, and 1.7% with RA27/3 (Bakshi, 1990) (Table 
1.2).
1.7. MOLECULAR BIOLOGY OF RV.
1.7.1. THE GENOME.
RV is a single stranded, positive polarity RNA virus (Baltimore, 1971 ; 
Hovi et al., 1970 and 1972; Robinson et al., 1969; Sedwick et al., 1970). 
The 408 RNA genome is a linear capped and polyadenylated molecule 
encapsidated in a capsid. The virus contains three glycosylated, membrane 
associated proteins, El (Mr = 58kD), E2a (Mr=47kD) and E2b (M, = 42kD), 
and one unglycosylated nucleocapsid protein, C (M/=33kD) (Oker-Blom,
1983). Further analysis of E2a and E2b proteins revealed that they have 
identical peptides suggesting that they are encoded by one gene. It was 
suggested that both proteins represent two glycosylation variants of the 
same gene product (Oker-Blom et al., 1983 and 1984 Hovi and Vaheri, 
1970). This was confirmed by pulse-chase experiments which showed that 
E2 was initially detected as a 39kD protein containing mannose sugars 
(Hobman et al., 1989). This glycoprotein was converted to 42kD by glycan 
processing enzyme in the Golgi compartments (Hobman et al., 1990). Earlier 
studies had also reported the presence of at least three major polypeptides 
in RV with molecular weights of 55-63, 42-50 and 30-35kD (Bardeletti et 
al., 1975; Ho-Terry et al, 1980 and 1982, Payment et al., 1975; Trudel et 
al., 1982; Vaheri et al., 1972; Bowden et al., 1984). The capsid (C) protein 
is surrounded by a lipid bilayer envelope in which the two virus-specific
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TABLE 1.2 PREGNANCY OUTCOME IN SUSCEPTIBLEWOMEN GOING TO TERM FOLLOWING RUBELLA 
VACCINATION DURING PREGNANCY OR WITHIN THE THREE MONTHS BEFORE 
CONCEPTION
Number of live births in women receiving:
Country
HPV77.DE5/
Cendehill RA27/3 NK* Total
Evidence of 
Infection
Abnormalities 
compatible 
with CRS
USA 94 121*^ — 215** 4/165° (2.42«/o) 0/215°
Federal Republic of 
Germany
112 16 128 1/128(0.78%) 0/128
Sweden 4 4 0/3 0/4
UK 1 13 7 21 0/18 0/21
Total 207 154 7 368 5/314 (1.59%) 0/368
a Not known, 
b Includes 2 sets of twins, 
c Number positive/number tested.
d Number of cases with CRS abnormalities/number examined.
(Best and Banatvala, 1987).
glycoproteins, El and E2 are embedded (Ho-Terry et al., 1982; Waxham et 
al., 1983; Oker-Blom et al., 1983).
Studies of RV-infected Vero cells revealed that they contain, in addition 
to the genomic 40S RNA, a 24S subgenomic RNA (Oker-Blom, 1984) that 
is synthesized from the 3'-terminal 3189 nucleotides of the genomic RNA 
(Frey et al., 1989; Dominguez and Frey, 1990). The subgenomic RNA 
contains a single long open reading frame (ORF) which is translated into a 
IIO kD  polyprotein that is then post translationally processed into the 
structural proteins (Fig. 1.8). The order of the structural proteins within the 
110k precursor is NH2-C-E2 El-COOH (Oker-Blom et al, 1984).
Two tentative 5'-termini were isolated after complete hydrolysis of 
the viral RNA. Both were resistant to the treatment with alkaline 
phosphatase which is typical of capped 5'-terminal structures. The study 
indicated that the 40s RNA has a structure typical of eukaryotic mRNA, 
where it is capped at its 5'-terminal and has a poly (A) tract at the 3' 
terminal (Oker-Blom, 1984). The cap structure is required for efficient 
translation as it serves as a ribosome recognition site (Rose et al., 1975 and 
1976; Petterson et al., 1980).
At the 5'-terminus of the nonstructural protein ORF, there is an AUG 
beginning at nucleotide 3 of the rubella genomic RNA. Translation initiated 
at this AUG would terminate at a UAG codon beginning at nucleotide 54, 
yielding a 16-amino acid product (Appendix A) (Dominguez et al., 1990). In 
most eukaryotic mRNAs the AUGs at which translation is initiated are 20- 
100 nucleotides from the 5' end of the RNA (Kozak, 1987). initiation of 
translation at AUGs less than 15 nucleotides from the 5' end of eukaryotic 
mRNAs is less efficient than at AUGs placed more than 15 nucleotides from 
the 5' end (Sedman et al., 1990), therefore, it is not uncommon to find that 
mRNAs which contain AUGs close to the 5' end also contain downstream
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AUGs at which translation is also initiated (Kozak, 1987), as would be the 
case in the rubella RNA. The ORF analysis revealed several long ORFs in the 
negative polarity RNA but it is not known if any of them are translated . 
Similar length ORFs are not present in the negative polarity of alphavirus 
genomic RNAs (Strauss and Strauss, 1986).
Three in-phase termination codons clustered in the 5' untranslated
region of the 24S RNA were found. These multiple stop codons are used to
ensure the complete termination of the translation of the non-structural
proteins. It was also reported that an inverted repeat (GCCAUUCGGG), at
nucleotides 114-122 and 137-146 (6478-6487 and 6502-6511 on the 
RNA
genomic^,can be arranged in a hairpin configuration that may function as a 
binding site in the initiation of the subgenomic RNA synthesis. This region 
is homologous to the region of the alphavirus genome upstream from and 
including the 5' end of the subgenomic RNA (Clark et al., 1987; Frey and 
Marr, 1988). This region is extremely conserved among alphaviruses (Ou et 
al., 1982).
Fifty-seven to 58 nucleotides of non-coding sequence extend from the 
end of the open-reading frame to the polyadenylation tract at the 3' 
terminus of the virus genome (Bardeletti et al., 1975, Frey et al., 1986, 
Vidgrenjgt/1987). This sequence is substantially shorter than in the 
alphaviruses, i.e. Semliki Forest Virus (264 residues) (Garoff et al., 1980 ), 
Sindbis virus (318 residues) (Rice and Strauss 1981) and Ross River Virus 
(524 residues) (Dalgarno et al., 1983). Sequence important for viral 
replication are known to be located within a short region close to the poly 
(A) tract and to be conserved among different members of the alphaviruses 
(Ou et al., 1981; Strauss and Strauss, 1983; Levis et al., 1986). No 
homology was found between the alphaviruses and RV within this region 
(Vidgren et al., 1987).
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The nonstructural proteins of rubella have not been characterized. 
Rubella does not shut off host cell macromolecules synthesis, making the 
quantitative study of both structural and nonstructural proteins synthesized 
very difficult to detect over the host cell background (Hemphil et al., 1988). 
Two global motifs indicative of replicase and helicase functions were found 
in the RV 5' proximal ORF (Dominguez et al., 1990).
Sequence homologous to three regions highly conserved among 
alphaviruses, were found in the RV genomic RNA. These regions consist of 
a stem-loop structure at the 5' end of the genome, a 51-nucleotide 
conserved sequence near the 5' end of the genome and a 20 nucleotide 
conserved sequence at the subgenomic RNA start site. Amino acid sequence 
comparisons between the ns ORF of RV and alphaviruses revealed only one 
short region, 122 aa, of significant homology, indicating that these viruses 
are only distantly related (Fig. 1.9) (Dominguez et al., 1990).
In the alphavirus genome, a single ORF of approximately 7.4 kb spans the 
5' two-thirds of the genomic RNA. The polyprotein translated from this ORF 
is post translationally processed into four nonstructural proteins, nsPI, 
nsP2, nsP3, and nsP4 (Strauss and Strauss, 1986). in Sindbis virus, Ross 
River virus, and Middleburg virus, there is an in-frame opal termination 
codon between the nonstructural proteins nsP3 and nsP4 which is 
occasionally read through (Strauss et al., 1983). However, Semliki Forest 
virus lacks this opal codon (Strauss et al., 1988). Mutation studies reveal 
that nsP4 is the RNA polymerase, nsPI functions in minus-polarity RNA 
synthesis and nsP2 functions in subgenomic RNA synthesis (Hahn et al., 
1989a, b) as well as being an autoprotease that is required for post- 
translational processing of the nonstructural proteins (Ding et al., 1989)
2 0
IlIS o % z
o
S
> -
LU
C
LL
C
Z
<
cz
<
rsjUJ
C
Z
co
U i
a
c
&
CL
C
a.
CD
•0)
W _
3 C a 
G)
O
O %
£ J
o  o
*!
0 ) 
3  
C
£ g
il
I
IW OT
l iC' a
I I
I.£ocô
'E
CO
c.
CO
i l
— en
| o
I I
1 1
en <J 
C (O
lî
en c  
0)  -
il
i sI!
Ci =
en u .si
l i
. .Jl
E £  =
 ^ 5
•) CO en
s 3 ;
CO
c c  
z
I c
*  en
I I
O Q)
en O i
G)
" 5
6
CD
O )
CO
b
-o»
II
. o
o G)
jZ ü
liCO iS
f l
lî
S I
î l .CO ü  TT 3
8 
E
CO
"cô c  
o
o
g
_  _  CO
c  CO en —
The cDNAs for the 24S RNA of the wild type strains M33, Judith and 
Therien and vaccine strains HPV77 and RA27/3 has been sequenced and 
expressed in different systems (Nakhasi et al., 1986 and 1989; Zheng et al., 
1989; Clarke et al., 1987; Terry, 1988; Frey et al., 1986; Vidgren et al., 
1987; Frey and Marr, 1988; Takkinen et al, 1988).
1.7.2. EXPRESSION OF THE STRUCTURAL PROTEINS.
Expression of all the structural proteins of RV has been carried out 
using an SV40 derived vector. The recombinant DNA was transfected into 
COS cells and produced three proteins of sizes 58, 44, 33kD corresponding 
to E l, E2 and C proteins. The presence of tunicamycin (glycosylation 
Inhibitor) significantly reduced the sizes of El and E2 to 51 and 30kD but 
had no effect on the C protein indicating that it is not glycosylated (Oker- 
Blom et al., 1983; Clark et al., 1988). This indicated that the RV structural 
protein precursor is processed to individual proteins which are then 
glycosylated in COS cells to yield proteins which are antigenically similar to 
the proteins expressed by RV- infected cells.
In an attempt to achieve abundant expression of El and E2, both 
sequences were expressed as a polyprotein in recombinant baculovirus- 
infected lepidopteran insect cells (SF9) where both proteins were translated, 
cleaved and glycosylated similarly but not Identically to those in COS cells. 
Although the baculovirus vector was capable of expressing El and E2 it was 
not clear whether the constructs here were optimal for the highest possible 
level for gene expression (Oker-Blom et al., 1989).
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1.8. REPLICATION OF RV.
Following attachment to a cell surface receptor (Mastromarino et 
al.,1989 and 1990), rubella virus is taken up into lysosomes (Mauracher et 
al, 1991). The low pH in the lysosome induces the El protein to become 
fusogenic and facilitates the fusion between the virus and the lysosomal 
membrane. It has been demonstrated that the replication of rubella virus is 
initiated at the 3' end of the genomic RNA and specifically 59 nucleotides 
from the poly (A) tail, where a 12 nucleotide stem-loop structure could be 
found (Fig. 1.10) (Nakhasi et al., 1990). The low pH also induces a solubility 
shift of the capsid in the lysosome allowing it to associate with the 
membrane, which causes uncoating. Upon membrane fusion the viral RNA 
is released into the cytoplasm (Fig. 1.11) (Katow et al., 1988; Mauracher et 
al., 1991). The virus spikes that are integrated with the lysosomal 
membrane during fusion and any unfused virus particles, are subsequently 
degraded in the cell. A similar uncoating process occurs with Semliki Forest 
Virus (Helenius et al., 1980).
As togavirus genomic RNA is of positive polarity, it serves as mRNA 
to produce the proteins involved in the replication of the virus. Following 
entry into the cell, genomic rubella RNA binds to ribosomes and only one 
portion of the genome is available for translation in the first round of protein 
synthesis ' . The function of the resulting products is to transcribe
the genomic +ve RNA into negative sense RNA. The transcribed negative 
strand in turn serves as a template for two size classes of positive 
molecules, the genomic and subgenomic RNAs. The subgenomic RNA is 
translated into a precursor polyprotein which is subsequently cleaved into 
the structural proteins of the virion. Full size positive sense genomic RNA is 
packaged into the nucleocapsid in the cytoplasm of the infected cell. 
Subsequently these nucleocapsids are enveloped and released, possibly by 
budding at internal membranes. Such replication process do not require
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Figure l.lONucieodde sequence of the rubella virus RNA stem-loop 
structure.
The nucleotide numbers are given at the 5' and the 3' ends. The 
numbers correspond to sequence numbers in Zheng et ai., 1989. The 
AG for this hairpin structure has been calculated to be —29.6 cal/mol 
at 25® (Frey et al., 1986) (Nakhasi Gt al., 1990).
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enzymes brought into the infected cells by the virion, as they are 
synthesized during replication (Kalkkinen et al., 1984, Oker-Blom et al., 
1984 and 1990 Mauracher, 1991).
The envelope glycoproteins E2 and El enter the secretory pathway 
of mammalian cells by translocation across the membrane of the rough 
endoplasmic reticulum (RER) (Walter et al., 1984 and 1986; Wickner et al., 
1985, Mauracher, et al, 1991, Hobman et al,1988, McDonald et al, 1991). 
The prototype translocation mechanism begins with a cytoplasmic 
interaction between the signal peptide (SP) in a nascent polypeptide chain 
and a cellular ribonucleoprotein component called the signal recognition 
particle (SRP). The SRP-SP-ribosome complex then binds to the signal 
recognition particle receptor located in the membrane of the RER. This 
interaction is accompanied by the release of the SRP and cotranslational 
passage of the polypeptide chain across the membrane of the RER. The 
signal peptide is cleaved by signal peptidase, located in the lumen of the 
RER, creating a new terminus for the mature protein. In the case of integral 
membrane proteins, translocation is interrupted by a hydrophobic membrane 
anchor, which mediates a stable association between the protein and the 
membrane (Fig. 1.12) (Gething et al., 1982; Jabbaret al., 1987; Sekikiwa 
et al., 1983).
The replication strategy and the virion structure of RV resemble those 
of alphaviruses, with the structural proteins of the alphaviruses being 
similarly translated as a polyprotein from a 26S subgenomic mRNA in the 
order NH2-C-E3-E2-E1-COOH. Alphaviruses assembly involves the 
nucleocapsid and the envelope. The C protein is auto-proteolitically cleaved 
from the nascent polypeptide precursor. After the cleavage, an N-terminal 
signal sequence appears to function leading to insertion of the nascent E2 
polypeptide chain into the endoplasmic reticulum (Strauss et al., 1986). A 
stop transfer signal (anchor) near the C-terminal end of the first
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Figure W2 Steps in the Folding of an Anctiored Protein witti Its C 
Terminus Outside and Its N Terminus Inside ttie Cvtoclasmic Com- 
panment P = Polar region and H = Hydrophobic region 
(Engelman and Steitz, 1981).
glycoprotein, E2, anchors the protein, followed by the insertion of the El 
glycoprotein by its signal peptide into the endoplasmic reticulum. The two 
glycoproteins are separated by a small polypeptide of approximately 60aa 
cut from the polyprotein precursor (Strauss et al., 1987).
1.9. SEQUENCE ANALYSIS OF THE VIRAL GENOME.
Rubella virus consists of a 408 single stranded polyadenylated genomic 
RNA. An analysis of the coding potential of the rubella genome reveals two 
long ORFs in the positive orientation. The 3' GRP begins at nucleotide 6507 
and ends at nucleotide 9696, is 3189 nucleotides in length encoding a 
polypeptide of 1063 amino acids which contains the structural proteins 
(Frey et al., 1986; Frey and Marr, 1988). The 5' ORF begins at nucleotide 
41 and terminates at position 6656 with an opal codon (UGA) which is 
followed 12 nucleotides downstream by a second in-frame opal codon. This 
ORF is 6615 nucleotides in length and encodes a 2205 amino acid 
polypeptide. These two ORFs overlap by 149 nucleotides. Thus, the 
organization of the rubella genome is similar to the alphavirus genome, with 
the 5' ORF of the rubella genome producing the nonstructural proteins and 
the 3' ORF producing the structural proteins.
The sequence of the 3'-terminal 4500 nucleotides of the RV genome 
which contains the structural protein open reading frame (ORF) has been 
reported for a number of strains: Therien, M33, HPV-77 and RA27/3 (Frey 
et al., 1986; Nakhasi, 1986; Clark et al., 1987; Vidgren et al., 1987; 
Takkinen et al.,1988; Frey and Marr, 1988; Zheng et al., 1989). Recently 
the sequence of the entire genomic viral RNA was also reported (Dominguez 
et al 1990). The base composition of the rubella genomic RNA is 14.9% A, 
15.4% U, 30.8% G and 38.7% C and thus it has the highest G/C content 
(69.5%) of any RNA virus sequenced to date. The high G/C content is
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evenly maintained throughout the rubella genome. The only region where it 
differs markedly from the 69.5% average is the first 65 nucleotides of the 
genome, which have a G/C content of only 47%. The lower G/C content in 
this region of the double-stranded replicative form, facilitate recognition and 
local dénaturation by factors Involved In initiation and synthesis of the 
genomic RNA (Dominguez et al., 1990). As mentioned previously the order 
of the structural proteins of RV subgenomic RNA is NH2-C-E2-EI-COOH, the 
properties of the individual proteins are now discussed.
1.9.1. THE CAPSID PROTEIN (C).
The subgenomic RNA open reading frame (ORF) starts with the C 
protein gene at an AUG initiation codon at nucleotide 77 (Takkinen et al.,
1988). The AUG codon is followed seven codons later with another in-frame 
AUG codon. //? vitro site-specific mutagenesis of each codon or both 
suggested that the first AUG serves as the sole translational start. 
Inactivation of the first codon does not halt translation, as the second in­
frame codon can also act as translation site (Clark et al., 1988; Frey et al.,
1989).
The capsid protein is unglycosylated and has a molecular weight of 
33kD (Oker-Blom et al., 1983). The protein is rich in basic amino acids and 
is very hydrophillic. It contains clusters of proline and arginine residues at the 
amino-terminus; this region is highly hydrophillic in nature, and is putatively 
the region of the protein which interacts with the virion RNA. It has been 
suggested that clusters of uncharged, hydrophobic, amino acids, found at
Ij
the carboxy-terminus of the protein, serves as the signal peptide for E2 wjere 
the cleavage between C and E2 occursby signalase in the lumen of the 
endoplasmic reticulum (Garoff et al., 1980; Dalgarno et al., 1983; Clark et 
al., 1987; Frey et al., 1988).
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The C protein has a blocked amino terminus which is believed to be 
required for efficient protein synthesis. Capping may also function to protect 
the mRNA from degradation by nucleases and to provide a feature for 
recognition by the ribosomes (Kalkkinen et al., 1984; Friefelder, 1983). This 
feature is similar to SFV (Kalkkinen et al., 1980, 1981a) and adenovirus 
(Jornvall et al., 1974).
The RV capsid protein differs from the alphavirus capsid protein with 
respect to its mechanism of cleavage from the polyprotein. The RV capsid 
protein requires the presence of microsomal membranes for its cleavage 
from the polyprotein in vitro (Clark et al., 1988), whereas the alphavirus 
capsid protein is an autoprotease and releases itself from the polyprotein 
precursor within the cytoplasm (Hahn et al., 1985; Melancon et al., 1987; 
Hahn et al., 1990). In alphaviruses the E2 membrane protein signal peptide 
remains part of the E2 protein after autoproteolysis of the C protein 
(Melancon et al., 1987) while the signal peptide of E2 glycoprotein in RV 
remains attached to the capsid protein (Suomalainen et al., 1990; Marr et 
al., 1991). Therefore, the processing of RV capsid protein is quite different 
from that of the closely related alphaviruses. It was also reported that there 
is a minimum length required for signal peptidase cleavage of E2 which is 
between 25-86 residues (McDonald et al., 1991).
1.9.2. E2 GLYCOPROTEIN.
The E2 glycoprotein is an envelope protein which is produced together 
with the capsid and El protein from the IIO kD  precursor polypeptide. The 
coding sequence for E2 is located upstream of the El coding sequence (Fig.
1.8.). Initially the protein was purified from rubella virus in two forms E2a 
and E2b which were identical in their amino acid sequence but have a 
molecular weights of 47 and 42kd respectively. Both proteins were found
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to be glycosylated and associated with the viral membrane (Oker-Blom et al.,
1984). It was suggested that E2a and E2b are translated from a single gene 
and that the size difference of E2 species is due to differential glycosylation 
or some other post-translational modifications (Kalkkinen et al., 1984; Oker- 
Blom et al., 1983). However in vitro and in vivo expression of E2 shows 
that E2 is present in only one form suggesting that the heterogeneity in size 
results from modifications occurring late in the virus maturation (Hobman et 
al., 1989; Oker-Blom et al., 1989).
The E2 protein is heavily glycosylated as judged by the difference in the 
molecular weight of 12,000-17,000 between fully glycosylated E2 in 
virions, and from tunicamycin-treated cells (Oker-Blom et al., 1983; Bowden 
et al., 1985; Clark et al., 1988). Sequence analysis of RV M33 strain has 
shown that E2 contains three potential N-linked glycosylation sites in the 
form of Asn-X-Ser (Clark et al., 1987) and four in the Therien strain 
(Appendix A)^ (Vidgren et al., 1987; Frey et al., 1988). N-linked 
oligosaccarides are high mannose-type carbohydrates, and are present on all 
the viral glycoproteins that have been characterized as 0-1 inked or mucin- 
type carbohydrates (Holmeset al., 1981; Nieman et al., 1981; Kari and 
Gehrz, 1988). The sugar residues are transferred to the growing polypeptide 
in the endoplasmic reticulum (ER) and are subsequently processed in the ER 
and the Golgi apparatus to yield the different types of oligosaccharides. O- 
linked oligosaccharides or mucin-type carbohydrates are monosaccharides 
added to the polypeptide backbone (Strous, 1979; Hanover et al.,1980; 
Serafini-Cessi et al., 1983). The E2 glycoprotein of RV strain M33 contains 
large, complex-type, N-linked carbohydrates and several smaller, 0-linked 
oligosaccharides (Lundstrom et al., 1991).
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1.9.2.8. E2 ANTIGENICITY.
The E2 glycoprotein is not as well studied as El for a number of 
reasons. Waxham and Wolinsky (1985) reported the generation of 
monoclonal antibodies (MAbs) specific for E2 glycoprotein. The MAbs 
against E2 were unable to precipitate E2 from detergent extracts of whole 
virus or to interact with intact virions. The MAb reacted only with the 
intracellular form of E2 and denatured E2 from purified virus. Binding only 
to the intracellular form was suggested as being due to conformational 
changes which occur during maturation of the protein into the virus particle. 
This in turn suggests that the antigenic sites to which this MAb attaches on 
the E2 glycoprotein become masked by the interaction of E2 with the El 
glycoprotein, similarly to Sindbis virus . However, the domains defined by 
anti-E2 MAbs, which resist dénaturation, were reported to be relatively large 
containing 116 aa residues (Wolinsky et al., 1991).
It has also been shown that the oligosaccharide moieties on E2 are 
much less sensitive to glycosidic enzymes than those on E l, suggesting that 
E2 epitopes may be buried under El in the glycoprotein spike complexes on 
the virion surface (Ho-Terry et al., 1984). However, Green and Dorsette, 
1986, developed one MAb which precipitated the E2 glycoprotein from 
detergent extracts of the RV and nondisrupted virus and exhibited NT 
activity. Thus it proved that at least one epitope on the E2 glycoprotein 
must be accessible on the external surface of the virion, and this epitope is 
involved in NT.
When antisera were developed specifically to RV strains HPV-77 or 
RA27/3, the RA27/3 antiserum contained a low titre of antibody against E2 
glycopolyprotein of HPV-77 virus. The antibodies to the E2 reacted 
specifically with the homologous antigen, with little cross reactivity to the 
heterologous E2 antigen. The antibody titres to El and C polypeptides
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remained constant regardless of the antigen. The authors suggested that the 
antigenic differences within the E2 glycoprotein involved strain specific 
epitopes (Gould et al., 1980; Dorsette et al., 1985).
1.9.2.b. E2 PROTEIN ORGANIZATION.
Sequence analysis of cDNAs coding for the E2 protein revealed a 
hydrophobic region of 23 residues, which has the characteristics of a signal 
peptide, immediately preceding the N-terminus of mature E2 (Perlman and 
Halvorson, 1983; Kalkkinen et al., 1984; Frey and Marr, 1988). This region 
confers a transmembrane configuration on the carboxy terminus of the C 
protein during the synthesis of RV structural protein (Fig. 1.8.) (Vidgren et 
al., 1987; Clark et al., 1987; Frey et al., 1988).
Pulse-chase experiments show that E2 is able to exit the endoplasmic 
reticulum and reach the Golgi compartment where it is processed by a- 
mannosidase II (Dunphy et al., 1985). Immunofluorescence studies in 
transfected COS cells demonstrated that E2 is transported to the cell surface 
in the absence of E l. The deletion of the signal peptide showed a rapid 
turnover of the untranslocated E2 as the protein was not detected neither 
in vivo or in vitro experiments (Hobman et al., 1989; Oker-Blom et al.,
1989). The cleavage of the individual proteins from the IIO kD  rubella 
structural protein precursor could be catalyzed by signalase, the enzyme in 
the endoplasmic reticulum which removes signal sequences from their 
associated protein (Frey et al., 1991). The E2 signal peptide when cleaved 
from E2 remains attached to the C terminus of the nucleocapsid C protein 
when translated in vitro (Suomalainen et al., 1990).
At the C-terminal end of E2 are three additional hydrophobic regions 
of uncharged amino acids, each composed of 19, 18, and 20 aa residues in 
length (Appendix A. The most C-terminal of these stretches is the putative
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signal sequence of El (Frey et al., 1986). The middle 18 aa residue stretch 
is the most hydrophobic of all and is followed by a heptapeptide, containing 
five arginine residues. This structure may form a membrane-spanning domain 
with an anchor on the cytoplasm side. The role of the 19aa region is unclear 
(Frey et al., 1988).
I.9.2.C. EXPRESSION OF E2 CODING SEQUENCE.
In vitro expression of the E2 coding sequence from RV M33 strain 
revealed that the protein was efficiently translocated into microsomal 
vesicles in the presence of 64 residues, including the signal peptide and part 
of the capsid sequence, at the amino terminus of the protein. The 
translocated protein was 6kD less in molecular weight than the expected 
size due to the removal of the 64 aa preceding the N-terminus of E2 by 
signal peptidase (Hobman et al., 1989). A study by Soumalainen, 1990, 
revealed that the E2 signal peptide remains attached to the carboxy-terminus 
of the C protein.
A construct lacking the signal peptide sequence failed to translocate 
and the protein was not glycosylated, in vitro expression, using baculovirus, 
of E2 and El with both their signal peptides yielded a precursor protein 
(84kD) which was processed and cleaved in the presence of the 
membranes. The same construct lacking the E2 signal peptide sequence fail 
to be processed (Hobman et al., 1989; Oker-Blom et al., 1990).
E2, full length ( + 64 aa), was also expressed in COS cells, of size 
42kD, and was reported to be transported to the surface of the cells. 
However, protein lacking the signal peptide had a rapid turnover of the 
untranslocated protein. These studies indicated that the signal peptide 
sequence is required for translocation of the E2 and E2/E1 polyprotein into
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the secretory pathway. It was also concluded that there are three 
requirementsfor proteolytic separation of E2/E1: (1) a functional E2 signal 
peptide, (2) microsomal membranes (RER) and (3) sequence downstream 
from the proximal half of the El signal peptide (cleavage site) (Oker-Blom et 
al., 1990). The amino-terminus preceding E2 was further reduced in size to 
contain 23 residues. The expression of this construct, in vitro (Marr et al., 
1991) and using a vaccinia virus based vector (Sanchez et al., 1991), 
proved that this length was sufficient for signal activity .
1.9.3. El GLYCOPROTEIN.
The El protein has a molecular weight of 58kD and is derived from 
the 110,000d precursor polypeptide which is translated from the 24S mRNA 
(Fig. 1.8), (Petterson et al., 1985, Oker-Blom et al., 1983 and 1984). It is 
speculated that the El is processed by proteolytic cleavage by cellular signal 
peptidase at the carboxy-terminus of E2. A cluster of arginines is present 
between the El and E2 proteins in the 1 lOkD polyprotein which serves as 
the cleavage site (Hobman et al., 1988 and 1989; Oker-Blom et al., 1990; 
Vidgren, 1987; and Nakhasi, 1986).
After El synthesis the protein is subsequently modified before 
incorporation into the virus particle, by the addition of carbohydrates, 
predominantly mannose and glucosamine (Bowden et al., 1985; Toivonin et 
al., 1983; Vaheri et al., 1972; Waxham et al., 1985).
The mature El contains a domain involved in virus attachment to the 
surface of erythrocytes or the host cell membrane and the initiation of 
Infection (Gerna et al., 1987, Ho-Terry et al., 1982; 1985, Trudel at al., 
1985, Umino, 1985).
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1.9.3.a. El ANTIGENICITY.
El is considered to be the major viral antigen to which most human 
rubella specific antibodies are directed. Waxham and Wolinsky (1985) have 
produced and characterized a panel of monoclonal antibodies to the 
structural polypeptides of RV. Six non overlapping antigenic sites were 
defined on the El glycoprotein of the Therien strain. Similar results were 
obtained by Green and Dorsette (1986) who identified at least two distinct 
epitopes involved in high level HI activity, and had neutralization activity, 
located on the El polypeptide. Only one of the epitopes is involved in NT 
activity. This study confirmed that the El glycoprotein has a role in 
haemagglutination (Ho, 1983, Waxham and Wolinsky, 1985).
Three rubella epitopes, ep2, ep3 and epi, have been mapped on 
strain Judith of RV which react with haemagglutination inhibiting and 
neutralizing antibodies. These epitopes form an antigenic domain of 40  
residues between amino acids 827-867. This domain contains stretches of 
highly hydrophillic amino acids. Since the nearest glycosylation site is 36 aa 
from the antigenic region, it was suggested that the haemagglutination 
inhibition antibody reacts with the amino acid and not with the 
oligosaccharides components of the RV El glycoprotein (Appendix A) (Terry 
et al., 1988; Ho-Terry et al., 1984 and 1986).
In a study of El glycoprotein epitopes by multiple peptide synthesis, it 
was found that octapeptides corresponding to ep2, ep3 and epi epitope 
regions were active and exhibited binding capacity to El monoclonal 
antibodies. It was concluded that ep2 involved amino acids are ®^°PER^ ^^  and 
ep3 ^®°ADDP^ ®^ . Epi which is the largest epitopic region was found to 
consist of two domains, tripeptide ^^ E^VW^ ^^  and octapeptide 
27®PVIGSQAR2®5 (Lozzi et al, 1990).
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1.9.3.b. El PROTEIN ORGANIZATION
Amino acid sequence data for El show that a stretch of 20 uncharged 
amino acids forms a highly hydrophobic region, immediately preceding the 
amino terminus of the protein. This sequence serves as an internal signal 
peptide sequence providing a mechanism for insertion of the newly 
synthesized molecules into the lumen of the endoplasmic reticulum (Strauss 
and Strauss, 1983). A sequence of 22 uncharged amino acids located near 
the carboxy terminus of the protein forms a transmembrane anchor region 
with 13 additional residues free on the cytoplasmic side of the membrane 
to interact with the capsid (Fig. 1.12). There are three putative N-linked 
glycosylation sites, Asn-X-Thr, within El sequence at residues 76, 177, and 
209 (Nakhasi, 1986; 1989; Zheng et al.,1989; Clark et al.,1987; Vidgren 
et al.,1987; Hobman et al.,1988; Marr et al., 1991).
I.9.3.C. EXPRESSION OF El CODING SEQUENCE.
It has been shown that the El glycoprotein carries at least three major 
epitopes (ep1-ep3). The epitopes are located close together near the middle 
region of the protein which made it possible to express the major El 
antigenic sites independently of the rest of the protein (Appendix A) (Terry 
et al., 1988). A subfragment together with the entire El coding sequenca 
were separately expressed in E. coli by fusion with the C-terminal end of S. 
aureus protein A. The S. aureus El protein was found to be antigenic In 
both cases, yet the epi epitope gave a weak reaction on ELISA which may 
be due to changes in protein conformation. El immunogenicity was also less 
active, compared to the intact virus, in boosting the levels of virus 
neutralizing antibody in experimental animals after initially priming with viral 
antigen. Although the system was successful for expressing El epitopes.
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the fusion protein would have a high-background reactivity due to the 
presence of an IgG binding site on protein A (Terry et al., 1989).
In attempts to develop a subunit vaccine, the entire El gene, including 9 
residues from its putative signal peptide, was cloned in an expression vector 
under the control of SV40 early promoter and expressed in COS cells 
(Nakhasi et al., 1986). The El gene with a deletion in its 16 NH2-terminal 
residues was also expressed under the control of the cytomegalovirus 
immediate early promoter and transfected in Vero cells (Mazancourt, 1989). 
Both expressed gene products proved to be antigenically active and similar 
to the viral antigens produced in RV-infected cells. However, the efficiency 
of production was not reported for the cloned genes.
Expression in of the El coding sequence in COS cells, under the 
control of a SV40 late promoter, using 69 residues from the C-terminus of 
E2 and preceded by an ATG initiation site from the C coding sequence was 
studied by Hobman et al., 1988. It was reported that the El product was 
antigenically similar to the native RV protein. The protein was also 
translocated into the endoplasmic reticulum. However, the El protein was 
not detected in the COS cells lysates when the El coding sequence was 
expressed without the putative signal sequence although the protein was 
detected when expressed in cell-free system, however it was not 
translocated in the presence of microsomes. This implies that rapid 
proteolysis of the untranslocated protein is the reason for not detecting the 
El protein in transfected COS cells. It also confirms that proteins which fail 
to undergo translocation can be extremely unstable in the cytoplasm 
(Gething and Sambrook, 1982; Jabbaret al., 1987; Sekikwa et al., 1983).
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1.10. EXPRESSION OF EUKARYOTIC GENES IN E. CPU
The supply of many eukaryotic polypeptides which have potential 
clinical or industrial use is often limited by their low natural availability. Gene 
cloning and expression in E. coli can provide a more productive system to 
produce antigenic proteins that can be used as vaccines or to raise or detect 
antibodies for research and diagnosis.
E. coli is the most widely used bacteria for recombinant DMA 
technology due to the development of systems for the efficient and 
controlled production of recombinant polypeptides eg. human growth 
hormones, R-endorphin and human rotavirus glycoprotein (Goeddel et al., 
1979; Shine et al., 1980; Johnson et al., 1989). Expressing foreign DMA 
sequences in E. coii requires the appropriate bacterial signals for initiating 
transcription and translation and a method for detecting clones that make 
the desired products.
1.10.1. INTRACELLULAR EXPRESSION.
Genes expressed intracellularly in £. coii, directly or as fusion proteins, 
can accumulate to high levels ranging up to 25% of total cell protein. The 
protein may be soluble but often accumulates in insoluble form as inclusion 
bodies as occurs with insulin A and B chains (Williams et al., 1982). By 
isolating these inclusion bodies from cells expressing Prochymosin it was 
demonstrated that these inclusions were predominantly composed of 
recombinant protein (Martson et al., 1984). A number of eukaryotic 
polypeptides expressed in E. coii directly eg. bovine growth hormone and 
IFN-& (George et al., 1985; Whitehorn et al., 1985) or as fusion proteins eg. 
B-globin and Myoglobin (Nagai et al., 1985; Varadarajan et al., 1985) were 
insoluble even though the authentic proteins are virtually produced in soluble
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form (Harris, 1983; Martson, 1986). Insolubility of the fusion protein can 
occur despite the fact that the eukaryotic sequence is a small proportion of 
the total protein sequence; for example 8-endorphin (31 amino acids) fused 
to S-galactosidase (Shine et al., 1980).
Chimeric fusion proteins are often synthesized very efficiently. Fusing 
a heterologous gene to a well characterized bacterial gene such as the 8- 
galactosidase (lacZ) is a common approach. The fusion protein synthesized 
Is larger than most E. coH proteins and therefore easy to identify on a protein 
gel (Casadaban et al., 1983). The fusion proteins are usually made at high 
levels and more stable than direct gene expression due to the fusion to a 
normal E.coH protein (Rose et al., 1983; Quarante, 1980).
Aggregated fusion proteins may be purified by simple cell lysis and 
centrifugation. They can be used for further studies without any 
modification. The isolation of inclusion bodies is a useful way of purifying 
insoluble proteins (Kleid et al., 1981 ; Pilancinski et al., 1984; Cabradila et 
al., 1986). Further purification methods used include immunoprécipitation 
(Liu et al., 1984), gel filtration and ion-exchange chromatography (Cabradila 
et al., 1986). Purified intact fusion proteins have been used in the 
development of vaccines for Bovine Papilloma virus (BPV) and Cholera toxin 
(Pilancinski et al., 1984; Jacob et al., 1985), in the development of 
diagnostic kits for HIV (Cabradila et al.,1986), in the development of 
antisera to identify polypeptides of Bovine Viral Diarrhoea virus (BVDV), 
herpes simplex virus type 1 (HSV-1) (Collett„,1988; Rudolph, 1990) and to 
demonstrate biological activity of the F^  portion of IgE (Liu et al., 1984).
If the eukaryotic polypeptide is required in isolation from the fusion 
protein, the strategy used is to place a protease cleavage site between the 
prokaryotic sequence and the eukaryotic sequence. Proteases such as Factor 
Xg, Trypsin or collagenase cut proteins at specific sites. This cleavage leaves
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the required protein free of the fusion partner and can be further purified by 
affinity chromatography.
1.10.2. SECRETED PROTEINS.
E. coli possesses two membranes, the outer membrane and the 
cytoplasmic membrane, which are separated by the periplasmic space. 
Proteins with signal peptides are synthesized in the cytoplasm and exported 
through the cytoplasmic membrane (Michaelis et al., 1982; Silhavy et al., 
1983). Very few proteins are secreted into the extracellular medium, across 
the outer membrane (Muller et al., 1983). Expression of genes via secretion 
offers several advantages over intracellular expression. The secreted proteins 
in the periplasm are protected from degradation; for example, proinsulin 
located in the periplasm is 10-fold more stable than when located in the 
cytoplasm (Talmadge et al., 1982). Folded eukaryotic proteins with correct 
disulphide bonds can occur, as in proinsulin. However, the level of 
expression compared to intracellular expression is very low, comprising only 
0.01% of total cell protein (Emericket al., 1985; Marston, 1986). Secretion 
of eukaryotic polypeptides can also prove toxic to E. coii, causing cell lysis 
as in 8-lactamase-proinsulin fusions (Brosius, 1984).
Recombinant eukaryotic polypeptides synthesized in E. coii can differ 
from their authentic counterparts. It is believed that there are a number of 
eukaryotic post-translational modifications of polypeptides which £. co//does 
not perform. These include glycosylation, acétylation and amidation 
(Martson, 1986).
£. coii does not posses the enzymes necessary for glycosylating 
polypeptides. There are however documented examples of recombinant 
proteins synthesized in £. coii which are biologically active despite the fact
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that they are not glycosylated. These include IFN-S and IFN-delta (Simons, 
1985; Edge and Gamble, 1984). These results demonstrate that 
carbohydrate residues are not essential for biological activity of some 
proteins.
1.11. EXPRESSION IN MAMMALIAN CELLS.
As discussed previously, E. coli has been used extensively for 
heterologous gene expression regardless whether the gene is of prokaryotic 
or eukaryotic origin. Post-translational modifications which are not 
performed by £. coii, such as glycosylation, acétylation and phosphorylation 
may only be performed correctly by eukaryotic cells (Johnson, 1983; 
Rosner, 1986; Kingsman et al., 1988). The host cell can also recognize 
localization signals within the expressed protein and will correctly transport 
it to the nucleus, cell surface, extracellular medium, etc. (Cullen, 1987).
Shuttle vectors used for mammalian cell transfections should be 
capable of replicating in both prokaryotic and eukaryotic cells. Such vectors 
normally consist of hybrid DNA sequences containing eukaryotic, viral, and 
prokaryotic control elements (Rigby, 1982 and 1983; Miller et al., 1987; 
Sanders, 1990). Prokaryotic elements are bacterial origin of replication and 
antibiotic resistance gene, while eukaryotic elements include translation 
initiation and translation termination signals, a eukaryotic 
promoter/enhancer, origin of replication, drug marker, polyadenylation site 
and cloning sites.
Eukaryotic expression vectors when transfected into mammalian cells 
can exist as either an episome if it has its own origin of replication or it can 
integrate into the genome. This may lead to gene rearrangements or 
expression may be repressed by its position into the cell chromatin (Sanders, 
1990).
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Transfection of DNA into mammalian cells is performed using 
chemicals such as DEAE-dextran with dimethyl sulphoxide (Stow and Wilkie, 
1978; McCutchan et al, 1968) or calcium phosphate precipitation 
(Sompayrac et aL,1981). Chemical methods of transfection can transform 
up to 50% of the cells, while using a physical method such as microinjection 
of the DNA in the nucleus can achieve up to 100% transformed cells 
(Capecchi, 1980). Electroporation, the application of high-voltage electric 
pulses to cells, can facilitate DNA uptake by transiently making pores in the 
cell membrane through which the DNA can electrophorese Into the cell 
(Neumann et al,1982; Potter et al, 1984; Stopper et al, 1988). This 
technique is particularly useful for transfecting suspension cell cultures.
COS cell lines are used as a transient expression system to test 
vectors as they rapidly give high levels of synthesis the required protein 
when a replication deficient SV40 genome is used to transform the cells 
(Gluzman, 1981). An early gene product, T-antigen, is required in order to 
replicate SV40 viruses. CV-1 monkey cells have been engineered to express 
either the wild type or a temperature-sensitive T-antigen (Gluzman, 1981 ; 
Weymouth et al, 1986). This produced COS cells which allow recombinant 
SV40 vectors, lacking the ability to produce their own T-antigen, to replicate 
to a very high copy number. These COS cells can therefore produce large 
amounts of heterologous proteins from genes carried in SV40-based vectors. 
The cells become so full of viral genomes (up to 200 000 molecules per cell) 
that the cells cannot survive for more than 2 weeks. Once a gene is 
expressed in this transient system it can be transfected into selected stable 
cell lines preparing for large scale production. Cells that are used for 
producing stable recombinant cell lines include Chinese hamster ovary 
(CHO), baby hamster kidney cells (BHK), mouse L-cells and Cl 27 cells 
(Sanders, 1990).
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Specific viral antigens expressed from transfected genes in 
mammalian cells may be used to generate new viral vaccines based on 
subunit antigens. This technology has been applied to the hepatitis B surface
antigen genes which were expressed in different cell lines (Statewa et al.,
herpes
1982; Siddiqui, 1983). Other viral antigens being expressed include,,simplex 
virus (HSV) glycoprotein D (Lasky et al., 1984) and HIV envelope proteins 
(Brunt 1987).
Expression in mammalian cell lines is mainly used for production of 
proteins of therapeutic use in humans or animals, such as the production of 
human interferon-8 (Zinn et al., 1982; Mitrani-Rosenbaum et al., 1983) or 
growth hormones (Ramabhadran et al., 1985). Mammalian cells also allow 
studies of protein processing, cellular physiology and developing gene 
therapy to correct genetic defects in animals and humans.
1.12. RECOMBINANT RUBELLA ANTIGENS.
Immunoassay kits for the detection of rubella IgM are expensive. This 
is partly due to relatively poor growth of the virus leading to inefficient RV 
antigen production which is costly and labour intensive. In the United 
Kingdom over 600,000 tests are performed annually to assess the level of 
antibodies to rubella virus. Variations in the quality of different batches of 
antigen may also contribute to occasional false positive results (Gould, 
1980; Ho-Terry, 1982), which could be partially responsible for the high rate 
of re-infections in individuals with vaccine induced rather than natural 
immunity to rubella (Meyer 1969, and Plotkin, 1969). Therefore there is a 
need for rubella antigen preparations which could eliminate the problem of 
batch variation. Improved production may be achieved by developing a 
recombinant subunit antigen, which can be produced in large amounts, is
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cost effective to prepare and can be easily stored and handled in countries 
outside the cold chain.
A serious concern of the current rubella vaccination programme is the 
risk to the fetus in mothers who are vaccinated during pregnancy, although 
evidence of fetal infection has not yet been reported, pregnancy remains a 
contraindication to rubella vaccination (Bart et al., 1985; Sheppard et al, 
1986). Ideally, rubella vaccines should be non-teratogenic and should not 
contain live virus which when given inadvertently to pregnant women, 
would replicate in the fetal tissues. For these reasons it is desirable to 
pursue the development of a subunit vaccine.
Structural genes of several rubella virus strains have been 
characterized and they all revealed sequence mutations. In this study the 
U.K. rubella virus isolate "Thomas strain" Is been studied. Other strains, 
isolates from U.S.A., Japan and Australia have been studied by others. The 
Thomas strain was obtained from a throat swab from a baby born with 
congenital rubella syndrome. The strain is closely related to the wild type 
virus, it has been passaged twice in rabbit kidney cells, once in African 
green monkey kidney cells (vero cells), twice in baby hamster kidney cells 
(BHK) and plaque purified three times and then grown up in vero cells. It is 
of interest to study the geographical variation between RV strains.
Since the El and E2 glycoproteins were identified as the sites where 
the antigenic domains, of RV, are present (sections 1.9.2.b and 1.9.3.a) it 
is of importance to produce large amounts of the proteins to be used as 
antigens in screening for anti-rubella antibodies in RV-infected individuals. 
Expression of foreign DNA sequences in E. coli is a rapid and economical 
method where gram amounts of proteins can be produced per litre (Harris 
and Emtage, 1986). Attempts were made to express subfragments of El 
directly but no protein was detected when pUC13 was used as an
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expression vector in E. coli. It was then decided to produce a more stablé 
protein of El by fusion to 8-galactosidase. The protein was produced in 
inclusion bodies. Production of recombinant proteins aggregated in inclusion 
bodies is useful for purposes of purification. Inclusion bodies are dense and 
sediment readily with low speed centrifugation. The purified proteins were 
proved to be antigenic and could be used in immunoassay kits (Section 
1.10.1).
However, since E. coii postranslation processing for eukaryotic 
proteins is unlike mammalian cell processing, and due to the requirement of 
authentic proteins for use as vaccines, El and E2 were expressed in 
mammalian COS cells. Expression in mammalian cells also facilitates studies 
on protein characterization and processing in its authentic form.
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CHAPTER 2
CHAPTER 2 
MATERIALS AND METHODS
A. MATERIALS
2.1. MAMMALIAN CELL-LINES.
COS-1:
Monkey CV-1 cells transformed with SV40 DNA containing a 6bp deletion 
in the origin of replication (ORI) which prevents replication of the viral DNA 
(Gluzman, 1981). Obtained from Celltech Ltd. (Slough, UK).
2.2. BACTERIAL CELL STRAINS.
ESCHERICHIA CO/./strain HB101\ F , proA2, recA, hsdR, hsdM (Boyer and 
Roulland-Dusoix, 1969). Obtained from MGL, University of Surrey, UK.
ESCHERICHIA COUsXXB\n JM109: RecAl, hsdR17, endAI, supE44, relAI, 
F , traD36, lacP, lacZ. Obtained from Pharmacia Ltd. (Uppsala, Sweden).
ESCHERICHIA COL! strain DH5a F, endAI, hsdR17, supE44, recAl, 
gyrA96, relAI, thi-1. Obtained from BRL Inc.
ESCHERICHIA COZ./strain M C I061: Rec+, araD139, X74, galU , galK*, hsr , 
hsm‘, strA, McrA', McrB' (Amersham).
ESCHERICHIA COZ./strain 866: RecAl, recBC (obtained from K. Willwand, 
Swiss).
VIRUS STRAIN. (Section 1.12). _
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2.3 VECTORS.
nEE6.HCMV.aDt 1 (dUSIOQO).
Plasmid pEEB.gpt contains an SV40 origin of replication supplied by 
an SV40 early promotor region driving transcription of xanthine-guanine 
phosphoribosyl transferase gene (gpt) from pSV2gpt (Whittle at al., 1987). 
The vector was based on pEE6 which supplied a bacterial ampicillin resistant 
marker and a bacterial origin of replication, permitting the selection and 
propagation of the vector on bacterial hosts. pEE6 is based on the plasmid 
pBR328 a derivative of plasmid pBR322. It contains the XmnI to Bell 
fragment of plasmid pCT54, a polylinker from pSP64 (Mulligan and 
Berg, 1981) with the BamHI and Sail sites deleted, and a polyadenylation 
signal, AATAAA (Wickens and Stephenson, 1984). The plasmid also 
contains the strong promoter/enhancer transcriptional control element from 
the human cytomegalovirus (HCMV) (Boshart et al., 1985) inserted into a 
unique Hindlll upstream of the EcoRI site. Modified from a vector obtained 
from Celltech Ltd. (Slough, UK) (Fig 2.1.).
PUEX1.
PUEX plasmid contains a truncated lacZ gene which produces an 
enzymatically active fragment and allows any gene to be fused to the 3' end 
of the lacZ gene (Casadaban et al., 1980; Quarante et al., 1980). The 
plasmid also contains a coding sequence for the first 9 amino acids of the 
cro gene of bacteriophage lambda fused to the lacZ gene. Expression of the 
hybrid gene cro-lacZ is controlled by the P, promoter of bacteriophage 
lambda (Zabeau and Stanley, 1982). Gene expression is controlled by the 
c/857 repressor gene, whose protein product switches off the Pr promoter. 
The crc-8-galactosidase hybrid proteins precipitate inside the cell and are 
partially protected from proteolysis (Stanley and Luzio, 1984). The plasmid 
carries a 8-lactamase gene which confers ampicillin resistance on the host. 
There are two related vectors, pUEX2 and pUEX3 designed to complement
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Figure 2.1 pEE6.hcmv.gpt, pUSIOOO
PA
gpt
MCS
hcmvy
Ss
H
Amp
MCS = Multiple cloning site 5’-Hindlll-Xbal-Clal-Smal-Sstl-EcoRI-3’
E = EcoRI H = Hindlll B = BamHI Ss = SstI
hcmv = Human cytomegalovirus promotor/enhancer 
-►  « Direction of transcription 
PA « Poly-A addition site 
gpt = gpt expression cassette
Amp » Ampicillin resistence marker 
cri *  origin of replication
pUEXI by providing multiple cloning sites in different reading frames/so that 
together the three plasmids cover all three possible reading frames. Obtained 
from Amersham (Fig. 2.2.).
2.4 MEDIA.
2.4.1 CELL CULTURE MEDIA.
All tissue culture reagents were obtained from Gibco BRL (Paisley, Scotland). 
DMEM.
Dulbecco's modified Eagle's basal medium (DMEM) containing 2mM 
glutamine, 18mM sodium bicarbonate and 10% (v/v) heat inactivated foetal 
calf serum (PCS).
2.4.2 MICROBIAL GROWTH MEDIA.
LB-Aoar.
lOg tryptone, 5g yeast extract, lOg sodium chloride and 15g Bacto-agar. 
Made up to 1 litre with distilled water and autoclaved.
LB-Broth.
lOg tryptone, 5g yeast extract and lOg sodium chloride. Made up to 1 litre 
with distilled water and autoclaved.
H top aaar.
lOg bacto tryptone, 8g NaCI and 12g agar. Made up to 1 litre with distilled 
water and autoclaved.
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2X TY medium.
16g bacto tryptone, lOg yeast extract and 5g NaCI. Made up to 1 litre with 
distilled water and autoclaved.
2X TY aaar.
2X TY medium plus 15g agar per 1 litre.
S.O.C. medium.
Reagents
Bactotryptone
Yeast extract
NaCI
KOI
MgClg, MgSO^ 
Glucose
Amount/100ml
2.0g
0.5g
1 mi of 1M stock sol. 
0.25ml of 1M stock 
1ml of 2M Mg stock 
1 ml of 2M stock
Final conc. 
2%
0.5%
lOmM
2.5mM
20mM
20mM
Made up to 100ml with distilled water and autoclaved.
X-GAL/IPTG Aaar.
LB-agar containing; lOOul ampicillin (lOOug/ml final conc.), lOOul X-Gal 
(20mg/ml) and 50ul IPTG (lOOmM), dissolved in 100ml molten agar.
Antibiotics.
Ampicillin was made 10Omg/ml stock solution in sterile water. The amount 
required was added immediately prior to use after cooling the media to 
approximately 50°C.
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2.5 BUFFERS AND SOLUTIONS.
Acrvlamide stock solution.
Acrylamide/ Bisacrylamide 30:0.8. Solution made up in deionized distilled 
water and stored in a dark glass bottle at 4°C.
Buffered phenol.
Phenol (BRL) is usually stored frozen at -20°C. As needed it is melted in 55- 
68°C waterbath. 1M Tris-HCI buffer pH 8.0 is mixed (1:1) with the melted 
phenol. 8-Hydroxyquiniline is then added to a final concentration of 0.1 %. 
This compound is an antioxidant, a partial inhibitor of RNase and a weak 
chelator of metal ions. In addition it gives a yellow colour which provides 
a convenient way to identify the phase.
Coomassie Brilliant Blue stain for PAGE.
0.1% Coomassie Brilliant Blue (BDH) dissolved in a solution of water, 
methanol and glacial acetic acid in a ratio of 5:5:2.
Denaturing solution for DIMA.
0.5M NaOH and 1.5M NaCI made up in deionized distilled water and 
autoclaved.
100X Denhardt's solution.
2% (w/v) Ficoll 400, 2% (w/v) PVP (Polyvinylpyrollidone) (Mwt 40,000) and 
2% (w/v) BSA dissolved in sterile deionized water and dispensed into 
aliquots before storing at -20°C.
DNA loading buffer.
0.25% (w/v) Bromophenol blue, 0.25% (w/v) Xylene Cyanol and 40%  (w/v) 
sucrose dissolved in deionized distilled water.
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Electroblottino buffer for western blotting.
Reagent amount/litre Final conc.
Tris-HCI 3.03gm 0.025M pH8.3
Glycine 14.4gm 0.19M
Methanol 200mls 20%
Liaation buffer.
T4 DNA ligase was purchased from Gibco BRL and included a prepared 5X 
ligation buffer. The buffer was used as recommended by the manufacturer.
Loading buffer for SDS/PAGE.
5% 2-Mercaptoethanol, 2% SDS, 10% glycerol or sucrose and 0.002%  
Bromophenol blue made up in deionized distilled water.
Neutralizing solution
1.5M NaCI, 0.5M Tris-HCI, pH 7.2, and 0.001 NagEDTA made up in 
deionized distilled water.
IPX Nick translation buffer.
500mM Tris-HCI, pH 7.2, lOOmM MgSO^, ImM Dithiothretol (DTT) and 
500ug/ml bovine serum albumin (BSA). Made up in deionized distilled water 
and filter sterilized.
PEG/SM buffer.
200g Polyethelene glycol 6000 (PEG) (Sigma) and 116.9g NaCI made up to 
one litre in SM buffer and autoclaved.
Phosphate buffer.
18.75mls of 2M NagHPO ,^ 31.25mls of 2M NaHgPO  ^and 50mls deionized 
distilled water.
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Reaction buffers.
Enzymes were purchased from BRL. Appropriate restriction buffers were 
provided at lOX concentration and were used as recommended by the 
manufacturers. The composition of the four commonly used buffers are 
shown below:
Reagent
Tris-HCI, pH7.4
Tris-HCI, pHS.O
MgClg
NaCI
KCI
Reacti
50mM
lOmM
React2
50mM
lOmM
50mM
Reacts
50mM
lOmM
lOOmM
React4
20mM
5mM
50mM
RIPA Ivsis buffer.
150mM NaCI, 1.0% Nonidet-P 40, 0.5% DOC, 0.1 % SOS, and 50mM Tris, 
pH.8.0 made up in deionized distilled water.
RNA loading buffer.
50% glycerol, 1 mM EDTA, 0.4% bromophenol blue and 0.4% xylene cyanol 
made up in deionized distilled water.
SDS/PAGE destaining buffer.
30% methanol and 10% acetic acid in distilled water.
5X SDS/PAGE elecroblotting buffer
139.6g glycine, 5g SDS and 15.15g Tris made up in distilled water and 
diluted to IX  for use.
SM buffer.
200mM NaCI, ImM MgS04.7H20, 0.01 % Gelatine and 50mM Tris-HCI, 
pH7.5 in deionized distilled water and autoclaved.
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2QX SSPE buffer.
3.6M NaCI/20mM EDTA and 0.2M NaHgPO/NaHPO^, pH7.7 in deionized 
distilled water and autoclaved.
20X SSC.
3M Sodium chloride and 0.3M Sodium citrate in deionized distilled water. PH 
adjusted to 7.0 before autoclaving.
Sodium Acetate.
3M Na Acetate, pH adjusted to 5.2 with Glacial Acetic acid.
IX  TBS buffer.
50mM Tris-HCI, pH 7.5, and 150mM NaCI in deionized distilled water. 
1XTBST buffer.
0.05% Tween 20 in TBS buffer.
TE buffer.
lOmM Trizma base and 1 mM EDTA in deionized distilled water, pH adjusted 
to 8.0 with HCI, and autoclaved.
IPX Tris Borate running buffer (TBE).
108g Tris base, 55g Boric acid and 9.3g NagEDTA made up to one litre in 
deionized distilled water and pH adjusted to 8.0 with HCI. This buffer is 
usually diluted to IX  when used for electrophoresis.
BOX Tris Acetate running buffer (TAE).
242g Tris, 57.1 mis glacial acetic acid and 2mM EDTA made up to one litre. 
The buffer is diluted to IX  upon use.
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2.6 SUPPLIERS.
Materials were obtained from the following sources unless otherwise 
specified in the text.
BACTERIAL GROWTH MEDIA.
Oxoid Ltd. (Basingstoke, UK).
CHEMICALS.
BDH Ltd. (Poole, UK), May and Baker Ltd. (UK), Koch Light Laboratories and 
Boehringer Mannheim Ltd. (BCD (Lewes, UK).
ENZYMES AND FINE CHEMICALS.
Gibco BRL Ltd. (Paisley, Scotland), Northumbria Biological Laboratories, 
Stratech Scientific Ltd, New England Biolabs, Pharmacia and Sigma Ltd. 
(UK).
PLASTICS.
Flow Laboratories Ltd. (Rickmansworth, UK), Imperial Laboratories Ltd. 
(Andover, UK), Nunc, Gibco BRL Ltd. (Paisley, Scotland) and Sterilin Ltd.
RADIOCHEMICALS AND MATERIALS.
Amersham International Ltd. (Amersham, UK).
TISSUE CULTURE MEDIA AND REAGENTS.
Gibco BRL Ltd (recently known as Life Sciences Inc). (Paisley, Scotland). 
FILMS.
Fuji and Polaroid.
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B. METHODS
Unless otherwise stated, buffers and solutions used are described in 
BUFFERS AND SOLUTIONS.
2 7 ANIMAL CELL CULTURE TECHNIQUES.
2.7.1 CELL CULTURE.
Reagents.
1. DMEM media.
2. Foetal calf serum.
3. Phosphate buffered saline: 170mM sodium chloride, 3.4mM  
potassium chloride, 1mM sodium hydrogen phosphate and 2mM 
potassium hydrogen phosphate; made up in distilled water and the pH 
adjusted to 7.2.
4. Trypsin EDTA (T/V): 0.05% (w/v) trypsin (Gibco, BRL Ltd.) in PBS 
and ImM EDTA.
Anchorage dependent cells (COS-1).
COS-1 cells were grown as monolayers in tissue culture flasks in DMEM 
with heat inactivated foetal calf serum (PCS) at 5 or 10% (v/v). Cells were 
subcultured when the growth was confluent by:
(i) rinsing the cell monolayer with PBS.
(ii) Incubating in trypsin/EDTA solution until the cells detached.
(iii) sedimenting the cells by centrifugation (80g/5 minutes).
(iv) diluting the cells 1:5 in fresh medium.
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2.7.2 FROZEN CELL STOCKS.
Freezing medium:
A sterile solution of DMEM growth medium with 20% FCS (v/v) and 
10%DMS0.
The cells were sedimented by centrifugation (80g/5 minutes) and 
resuspended in freezing medium at 5 to 10 x 10® cells/ml. 1ml aliquots of 
this suspension were pipetted into ampoules, placed inside a polystyrene 
box and frozen at -70°C for 4 to 24 hours. The ampoules were then stored 
at-196°C under liquid nitrogen.
To recover cells from liquid nitrogen storage, an ampoule was thawed 
rapidly and the cell suspension diluted with 10ml growth medium. Cells 
were sedimented by centrifugation (80g/5 minutes), and the supernatant 
discarded. The cell pellet was resuspended in 10ml of fresh growth medium 
(containing 10% (v/v) FCS), transferred to a tissue culture flask, and 
incubated at 37°C with an overlay atmosphere of 5% carbon dioxide in air.
2.7.3 CELL COUNTING AND VIABILITY.
Cell counts were determined by diluting aliquots of cells in Trypan Blue 
and counting using a Fuchs-Rosenthal Haemocytometer. Exclusion of the 
dye was taken as an indication of cell viability. Cells with an intact cell 
membrane were impermeable to the dye and were considered to be viable. 
Cells, however, with a 'leaky' cell membrane incorporated the dye and were 
considered to be non-viable. The cell viability was calculated from the 
following equation;
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% VIABILITY = (V/T) x 100
where; V = viable cells/ml 
T = total cells/ml
2.7.6 DEAE-DEXTRAN MEDIATED TRANSFECTION OF COS-1 CELLS.
COS-1 cells were transformed with plasmid DNA using DEAE dextran. In this 
method a DEAE dextran/DNA co-precipitate is formed, which is then taken 
up into the cell.
Reagents.
Sterile solutions of:
1. DNA dissolved in lOOmM sodium chloride, lOmM Tris-HCI (pH7.5) to 
give 500ng/35mm^ plate.
2. IX  PBS.
3. DEAE-dextran (Mwt 500,000) (Sigma Ltd.) lOmg/ml in PBS.
4. 80mM chloroquine (Sigma Ltd.).
5. DMSO (Gibco BRL Ltd.).
Protocol.
Cells were seeded in 35mm 6 well Costar plates at 3 x 10® cells per 
plate. The cells were incubated for until the cell monolayer was 
subconfluent. The transfection mixture was prepared in a sterile 
microcentrifuge tube by resuspending sterile supercoiled plasmid DNA in PBS 
(190ul final volume) using a vortex mixer, and then adding lOul DEAE- 
dextran solution.
Culture medium was aspirated from the COS-1 cells and the cell sheet 
rinsed with PBS pre-warmed to 37°C. The PBS was aspirated and the
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transformation mixture distributed evenly over the cell monolayer. The plate 
was incubated at 37°C for 30 minutes with gentle shaking to prevent drying. 
2ml of growth medium supplemented with 80uM chloroquine was added 
and the plate re-incubated for 3 hours. The medium was then aspirated and 
replaced with 1 ml of medium containing 10% DMSO (v/v) for 2.5 minutes. 
This was removed and 4 ml of culture medium added. The cells were 
incubated at 37°C in an atmosphere of 5% carbon dioxide (v/v) in air and 
analysed 48 to 72 hours post-transfection.
2.7.7 RADIOLABELLING OF COS-1 CELLS PROTEINS.
Culture medium was aspirated from the COS-1 cells and the cell sheet 
was rinsed with prewarmed methionine-free medium, and 0.25 ml of the 
same medium was added to the cells/well. [®®S] methionine was added 
50//ci/well and the cells were incubated 2-4 hrs at 37°C 5% COg incubator. 
Cells were washed with PBS and harvested for further analysis.
Cells could be lysed by addition of RIPA lysis buffer directly on the plate 
and incubated on ice for 30 minutes with occasional rocking. The lysate 
was transferred to microcentrifuge tube and spun at 10,000rpm for 10 
minutes at 4°C.
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2.8 MOLECULAR BIOLOGY TECHNIQUES.
2.8.1 MAINTENANCE OF ESCHERICHIA COL/STRAINS.
Escherichia coii cultures were maintained on LB-agar plates, with 
antibiotics if appropriate, and subcultured every 6 to 8 weeks. For the long 
term storage of bacteria they were frozen at -70“C in LB-broth containing 
15% glycerol.
2.8.2 NUCLEOTIDE EXTRACTION METHODS.
A. EXTRACTION OF CYTOPLASMIC RNA FROM EUKARYOTIC CELLS. 
- Vanadvl-Ribonucleoside Complexes (VRC) method.
RNA was isolated from mammalian cells using a modification of the 
method described by Sanders and Wilson, (1984). Precautions were taken 
throughoutto minimise ribonuclease activity by using vanadyl-ribonucleoside 
complexes, a strong RNase inhibitor, during the initial stages of extraction, 
and by treating glassware overnight in a 0.1% (v/v) diethyl-pyrocarbonate 
solution (Sigma Ltd.), and by wearing disposable gloves throughout the 
procedures.
Reagents.
1. PBS.
2. Vanadyl-ribonucleoside complexes (200mM) (BRL Ltd.).
3. Lysis buffer: 0.14M sodium chloride, 1.5mM magnesium chloride, 
lOmM Tris-HCI (pH8.6) and 0.5% (v/v) Nonidet-P 40 (Sigma Ltd.).
4. TSE: 0.2M Tris-HCI (pH7.5), 25mM EDTA, 0.3M sodium chloride, 
2% (w/v) SDS.
5. Phenol/chloroform: Distilled phenol (BRL Ltd.) and chloroform (BDH 
Ltd.) mixed 1:1 (v/v).
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Protocol. ,
A cell pellet was obtained of 5 to 10 x 10^ cells/ml for suspension cells 
by centrifuging a liquid culture at 80g for 5 minutes, or for anchorage- 
dependent cells by removing the cell monolayer with trypsin-EDTA (T/V) and 
subsequent centrifugation. Pellets were washed twice in cold PBS and held 
on ice. Cells were lysed by adding 0.5ml vanadyl ribonucleoside complexes 
(VRC) directly to the pellet and resuspending in 4.5ml lysis buffer. The 
lysate was centrifuged (1630g/3 minutes) to sediment the nuclei and the 
supernatant containing the cytoplasm decanted into a 50ml oakridge tube 
containing 5ml TSE, 10ml distilled water and 15ml phenol/chloroform and 
mixed. The nuclear pellet was held in ice and used if required for DNA 
extraction.
RNA samples were gently inverted on a rotating wheel for 30 to 50 
minutes, centrifuged (1630g/15 minutes), and the top aqueous layer 
transferred to a clean oakridge tube. A phenol/chloroform extraction was 
performed by adding an equal volume of phenol/chloroform to the sample 
and gently mixing by inverting on a rotating wheel for 15 to 30 minutes. 
Samples were centrifuged (1630g/15 minutes) and the aqueous layer 
decanted. A further phenol/chloroform extraction was performed. 2.5 
volumes of ice cold analar ethanol was added to the final aqueous phase, 
mixed, and the sample incubated at -70°C for a minimum of 4 hours to 
precipitate the RNA. Precipitated RNA was pelleted by centrifugation at 4°C 
(12,000g/15 minutes). The pellet was washed with 70% ethanol and air 
dried. RNA was resuspended in lOOul distilled water and stored at -70°C.
- RNAzol method.
RNAzol is supplied by (Biogenesis Ltd.). The method is based on the 
formation of complexes of RNA with guanidinium and water molecules, and 
abolishes hydrophillic interactions of DNA and proteins.
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Reagents.
1. RNAzol solution.
2. Chloroform.
3. Isopropanol.
4. 75% Ethanol.
Protocol.
The culture sample is homogenized with RNAzol 2ml/100mg (0.2ml/10® 
cells). Solubilization is aided by passing the lysate few times through the 
pipette. Chloroform is added, 0.2ml/2ml of homogenate and the solution 
incubated on ice for 5 minutes followed by centrifugation at 12,000rpm for 
15 minutes. Aqueous phase is transferred to a fresh tube and the RNA 
precipitated by the addition of an equal volume of isopropanol and stored at 
4°C  for 15 minutes. RNA is pelleted by centrifuge at 12,000rpm for 15 
minutes. The RNA pellet is washed with 75% ethanol and dried under 
vacuum for 10-15 minutes. The pellet is resuspended in sterile deionized 
water.
B. RNA EXTRACTION FROM E. coli.
Solutions.
Lysis buffer:
1 % SDS
0.2M Tris-HCI, pH 7.5
0.2M NaCI 
40mM EDTA 
Buffered phenol
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Protocol.
The lysis buffer and the phenol are preheated to 64°C. After induction 
of e.g. 30ml the culture is centrifuged for 5 minutes at 4°C up to BOOOrpm. 
The cells are resuspended in 2ml of sterile deionized water and 2ml of lysis 
buffer sitting in a boiling waterbath. After 1-2 minutes equal volume of 
phenol is added and mixture is vortexed 2-3 minutes, cooled and spun for 
5 minutes, 5000 rpm, at 4°C. The top layer is collected and re-extracted 
with cold phenol. The top layers are combined and 2 volumes of ethanol is 
added and precipitated at -70°C overnight. Centrifugation is carried out for 
20 minutes at 1 BOOOrpm at 4°C. The pellet is dissolved in sterile deionized 
distilled water. The RNA now is ready for quantitation.
0. RNA EXTRACTION FROM VIRUS.
Reagents.
1. Guanidinium Thiocyanate Solution:
Dissolve 50g Gu-thiocyanate and 0.5g n-lauryl sarcosine in 30ml sterile 
distilled water. Heat and stir to dissolve. Add 2.5ml 1M Sodium citrate 
buffer pH 7.0. Adjust pH of solution to 7.0 with few drops of 10M NaOH. 
Add 0.7ml of 2-mercaptoethanol and make up the solution to 100ml with 
sterile distilled water. Filter sterile and keep for two weeks only.
2. Guanidine Hydrochloride Solution:
Dissolve 72g Gu-hydrochloride in 36ml sterile distilled water, heat and stir 
to dissolve. The pH should be 4.5. Add 2.5ml 1M sodium citrate buffer (pH 
7.0). Add 5ml of 0.1M 2-mercaptoethanol. Adjust pH to 7.0 and make up 
to 100ml with sterile distilled water. Keep for 1 month only.
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3. 7.5 Caesium Chloride Solution:
Dissolve 63g Caesium chloride in 49ml sterile distilled water and add 1.25ml 
Sodium acetate pH5.
4. 1M Sodium Citrate Buffer pH7.0:
98ml of 1M Sodium citrate (or tri-Sodium citrate) and 2ml of 1M 
Hydrochloric acid (or 1M citric acid). Adjust pH to 7.0.
Protocol.
The virus pellet was washed with PBS and resuspended in 18ml 
Guanidinium thiocyanate buffer. 3ml of 7.5M CsCI and 25mM Sodium 
Acetate were placed in the bottom of a Beckman ultracentrifuge tube. 9ml 
of Gu-thiocayanate treated virus was layered onto the CsCI cushion and 
centrifuge for at least 15hrs at 30K. RNA is pelleted at the bottom of the 
tube. Just above the pellet is a viscous layer of DNA and above that the 
CsCI interphase.
The DNA and CsCI were aspirated with a pasteur and cut off the bottom 
of the tube with a scalpel. The pellet was resuspended in 400ul sterile 
distilled water and heated for 5 minutes at 65°C. 2.6ml Guanidine 
hydrochloride solution was added, mixed by vigorous shaking, and warmed 
briefly at 68°C to insure complete dispersion. 75ul Sodium acetate and 
1.5ml ethanol were added and the mixture was incubated for minimum of 
3hrs at -20°C at 15 minutes in dry ice bath to precipitate RNA. Centrifuge 
at 10,000rpm for 10 minutes and the pellet was resuspended in 2.5ml 
sterile distilled water. The centrifugation step was repeated. The pellet was 
resuspended in another 2.5ml water with another centrifugation step. Both 
supernatants were combined and 1/10 vol. 3M Sodium Acetate pH 4.5 and 
2 vol. cold ethanol were added and precipitated 15 minutes in dry ice bath. 
Centrifuge at 10,000rpm for 20 minutes. The pellet was dissolved in the 
required volume of sterile distilled water. O.D. was measured.
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Quantification of RNA.
The RNA concentration was calculated spectrophotometrically by 
measuring the absorption at 260nm. An optical density (OD) of 1 at 260nm 
is equivalent to an RNA concentration of 40ug/ml, therefore;
RNA concentration = (ODggg x 40 x dilution) ug/ml
An indication of the quality of the RNA was obtained by measuring the 
absorbance at 280, 260 and 230nm. A pure RNA preparation has an OD 
260:230 ratio of around 2.3, and an OD 260:280 ratio of around 2.
D. DNA EXTRACTION FROM EUCARYOTIC CELLS.
High molecular weight DNA was isolated from mammalian cells 
essentially as described by Maniatis era/., (1982).
Reagents.
1. PBS.
2. NTE: TE (lOmM Tris-HCI (pH8) and ImM EDTA) containing 0.5%
(v/v) Nonidet-P 40 (NR 40).
3. Lysis buffer: 50mM Tris-HCI (pH7.2), 5mM EDTA, 1.5% (w/v) SDS.
4. Phenol (pH8): Distilled phenol saturated with 1M Tris-HCL pH 8.0.
Protocol.
A cell pellet of 5 to 10x10^  cells/ml was obtained as described above 
in the RNA extraction protocol. Pellets were washed twice in PBS and 
resuspended in 10ml NTE and left on ice for 5 minutes. The nuclei were 
then sedimented by centrifuging at 4°C (1630g/5 minutes). Alternatively, if 
an RNA extraction was being performed on the same cells, the nuclear pellet 
was obtained after the cells had been lysed with vanadyl ribonucleoside 
complexes and RNA lysis buffer.
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Nuclei were lysed by adding 10ml lysis buffer and pipetting up and down 
a 10ml plastic pipette 5 times. Samples were incubated at 37°C for 1 hour 
with DNase-free RNase (50ug/ml) (BRL Ltd.), and then at 55°C for 4 hours 
with Proteinase K (50ug/ml) (Sigma Ltd.). A phenol extraction was 
performed by adding an equal volume of phenol (pH8) to the sample and 
gently inverting on a rotating wheel for 1 to 2 hours. Phenol resistant 50ml 
oakridge tubes were used throughout the extraction procedures. Samples 
were centrifuged (1630g/15 minutes) and the top aqueous layers removed 
using a wide bore pipette. A second phenol extraction was performed and 
the samples were then mixed with an equal volume of chloroform and 
centrifuged as before.
Two volumes of ice cold analar ethanol were added to the final aqueous 
phase and samples incubated at -20°C for 1 hour to precipitate the DNA. 
DNA was pelleted by centrifugation at 4°C (12,000g/30 minutes), washed 
with 70% ethanol, dried, and resuspended in lOOul TE. Samples were 
stored at 4°C. The DNA concentration and an estimate of the DNA quality 
was determined spectrophotometrically.
E. SMALL-SCALE EXTRACTION OF PLASMID DNA FROM E.COU.
Plasmid DNA was isolated on a small-scale from bacterial cultures using 
two procedures described by (Maniatis et aL, 1982; Holmes and Quingley, 
1981).
Boiling method.
Reagents.
1. STET: 50mM EDTA (pH8.0), lOmM Tris-HCI (pH8.0), 8% (v/v)
sucrose, 0.5% (v/v) triton X-100 (BDH Ltd.).
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2. Lysozyme: (Sigma Ltd.) 10mg/ml in lOmM Tris-HCI (pH8.0).
3. TE buffer: lOmM Tris-HCL (pH8.0) and ImM EDTA.
Protocol.
A single colony of the culture of interest was inoculated into 2ml of LB- 
broth containing the appropriate antibiotic for selection. The culture was 
grown overnight in a 37°C shaking incubator. 1ml of the culture was 
transferred into a microcentrifuge tube and centrifuged (10,000g/5 minutes) 
to pellet the cells. The supernatant was discarded and the pellet 
resuspended in 10Oul of STET. Cells were lysed by adding 10ui of lysosyme 
solution, mixing using a vortex mixer, and boiling for 40 seconds. The lysate 
was centrifuged (12,000g/15 minutes) and the supernatant decanted and 
mixed with an equal volume of propan-2-ol. Samples were incubated at - 
70°C for 20 minutes and then centrifuged at 4°C (12,000g/15 minutes) to 
sediment the precipitated DNA. The DNA pellet was washed with 70%  
ethanol, dried, and then resuspended in 30ul TE buffer.
Alternatively another method was used for minipreparation of plasmid DNA: 
Alkaline Ivsis method. (Birnboim and Doly, 1979).
Reagents required:
(I) Solution I.
50mM Glucose, lOmM EDTA pH 8.0 and 25mM Tris.HCI pH 8.0.
(ii) Solution II.
0.2M NaOH and 1.0% w/v SDS.
(iii) Solution III.
Potassium acetate (3M potassium 5M acetate) Prepared as follows: 
60ml 5M potassium acetate, 11.5 ml glacial acetic acid and 28.5ml water 
and autoclaved.
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Protocol.
Overnight cultures (1.5ml) of bacteria, grown in LB broth containing an 
appropriate antibiotic, were collected by centrifugation and resuspended in 
150 ul of ice-cold solution I. The cells were incubated at room temperature 
for 5 minutes, then lysed and chromosomal DNA denatured by the addition 
of 250ul of freshly prepared solution II. After 5 minutes on ice, the 
denatured DNA was precipitated by the addition of 200ul of ice-cold 
solution III. After a further 5 minutes on ice, the denatured chromosomal 
DNA was pelleted by centrifugation (10000 x g, 5-10 mins) leaving the 
plasmid DNA in the supernatant. The supernatant was transferred to a fresh 
tube and extracted with phenol/chloroform. The aqueous phase was then 
transferred to a fresh tube and plasmid DNA precipitated from solution with 
two volumes of ethanol.
D. LARGE-SCALE PLASMID EXTRACTION FROM E.COU.
Large-scale preparations of plasmids from Escherichia coii were carried 
out using 10ml Caesium Chloride-Ethidium Bromide density gradients 
(Maniatis era/., 1982).
Reagents.
1. Tris-Sucrose: 50mM Tris-HCI (pH8.0) and 10% (v/v) sucrose.
2. Lysozyme: (Sigma Ltd.) lOmg/ml in 0.25M Tris-HCI (pH8.0)
3. 0.25M Tris-HCI (pH8.0).
4. Brij-Doc: TE buffer (pH8.0) containing 1 % (w/v) Brij 58 (Sigma Ltd.) and
0.4% (w/v) sodium deoxycholate (Sigma Ltd.).
5. Ethidium bromide solution: lOmg/ml in distilled water.
6. Caesium chloride.
7. Isopropanol saturated with caesium chloride: 10g CsCI dissolved in 10ml 
STE and 100ml Isopropanol was added and the mixture allowed to settle 
overnight.
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8. Isopropanol.
9. Ethanol.
Protocol.
A single colony of the bacterial strain containing the plasmid of interest 
was inoculated into 10ml LB-broth containing the appropriate antibiotic for 
selection. The culture was grown overnight at 37°C in a shaking incubator. 
4mls of the overnight culture was inoculated into 150ml of pre-warmed LB- 
broth (containing the appropriate antibiotic) and the flask re-incubated until 
the cells had grown sufficiently to give an optical density of 0.9 at 650nm 
(around 3 to 4 hours). Chloramphenicol was added (170 ug/ml) and the 
culture incubated for a further 4 to 18 hours.
Cells were sedimented by centrifugation (800g/10 minutes). The cell 
pellet was resuspended in 3.5ml Tris-Sucrose and held in ice for 5 minutes. 
Cells were lysed by adding 2ml freshly prepared lysozyme solution, mixing, 
and holding in ice for 5 minutes. 4mi Brij/Doc solution was added, samples 
mixed by pipetting up and down a 10ml plastic pipette, and the lysate re­
incubated in ice for 30 minutes to ensure complete lysis. Cell debris and 
most of the chromosomal DNA was removed by centrifugation at 
20,000g/20 minutes at 4°C and the supernatant (cleared lysate) recovered 
by decanting carefully into a fresh tube. Caesium chloride and ethidium 
bromide were added to the lysate to give final concentrations of 0.95g/ml 
and 500ug/ml respectively.
The lysate was placed into a Beckman Quick Seal polyallomer 
ultracentrifuge tube and the tube heat sealed. Samples were placed in a 
"Beckman" Ti 70.1 orTi 75.1 rotor and centrifuged at 18°C for 24-48 hours 
at 45,000rpm in a "Beckman" L5 or L8 ultracentrifuge. Centrifugation time 
varied depending on whether half or full gradients were used.
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Plasmid bands were visualised using a UV light at 312nm. Bands were 
extracted by puncturing the top and the side of the ultracentrifuge tube just 
below the band with a 19G disposable needle and drawing it into a 1ml 
syringe.
Ethidium bromide was removed from the plasmid sample by adding an 
equal volume of propan-2-ol saturated with caesium chloride and mixing 
thoroughly. Samples were allowed to separate into 2 phases and the top 
propan-2-ol phase containing the ethidium bromide was discarded. This 
process was repeated until all of the ethidium bromide had been removed.
Plasmid DNA was precipitated by adding to each 200ul of extract 250ul 
of distilled water, 50ul of 3M sodium acetate (pH5.2), and 500ul of propan- 
2-ol. Samples were incubated in ice for 30 minutes and the DNA pelleted by 
centrifugation at 4°C (12,000g/15 minutes). The pellet was washed with 
70% ethanol, vacuum dried, and resuspended in TE buffer or sterile water.
2.8.3 IN VITRO MANIPULATION OF DNA.
A. PRECIPITATION OF DNA.
Reagents.
1. 3M sodium acetate (pH5.2).
2. Ethanol (analar).
3. Propan-2-ol (analar).
4. TE buffer (pH8.0).
Protocol.
To one volume of DNA solution was added a 0.1 volume 3M sodium 
acetate (pH5.2) and 2.5 volumes of ethanol or one volume of propan-2-ol.
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Tubes were mixed by inversion and then incubated either in a dry-ice/ethanol 
bath for 10-15 minutes, or overnight at -20°C. DNA was sedimented by 
centrifuging at 12,000g for 10 minutes or longer depending on the amount 
on DNA. The pellet washed in 70% ethanol and dried. It was then 
resuspended in TE buffer and stored at either 4°C or -20°C.
B. QUANTITATION OF DNA.
DNA concentration and quality was determined by two methods, (i) the 
spectrophotometricmethod etal., 1982), and (ii), the comparative
intensity method.
The spectrophotometric method measures the amount of UV irradiation 
absorbed by the nucleic acid bases. DNA was diluted in distilled water and 
placed in a quartz cuvette. The absorbance values at 260nm and 280nm 
wavelengths were measured using a "Pye Unicam" model PU8820 UV/VIS 
spectrophotometer. The ratio of the readings at these wavelengths provides 
an estimate of the purity of the DNA preparation. An OD 260:280 ra\io of
1.7 or greater indicates a DNA solution of high purity with little protein 
contamination. An absorbance of 1.0 at 260nm is equivalent to a DNA 
concentration of 50ug/ml. Therefore, the DNA concentration of the 
preparation can be calculated.
DNA concentration = (ODggg x 50 x dilution) ug/ml
The presence of RNA which also absorbs UV and the products of DNA 
degradation can result in a value higher than the true DNA concentration.
The comparative intensity method was used to determine the DNA 
concentration when there was insufficient sample available to use the
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spectrophotometer. An aliquot of the DNA sample was electrophoresed on 
an agarose gel with a known amount of DNA (molecular weight markers). 
The gel was stained with ethidium bromide and photographed using a UV 
transilluminator (312nm). The intensity of fluorescence of ethidium bromide 
stained DNA under UV light is directly proportional to the total mass of the 
DNA (Maniatis et aL, 1982). Therefore, by comparing the intensity of the 
DNA of interest to that of the DNA size fragments of a known concentration 
an estimate of the amount of DNA in the sample can be calculated.
C. RESTRICTION ENZYME DIGESTS.
Restriction enzymes were used to "digest" DNA at specific locations for 
a variety of purposes, for example vector construction and analyses of 
chromosomal DNA for gene sequences. A typical restriction digest was set 
up as follows:
lOul DNA (up to lug).
2ul 10X restriction enzyme buffer.
7ul distilled water.
lul restriction enzyme (lOu/ul).
The reaction mixture was then incubated at the required temperature for 
60 to 90 minutes. Each restriction enzyme has a specified incubation 
temperature (usually 37°C) and its own buffer. Restriction enzymes and 
buffers were purchased from BRL Ltd. and used according to the 
manufacturer's instructions.
D. AGAROSE GEL ELECTROPHORESIS.
Agarose gels can be used to separate nucleic acid molecules of different 
sizes and shapes. Gel composition, agarose concentration, gel buffer.
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voltage, running time and the amount of sample varied according to the 
particular circumstances.
DNA GELS.
Reagents.
1. Tris acetate buffer (TAE): 40mM Tris-acetate, 20mM glacial acetic acid, 
2mM EDTA (pH8.3). Prepared as a BOX stock solution in distilled water 
and diluted as required.
2. DNA loading buffer: 10% (w/v) ficol (Mwt 400,000), 0.05%  (w/v) 
bromophenol blue.
3. High molecular weight DNA markers: Lambda DNA Hindlll fragments 
(125bp-23kb ladder) 400-800ug/ml.
4. Low molecular weight DNA markers: 0X174  /?FDNA Haelll fragments 
(72 to 1,353bp ladder) 400-800ug/ml.
5. Ethidium bromide stain: 0.5ug/ml in distilled water or TAE buffer.
Protocol.
DNA was electrophoresed through 0.8% (w/v) TAE buffered gels unless 
otherwise specified. Horizontal gel electrophoresis kits were used as 
recommended by the manufacturers (BRL Ltd.). Gels were prepared by 
dissolving 0.8g agarose (ultrapure) in 100ml TAE buffer by slowly boiling. 
The molten agarose was cooled to 50°C and then poured into the assembled 
gel plate. The gel was allowed to set, placed in the gel tank, submerged in 
TAE buffer (gel electrophoresis buffer) and the gel comb removed. Samples 
were mixed with 3-4ul DNA loading buffer and loaded into individual wells 
In the gel. Samples were initially electrophoresed into the agarose gel at 
100V, the voltage was then adjusted according to the experimental 
circumstances.
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DNA molecular weight markers were included on each gel (500ng/track). 
Either high or low molecular weight markers were used, depending on the 
sizes of the DNA fragments to be analysed. High molecular weight markers 
were stored at 4°C and prepared by incubating at 55°C for 2 minutes and 
then cooling in ice prior to loading in the gel. Low molecular weight markers 
were stored at -20°C and loaded directly in the gel after thawing.
Following electrophoresis the gel was stained with ethidium bromide for 
5 to 10 minutes. The ethidium bromide stained DNA bands were visualised 
using a UV transilluminator (312nm) and photographed using an orange filter 
(23A) and Polaroid 665 or 667 film.
RNA GELS.
Reagents.
1. MOPS/EDTA: 50mM MOPS and 1 mM EDTA (pH7.0).
2. RNA loading buffer.
3. RNA molecular weight markers: 6 synthetic poly(A)-tailed RNA's (0.24 
to 9.5Kb ladder). 1 mg/ml in lOmM HEPES (pH7.2) and 2mM EDTA.
Protocol.
RNA samples were electrophoresed through 1.5% formaldehyde 
denaturing gels. Gels were prepared by dissolving 1.5g agarose in 72ml 
distilled water, cooling to 70°C, and adding lOmIs 10X MOPS/EDTA and 
18mis 37% (v/v) formaldehyde in a fume hood. The gel was poured into an 
assembled gel plate and allowed to set. Gels were placed in a horizontal gel 
tank, submerged in IX  MOPS/EDTA (electrophoresis buffer) and the gel 
comb removed.
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RNA samples were prepared by precipitating the required volume of RNA 
using a 0.1 volumes of sodium acetate (pH5.2), 2.5 volumes ethanol and 
incubating in a dry-ice/ethanol bath for 10 minutes/ or at -70°C for 60 
minutes. Precipitated RNA was pelleted by centrifugation at 4®C 
(12,OOOg/20 minutes) and the pellet dried and resuspended in 4.5ul sterile 
distilled water. 2ul MOPS/EDTA buffer, 3.5ul formaldehyde, and lOul 
formamide were added and the sample heated at 70°C for 10 minutes, and 
then chilled on ice. 2ul RNA gel loading buffer was added and the sample 
loaded in to individual wells in the gel. Electrophoresis was initially carried 
out at 100V for 5 minutes and then at 25 to 60V until the leading dye front 
had migrated 8-12cm. RNA molecular weight markers were included on each 
gel. If required, the gels were stained in ethidium bromide for 5 minutes, 
then destained for 1 hour to overnight and photographed as for the DNA 
gels.
An alternative method for RNA visualization is to include 1 ul of 400//g/ml 
ethidium bromide in each sample.
If a gel is required for northern blotting, it is not to be stained. The size 
marker is to be cut and ethidium bromide stained, and destained in distilled 
water overnight at 4°C.
E. RECOVERY OF DNA FROM AGAROSE GELS.
DNA was recovered from agarose gels using the "GENECLEAN” method. 
The method utilizes a commercial kit called "GENECLEAN", which is based 
on the affinity of DNA molecules to bind to a silica matrix (glass milk). The 
affinity can be raised or lowered by varying the conditions, enabling the 
recovery of DNA with high efficiency. All the reagents (except TE buffer)
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were supplied with the kit and used according to the instructions 
recommended by the manufacturer.
Reagents.
1. Sodium iodide solution.
2. "Glassmilk" silica matrix suspension.
3. "NEW" buffer (sodium chloride, ethanol. Water).
4. TE buffer (pH8): lOmM Tris-HCI and 1mM EDTA.
The DNA sample was electrophoresed through TAE agarose gels as 
previously described and a gel slice(s) containing the required DNA 
fragment(s) excised from the gel and weighed. 2-3 volumes of sodium 
iodide solution were added and then incubated at 55°C until the agarose gel 
slice was completely dissolved.
"Glassmilk" suspension was added to the DNA solution (5ul per 5ug 
DNA) and mixed thoroughly. Samples were placed on ice for 5 minutes to 
allow binding of the DNA to the silica matrix. The silica matrix was pelleted 
by centrifugation (10,000g/5 seconds) and the sodium iodide supernatant 
discarded. The pellet was washed by resuspension in 400ul ice cold "NEW" 
buffer and the silica matrix sedimented by centrifugation (10,000g/5 
seconds). The supernatant was discarded and the washing procedure 
repeated twice more before resuspending the pellet in 5 to lOul of TE 
buffer. The suspension was incubated at 55°C for 3 minutes and pelleted 
by centrifugation (10,000g/10 seconds). The supernatant containing the 
DNA was recovered and the pellet resuspended in another aliquot of TE 
buffer and the incubation and centrifugation steps repeated. The recovered 
DNA was stored at -20°C.
Prior to use the purified DNA fragments were incubated at 55°C and 
centrifuged (12,000g/10 seconds) to sediment any residual glassmilk from
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the sample. An aliquot was run on an agarose gel and the DNA 
concentration determined by the comparative intensity method.
F. DEPHOSPHORYLATION OF DNA.
Following digestion of DNA with restriction enzymes, phosphate groups 
are exposed at the 5' terminus. These groups can be removed 
(dephosphorylated) by the enzyme "calf intestinal phosphatase" (CIP) 
(Chaconas and Van de Sande, 1980). Removal of the 5' phosphate groups 
prevents self-ligation of the DNA molecule, and consequently maximises the 
potential formation of recombinant molecules in ligation reactions.
Reagents.
1. Phenol/chloroform: Distilled phenoLchloroform 1:1 (v/v).
2. Calf Intestinal Phosphatase (CIP) lU/ul (Sigma Ltd.).
3. 10X "CIP" buffer: 0.5M Tris-HCI (pHS.O), lOmM magnesium chloride, 
Im M  zinc chloride, lOmM spermidine (Sigma Ltd.).
Protocol.
The DNA was digested to completion using the appropriate restriction 
enzyme. The enzyme was then inactivated by heating at 68°C for 10 
minutes and then chilled in ice. Alternatively, if the restriction enzyme was 
resistant to heat, the enzyme was inactivated by extracting with an equal 
volume of phenol/chloroform, followed by a further extraction with 
chloroform. The DNA was then ethanol precipitated and resuspended in 
17ul TE buffer. 2ul of 10X CIP buffer and lul CIP were added and the 
sample incubated at 37®C for 1 hour. The reaction was stopped by heat 
inactivating the CIP at 68°C for 10 minutes followed by phenol/chloroform 
extraction. The DNA was ethanol precipitated, dried and the pellet
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resuspended in 11 ul TE buffer (pH8). A lul aliquot was run on an agarose 
gel to determine the DNA concentration using the comparative intensity 
method. The remaining sample was used for subsequent ligation reactions.
G. PHOSPHORYLATION OF NUCLEIC ACIDS (KINASfNG).
The 5'-hydroxy terminus of nucleic acids were phosphorylated using the 
enzyme T4 polynucleotide kinase (Maniatis eta!., 1982). The addition of 5' 
phosphate groups enables the subsequent ligation of the DNA molecule. 
Reagents.
1. T4 polynucleotide kinase (PNK) TOU/ul (Sigma Ltd.).
2. 10X kinase buffer: 0.5M Tris-HCI (pH7.6), 0.1M magnesium chloride, 
50mM dithiothretol (BDH Ltd.), ImM spermidine (Sigma Ltd.) and Im M  
EDTA.
3. 2mM ATP solution (Sigma Ltd.) prepared in distilled water.
Protocol.
The following reaction mix was set up:
Dephosphorylated DNA.
2ul 10X kinase buffer.
2ul 2mM ATP.
2ul T4 polynucleotide kinase.
made up to 40ul with sterile deionized water.
The reaction mixture was incubated at 37°C for 1 hr and then stopped by 
addition of 2ul of 0.5M EDTA. It was extracted once with 
phenol/chloroform, and the DNA was ethanol precipitated. Dried DNA was 
dissolved in sterile deionized water.
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H. SYNTHESIS OF OLIGONUCLEOTIDES.
Oligonucleotides were chemically synthesized using an "Applied 
Biosystems" DNA synthesizer model 381 A, according to the manufacturers 
instructions. The oligonucleotides were extracted from the columns on 
which they were synthesised using 18M ammonium hydroxide, and 
deprotected at 55°C for 12 hours in 18M ammonium hydroxide. The 
nucleotides were ethanol precipitated and resuspended in TE buffer. The 
concentration of the oligonucleotide was then calculated 
spectrophotometrically.
I. POLYMERASE CHAIN REACTION (PCR).
DNA samples were prepared by the alkaline lysis method from overnight 
cultures. 1-1 Ong of sample DNA was used in 50ul reaction of 0.2mM  
dNTPs, 700ng of synthetic primers, 5ul of 10X reaction buffer and lul Taq 
Polymerase (Boehringer Ltd.). PCR was performed at 94°C for dénaturation 
(1 min.), 37-40®C for annealing (1 min.), and 72°C for extension (5 min.).
J. DNA LIGATION.
Reagents.
1. T4 DNA ligase. lU/ul (BRL Ltd.)
2. 5X ligase buffer: 20mM Tris-HCI (pH7.5), 4mM magnesium chloride,
O.BmMATP, lOmM dithiothretol.
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Protocol.
Protruding single strand ends.
The DNA molecules to be ligated were digested with the appropriate 
restriction enzyme(s). Modifications including adaptor attachment, 
dephosphorylation etc. were made if required. The DNA molecules were 
then resuspended in buffer, such that the concentrations of the DNA and the 
ratio of the different DNA molecules would result in maximum recombinant 
molecule production (Maniatis et a!, 1982). Usually vector to insert ratios 
of 1:2 and 1:4 were used. A typical ligation mixture was set up as shown:
lOul DNA (vector and insert 1-5ng).
4ul 5X ligation buffer.
5ul distilled water, 
lul T4 DNA ligase.
The mixture was incubated at 14°C overnight.
Blunt ended ligation.
For blunt end DNA ligation, up to 3 units of ligase was used and the ligation 
mixture was incubated at 9-12°C overnight waterbath.
2.8.4 TRANSFORMING ESCHERICHIA CPU  STRAINS WITH PLASMID 
DNA.
The transformation o i Escherichia coli with exogenous DNA Involves
three stages. First the cells have to be 'made competent' to take up the
DNA, second, the DNA has to be introduced into the cell, and third, the host
cells which have received the DNA (ie. the transformed cells) have to be
Several
selected from those which have not. ^Strains oi Escherichia coii were 
transformed with plasmid DNA during the project, Escherichia coii strain
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JM109, Escherichia coii sixa\n MC1061, Escherichia coii strain DH5>‘ and 
£sc/7er/c/7/a co//strain H B /O /, using different protocols.
ESCHERICHIA COZ/STRAIN JM109.
Transformation and storage solution (TSS): 10% (w/v) PEG (MW 
3500 (Sigma Ltd.), 5.0% (v/v) DMSO, 20mM magnesium chloride and
\
20mM magnesium sulphate. Prepared in LB-broth and the pH adjusted to
6.5.
Protocol.
Escherichia coii JM109 cells were made competent using the method of 
PEG assisted transformation (Chung and Miller, 1988). In this method 
bacterial cells were grown to early log phase (OD 0.6 at 600nm) in LB-broth. 
Cells were sedimented by centrifugation at 3,000rpm for 10 minutes at 4°C 
(MSE chillspin), resuspended in 0.1 volumes of transformation and storage 
buffer (TSS), and incubated in ice for 10 minutes. The competent cells 
were then dispensed into pre-cooled microcentrifuge tubes in lOOul aliquots 
and either used for transformation or frozen in a dry ice/IMS bath and stored 
at-70°C.
Competent cells were transformed by adding 1 -1 Ong of DNA to the cells. 
The cells were incubated in ice for 30 minutes. 0.9mls TSS containing 
20mM glucose was added and the cells incubated at 37°C in a shaking 
incubator for 1 hour. Aliquots were then plated out on selective media, to 
select for the cells transformed with the exogenous plasmid.
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ESCHERICHIA COU STRAIN  DH5a.
Protocol.
Commercially prepared competent Escherichia coii DH5a competent 
cells were obtained from BRL Ltd. (Paisley, Scotland) In 0.2ml aliquots. The 
cells were thawed slowly on ice, dispensed into 20ul aliquots in pre-chilled 
microfuge tubes, then rapidly frozen in a dry ice/IMS bath and stored at - 
7 0 X .
Competent cells to be transformed, were thawed gently on ice and 
mixed with 1 to lOng of plasmid DNA (in a total volume of l ul). The cells 
were held in ice for 30 minutes and then heat shocked at 42°C for 45 
seconds and chilled in ice for 2 minutes. 80ul of SOC medium was then 
added to each tube and the tubes shaken at 37°C at 225rpm for 1 hour. 
Cells were plated out on LB-plates with the appropriate antibiotic to select 
for the cells transformed with the plasmid DNA, and incubated at 37°C 
overnight. Transformants were subsequently re-plated to give individual 
colonies on LB-plates (with antibiotics). Control transformations were 
performed in duplicate using pBR322 DNA and cultured on LB-plates with 
and without antibiotics. The same transformation procedure was applied to 
Escherichia coii strain M C705/ and Escherichia coii strain 7 /5 /0 /
2.8.5. HYBRIDIZATION TECHNIQUES.
Hybridization techniques are based on the ability of complementary 
single stranded DNA or RNA molecules to bind or re-associate with one 
another to form a hybrid. They provide a very sensitive method of detecting 
related nucleotide sequences. The stability of the hybrid is affected by 
several factors, such as; the temperature, G-fC content, and the degree of 
homology between the two nucleic acid strands.
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Hybridization reactions involve 5 stages:
1. Immobilization of the nucleic acid onto a solid support.
2. Preparation of the nucleic acid probe and labelling.
3. Hybridization.
4. Washing.
5. Autoradiography.
1. IMMOBILISATION OF THE NUCLEOTIDE TO A SOLID SUPPORT. 
Reagents.
1. 20X SSC: 3M sodium chloride, 0.5M sodium citrate (pH7.0).
2. Denaturing solution.
3. Neutralising solution.
Protocol.
Nylon membrane filters (Hybond-N, Amersham International Ltd.) or 
nitrocellulose membrane filters (Hybond-C, Amersham International Ltd.) 
were used as a solid support. DNA was immobilized onto the membranes 
using Southern blot transfer (Southern, 1975), and RNA by Northern blot 
transfer (Kourilsky, et al., 1974; Meinkoth and Wahle, 1984).
"SOUTHERN" BLOTTING.
DNA to be analysed was first digested with the appropriate restriction 
enzyme(s) and electrophoresed through a TAE agarose gel. DNA molecular 
weight markers included on the gels were labelled using [a/p/?a-^^P]-d ATP as 
described in the subsequent "labelling" section.
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The Southern gel was stained with ethidium bromide and photographed 
on a UV transilluminator. The gel was rinsed with distilled water, 
submerged in several volumes of denaturing buffer, and gently shaken. 
After 30 minutes the gel was rinsed with distilled water, placed in several 
volumes of neutralising solution, and agitated for a further 30 minutes.
The DNA was transferred onto a nylon membrane by blotting with SSC 
buffer. The gel was first rinsed in 2X SSC buffer and placed on a piece of 
3MM Whatman paper, supported by a glass plate, with both ends of the 
paper dipping into a reservoir of 20X SSC buffer. A piece of membrane 
filter, cut slightly larger than the gel, was then placed on top and air bubbles 
were removed by rolling a 10ml pipette over the filter. Two pieces of 3MM  
paper slightly larger than the gel were saturated with 2X SSC and placed on 
top of the membrane filter, followed by 2 dry pieces of 3MM paper, and 
finally a stack of tissues. A glass plate was placed on top of the assembly 
followed by a weight of at least 500g. This was left blotting for a minimum 
of 12 hours. The tissues were replaced when they became saturated with 
SSC.
The blotting apparatus was dismantled and the filter rinsed in 6X SSC. 
The filter was baked at 80°C for 90-120 minutes to "fix" the DNA on the 
membrane filter and stored in the dark. Alternatively the filter was wrapped 
in Saran Wrap and placed, DNA side down, on a standard UV 
transilluminator for 2-5 minutes.
COLONY HYBRIDIZATION {ESCHERICHIA COLD.
Colony hybridization was carried out when large numbers of isolated 
clones needed to be screened for the presence of a particular DNA insert in 
the plasmid vector. The protocol used was essentially as described by 
Grunstein and Hogness (1975).
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Protocol.
A nitrocellulose filter was placed on an LB-plate containing the required 
antibiotic to select colonies containing the plasmid of interest. Using sterile 
toothpicks, individual bacterial colonies were transferred onto both the filter 
and a master LB-plate. Small streaks (2-3mm) were made in a grid pattern, 
with up to 100 colonies streaked per plate. A non-recombinant plasmid 
was included as a control. The plates were incubated at 37°C until the 
bacterial streaks had grown to a width of 0.5-1 mm. The filter was 
transferred to a LB-plate containing chloramphenicol (1 Oug/ml) to amplify the 
plasmid and the plates were incubated for a further 10 hours at 37°C. The 
filter and master plate were marked so that the orientation of the colonies 
could be determined. The master plate was stored at 4°C.
An alternative procedure was also used to transfer colonies onto the 
filter by placing the filter directly onto the plate containing colonies to be 
screened. The filter was marked in advance for orientation either by 
punching holes with a needle through the media, cutting the edges or by 
water resistant marker.
Bacterial colonies on the filters were then lysed and the liberated DNA 
bound to the nitrocellulose filter. This was performed by placing the filters, 
colony side up, on 3MM paper-saturated with 10% (w/v) SDS for 3 minutes 
to lyse the cells, followed by transferring the filters to 3MM paper saturated 
with denaturing solution. After 5 minutes, the filter was neutralised, by 
transferring it on 3MM paper saturated with neutralising solution for 5 
minutes. The filters were air-dried for 30 minutes and the baked at 80°C in 
a vacuum oven for 90 minutes to 'fix' the DNA to the membrane or UV 
cross-linked to the nylon membrane for 4-5minutes.
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"NORTHERN" BLOTTING.
RNA to be analysed was electrophoresed through a denaturing 
formaldehyde gel (section D). The gel was rinsed in 2X SSC buffer and the 
RNA transferred, by blotting, to a nylon membrane filter as described for the 
Southern blot. To fix the RNA on the membrane filter the membrane was 
air dried for up to an hour, wrapped in Saran-Wrap, and placed RNA side 
down on a UV transilluminator (312nm) for 4 minutes.
2. RADIOLABELLING DNA.
DNA probes were used to detect the presence of the specific gene 
sequence of interest. Probes were labelled by the random primers using a 
"MultiPrime" labelling kit according to the manufacturer's instructions 
(Amersham International Ltd.). All the reagents were supplied in the kit.
In this method, random hexanucleotide sequences, which hybridize to 
single stranded DNA at numerous points along its length, are used to prime 
DNA synthesis along the length of the DNA probe template. The addition 
of a labelled dNTP, with other cold dNTP's, results in the production of 
radioactive DNA probes. The newly synthesized strand, carrying the label, 
was separated from the template by heating in a boiling water bath for 5 
minutes followed by cooling on ice.
Radiolabelled molecular weight markers.
DNA molecular weight markers run on Southern gels were labelled by 
"nick translation" with [alpha-^^P] dATP using the following reaction: 
lOul DNA molecular weight markers (40ng). 
lul 10X restriction enzyme buffer 3.
6ul distilled water.
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lul [a/p/7a-®^p] dATP.
lul DNA polymerase 1 (lOU/ul).
The reaction mixture was incubated at room temperature for 5 minutes and 
then at 55°C for 10 minutes. It was cooled on ice and then diluted with 
30ul TE. lOul was loaded per well. The labelled markers were stored in a 
lead pot at -20°C for up to 2 weeks.
3. HYBRIDIZATION.
Reagents.
1. DNA hybridisation buffer: 5X Denhardt's solution, 5X SSC, 0.5%  (w/v) 
SDS, 0.5mg/ml single stranded salmon sperm DNA.
2. RNA hybridisation buffer: 5X Denhardt's solution, 5X SSPE, 50% (v/v) 
deionized formamide (BRL Ltd.), 0.25% (w/v) SDS, 0.65mg/ml single 
stranded salmon sperm DNA.
3. 20X SSPE.
4. 100X Denhardt's solution.
Protocol.
During this project, hybridisation reactions were initially performed in 
heat-sealable plastic bags containing luer ports through which buffers and 
solutions were introduced or removed. The bags were purchased from 
Hybaid Ltd. The membrane filter was placed in a bag, sandwiched between 
2 gauze meshes, and the bag heat sealed. 25ml pre-warmed hybridization 
buffer was placed in the bag and the air removed using a vacuum pump. 
Any remaining air bubbles were removed with a 20ml syringe. The bag was 
then incubated at the required temperature in a shaking water bath for a 
minimum of 2 hours. Typically 65°C was used for Southern blots and 42“C 
for Northern blots.
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After incubation, air was re-introduced into the bag. The probe was 
diluted with 5ml of hybridization buffer and placed in the bag. The probe 
was thoroughly mixed with the buffer and dispersed over the filter, then air 
was removed and the bag incubated overnight.
Later in the project a "Hybridization oven" (Hybaid Ltd.) was used for 
hybridization reactions. The filters were soaked In 2X SSC and then rolled 
in a nylon gauze and placed into a hybridization bottle. 10ml of pre-warmed 
hybridization buffer was added to the bottle which was then transferred to 
the hybridization oven and incubated at the required temperature, with 
rotation, for 1 to 3 hours. Hybridization buffer was removed from the bottle 
into a universal, the probe added and mixed. This solution was replaced into 
the bottle and incubated in the oven, with rotation, for a minimum of 12 
hours.
4. FILTER WASHING.
Reagents.
1. Wash solution: 3X to O.IX SSC and 0.1% (w/v) SDS. The
concentration of SSC depended on the stringency of the washing 
conditions.
2. Southern blot probe-removing solution: O .IX  SSC, 0.1 % (w/v) SDS, and
0.2M Tris-HCI (pH7.5).
3. Northern blot probe-removing solution: 5mM Tris-HCI (pH8), 2mM
EDTA, O .IX Denhardt's solution.
Protocol.
Hybridization buffer was discarded from either, the bag or the bottle, and 
the filter removed into a plastic container. Standard procedures for working 
with radioactive material were carefully followed. The filter was rinsed in
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2X SSC, submerged in pre-warmed wash buffer and gently agitated. Wash 
buffer was replaced every 15 minutes. The concentration of SSC used in 
the wash buffer ranged from 3 to O.IX SSC, and the wash temperature 
from 65 to 45°C, depending on the stringency required. Usually DNA filter 
membranes were washed at 65®C and RNA filter membranes at 45®C. A 
final rinse was given in 2X SSC for 5 minutes, the filter was then placed on 
a glass plate and wrapped in Saran Wrap.
5. PROBE REMOVAL FOR REHYBRIDIZATION.
To enable filters to be hybridised with more than one type of DNA probe, 
the original probe was removed using stringent washing conditions. DNA 
filters were washed in 0.4M sodium hydroxide at 45°C in a shaking water 
bath for 30 minutes, then transferred to Southern blot probe-removing 
solution (O.IX SSC, 0.1 % (w/v) SDS and 0.2M Tris-HCI, pH7.5) at 45°C for 
a further 30 minutes. RNA filters were washed for 1 to 2 hours at 65°C In 
Northern blot probe-removing solution (0.005M Tris-HCI, pHS.O, 0.002M  
NagEDTA and O .IX Denhardt's solution). Filters were checked with a 
monitor and autoradiographed for 24 hours to ensure removal of the probe. 
Stored filters were kept moist by wrapping in Saran-Wrap and placing at - 
70°C.
6. AUTORADIOGRAPHY.
The filter wrapped in Saran Wrap was placed in an autoradiograph 
cassette. A piece of RX X-Ray film (Fuji) was put on top of the filter. The 
autoradiograph was left at room temperature or -70°C for 3 hours to several 
days depending on the strength of the signal. Autoradiograph cassettes used 
at -70®C contained an intensifying screen. The autoradiograph film was 
developed by submerging in Kodak liquid X-ray developer for 5 minutes.
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rinsing in a water bath, and transferring to Kodak rapid fixer for 5 minutes. 
The film was washed in running water and dried in a warm cabinet.
2.8.6. DNA SEQUENCING.
DNA sequencing was carried out on 1-2 ug of template DNA using 
BioScience Sequenase™ kit. The kit is based on the dideoxy chain 
termination method of Sanger et al., (1977) and includes all the buffers, 
solutions and enzyme required to catalyse the addition of deoxynucleotides 
(and their derivatives) to the 3 ' ends of a DNA chain.
A. PREPARATION OF SINGLE STRANDED TEMPLATE DNA.
M13 Template DNA.
Single stranded, recombinant M l3 template DNA was prepared from 
phage stocks. 5/yl from phage stock was used to inoculate mid-log phase 
JM109 (1.5ml) and the culture grown, with vigorous shaking, at 37°C for 
6-7 hours. Cells were removed two successive centrifugation (10000 x g, 
5 mins). 1ml of PEG 6000 (250//I, 20% w/v, 2.5M NaCI) was added 
to the supernatant, the solutions mixed and placed on ice for 15 minutes. 
A phage pellet was collected by centrifugation (1000 x g, 10 mins, 4°C) and 
resuspended in 100//I TE pH 8.0. The solution was extracted with 
phenol/chloroform and phage DNA precipitated with ethanol in a dry 
ice/ethanol bath for 15 minutes. The DNA was resuspended in 100//I TE pH 
8.0, 0.5mg/ml proteinase K was added and the solution incubated at room 
temperature for 30 minutes. Phenol/chloroform extraction and ethanol 
precipitation were repeated with the DNA pellet resuspended in 20//I TE, 
pH 8.0. The amount of single stranded DNA prepared was estimated by 
ethidium bromide staining after agarose gel electrophoresis.
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PUC Template DNA.
Double stranded, recombinant plasmid DNA (1-2/yg of caesium chloride 
density gradient DNA) was denatured and prepared for sequencing using the 
method of Zang et al., (1988) with the following modification. Denatured 
DNA was rapidly cooled in a dry ice/ethanol bath for 10 minutes after the 
neutralising step.
B. PREPARATION OF DNA SEQUENCING GEL.
5% acrylamide gel was polymerised using a molar ratio of acrylamide to 
N,N'-methylenebisacrylamide of 19:1, in 8.3M urea, lOOmM Tris-borate (pH 
8.3) and 2mM EDTA.
Add 420ul freshly prepared 10% ammonium persulphate (1 OOmg/ml) and 
75ul of TEMED mixed immediately and the gel was left to polymerize.
A 4% gel was used for reading 600-800bp from the primer. This was
achieved by increasing the concentrations of the dNTPs in the labelling
reaction 3-5 fold and the labelling reaction was lengthened to 5 minutes.
This increase in concentration applied to the ^^P-dATP as well.
Electrophoresis at 50 Watts
The gel was cast between two glass plates previously coated with 10ml 
dimethyl dichlorosilane (repellent) for the front small plate and 30ul gamma- 
methacryloxypropyl-trimethoxysilane (adhesive) in 10ml ethanol containing 
150ul of 10% acetic acid for the large back plate. The gel was pre- 
electrophoresed for 15-30 minutes and the DNA electrophoresed at 75W  
constant power in IX  TBE electrophoresis buffer. After electrophoresis, the 
plates were separated, leaving the gel attached to the back plate. The DNA 
was fixed in the gel by Immersion in 10% methanol, 10% acetic acid for 20 
minutes then rinsed thoroughly under running water for 5 minutes to remove 
the urea, before drying in a hot air oven at 80°C for 1 hour. The gel was
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then placed in direct contact with Fuji-RX film in an X-ray cassette and kept 
In the dark for 16-48 hours.
2.9. DETECTION OF PROTEINS
The detection of proteins involves several stages:
1. The preparation of protein extracts.
2. The separation of protein by electrophoresis through an SDS 
polyacrylamide gel (SDS/PAGE) (Laemmli, 1970).
3. Detection of protein bands by Coommassei Brilliant Blue, Silver stain cr 
radiolabelling of the proteins.
4. Detection of antigens by antibodies.
2.9.1 PREPARATION OF PROTEINS:
a. "CRUDE" PREPARATION OF PROTEINS.
Cells from a growing culture (1 ml) were harvested by centrifugation for 
2 minutes In a microfuge tube. The pellet was resuspended in SOul of 1M 
Tris-HCI pH 8.0. 10ui of loading buffer was added and mixed thoroughly. 
The mixture was then placed in a boiling waterbath for 5 minutes. The 
sample was immediately loaded onto a SDS/PAGE.
b. ISOLATION OF PROTEINS FROM BACTERIAL OVEREXPRESSION 
SYSTEMS.
- INCLUSION BODIES. (Harlow et al., 1988).
Reagents.
1. Solution A: lOOmM NaCI, ImM EDTA, 50mM Tris pH 8.0.
2. Solution B: lOOmM NaCI, ImM EDTA, 0.1% sodium deoxycholate, 
50mM Tris pH8.0.
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3. MgClj.
4. DNase I (BDH).
5. Solution C: 1% NP-40, lOOmM NaCI, ImM EDTA, 50mM Tris pH 8.0. 
Protocol.
The bacterial culture was centrifuged at 7000g for 5 minutes and the 
pellet was resuspended in solution A to a final cell concentration of 10% 
(vol/vol). Lysozyme was added to 1 mg/ml. The mixture was spun at 
BOOOrpm for 10 minutes, after incubation at room temperature for 20 
minutes. The supernatant was discarded, at this stage the pellet can be 
stored by quickly freezing the tube in a dry ice/ethanol bath and stored at - 
70°C. The spheroblasts pellet was resuspended in 10% (vol/vol) solution B 
and incubated on ice with occasional mixing for 10 min. MgClg was added 
to a final concentration of 8mM and DNase I to a final concentration of 
10ug/ml. The mixture was incubated at 4°C with occasional mixing until the 
viscosity disappeared. More DNase was added if necessary. Inclusion bodies 
were pelleted by centrifugation at lO.OOOrpm for 10 min and the pellet was 
washed once with solution C and then with solution A.
The antigen now is ready for further purification by SDS-PAGE or 
injection. For injection final product should be broken into small pieces by 
sonication, solubilization of the protein is not important, as particulate 
antigens make excellent immunogens. If solubilization is desired, the 
particles could be dissolved in a strong dénaturant such as 8M urea, and 
dialyze versus PBS prior to injection.
C. IMMUNOPRECIPITATION.
Reagents.
1. Standard buffer: 50mM Tris.HOI pH 7.4, 5mM MgClj, 25mM S- 
mercaptoethanol, and 50ug/ml phenylmethylsulfonyl fluoride (PMSF).
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2. Procep-A beads (Bioprocessing Ltd.) or Protein A-Sepharose beads.
3. Triton X-100.
4. Wash buffer: lOmMTris.HCI pH 7.6, 140mM NaCI, 0.5% Triton X-100.
Protocol.
The culture (bacterial or animal cells) was harvested and washed twice 
in 200ul standard buffer. The pellet was resuspended at a protein 
concentration 10-15 mg/ml, and cells were disrupted by sonication. 
Alternatively the cells could be lysed with RIPA lysis buffer. Cell debris was 
removed by centrifugation full speed for 2 minutes in a top bench 
microcentrifuge. The lysate was pretreated with Procep A beads (20ul/ml of 
lysate) for 30 min. on ice and the beads were spun out as before. Triton X- 
100 was added to 0.5%. 10ui of polyclonal serum or 2ul of monoclonal 
antibodies were added and incubated on ice for 2 hrs. Procep-A beads were 
added and incubated for 30 min. with shaking. The beads were spun down 
in a top bench microcentrifuge for 1 minute full speed and washed four 
times with 200ul of wash buffer. The beads-immune complex was analysed 
either by loading it, in a loading buffer, directly onto SDS-PAGE or the 
complex could be dissociated from the beads by boiling for 5 minutes.
2.9.2. ANALYSIS OF PROTEINS BY SDS/PAGE.
SDS polyacrylamide gel electrophoresis (PAGE) is used for analysis of 
translation products. The proteins are dissociated under reducing conditions 
to constituent polypeptide chains by R-mercaptoethanol and the strongly 
anionic detergent SDS which binds to proteins. The polypeptides are 
separated on the basis of their molecular weight.
The samples for electrophoresis are mixed with sample buffer and boiled
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for 2 min. before loading onto the gel. Choice of resolving gel concentration 
depends on the molecular weight of the required protein.
Reagents.
1. Stock of acrylamide/bis acrylamide (30:0.8) solution.
2. 1M Tris.HCI pH 8.8.
3. 1M Tris.HCI pH 6.8.
4. 1.5% ammonium persulphate, freshly prepared.
5. TEMED (Sigma).
6. Distilled water.
7. Sample buffer.
8. 5X Reservoir buffer: 139.6g glycine, 5g SDS, 15.15g Tris.HCI made up 
to 1 litre with distilled water. Dilute to IX  with distilled water upon use.
9. 1:1 propan-1-ol and water.
Protocol.
Wear disposable plastic gloves throughout.
Clean glass plates with detergent then with ethanol and allow to air dry. 
Assemble apparatus using 1.5mm gel spacers. Mix the following in order. 
This mixture is used to pour a 12% resolving gel:
16.0ml 30:0.8% acrylamide/bis acrylamide.
14.8ml 1M Tris.HCI pH 8.8.
6.8ml distilled water.
0.4ml 10% SDS.
20ul TEMED.
2.0ml 1.5% ammonium persulphate.
Gently pour the acrylamide solution into glass plates, avoiding bubbles. 
Overlay gently with 1 -2ml of propanol and water (1:1) using a pasteur 
pipette. Try not to break the smooth surface of the acrylamide. Allow to 
polymerize 30-60 min. Polymerization Is usually indicated by a sharp line 
between the gel and overlay. Remove the propanol and dry the surface. Mix
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the following to make a "stacking gel":
2.5ml 30:0.8% acrylamide/bisacrylamide.
2.5ml Tris.HCI pH 6.8.
13.8ml distilled water.
0.2ml 10% SDS.
15ul TEMED.
1.0ml 1.5% ammonium persulphate.
Wash the interface of the resolving gel with stacking gel buffer and removed 
completely. Pour the stacking gel solution on top of the resolving gel. Insert 
comb and allow to polymerize for about 15 min. Mount the gel in the 
electrophoresis tank and remove the comb. Fill the chambers with reservoir 
buffer. Load samples after boiling for 2 min. Electrophorese at 120-150V for 
4-5 hrs until the Bromophenol dye reaches the bottom of the gel.
2.9.3. DETECTION OF PROTEINS.
a. COOMASSIE BRILLIANT BLUE STAIN. (Harlow and Lane, 1988).
The protein gel bands can be visualized by placing the gel in a gel 
containing 0.1 % Coommassie Brilliant Blue in distilled water, methanol, 
glacial acetic acid (5:5:2). Gently agitate gel at 40-50°C for 1 hr; Remove 
excess dye from gel by destaining under the same conditions in a solution 
containing 30% methanol and 10% acetic acid in water for at least Ihr or 
overnight at room temperature with successive changes of the solution as 
required.
b. Silver staining.
Silver staining is a very sensitive technique for protein detection, 
sensitivity is up to 1-10ng per band (Harlow and Lane, 1988).
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Reagents.
1. 30% ethanol.
2. 20% AgNOa stock solution.
3. 1% acetic acid.
Wear gloves and use only clean glassware. Fingerprints will stain, and 
dirty glassware will affect the sensitivity of the reaction.
Protocol.
After running SDS-PAGE, the gel is placed in 5 gel volumes of 30%  
ethanol, 10% acetic acid for 4 hrs, or overnight, with shaking. The solution 
is removed and 5 gel volumes of 30% ethanol is added. The gel is incubated 
for 30 min. at room temperature shaking, repeat a second time. Ethanol is 
removed and 10 gel volumes of deionized water is added with incubation for 
10 min. at room temperature with shaking. This wash is repeated twice. 
Water was removed and 5 gel volumes of 0.1 % AgNOg solution (diluted 
from stock). Incubation was carried out for 30 min. at room temperature 
with shaking. The solution was removed and the gel was washed for 20 
sec. under a stream of deionized water. 5 gel volumes of 2.5% sodium 
carbonate, 0.02% formaldehyde was added and incubated with shaking at 
room temperature. Protein bands should appear after few minutes. 
Incubation was continued until the background began to darken. The 
reaction was stopped by washing in 1 % acetic acid followed by several 
changes of deionized water of 10 min. each.
c. FLUOROGRAPHY.
Radiolabelled proteins may be visualized indirectly by fluorography. The 
gel is placed in a fixative containing 7% acetic acid in distilled water for 
approximately 30 min. Remove the fixing solution and soak the gel in 
volume of "Amplify" (Amersham). Agitate for 20 min. Place the gel on 3mm
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Filter paper and dry under vacuum at 80°C on a slab gel dryer (Biorad) for 
2 hrs. Expose the gel to X-ray film (Fuji) at -80°C in a film cassette. Develop 
film according to manufacturers'instructions.
2.9.4. DETECTION OF ANTIGENS BY ANTIBODY,
a. WESTERN BLOT.
Reagents.
1. TBS: 50mM Tris pH 7.5, 150mM NaCI.
2. TBST: TBS and 0.05% Tween 20.
3. Bovine serum albumin (BSA) (Sigma).
4. Reservoir buffer: 3.03g Tris, 14.4g Glycine and 200ml methanol made 
up to 1 litre with distilled water. Normally 3 litres required to fill the 
reservoir.
5. Colour development solutions:
- For alkaline phosphtase conjugate:
3.3mg Nitroblue tétrazolium (NBT) and 1.6mg Bromochloroindyl 
phosphate (BCIP) (Sigma) dissolved in 10ml of the following buffer: lOOmM 
Tris-HCI, pH.9.5, lOOmM NaCI and ImM MgCI2.
- For horse radish peroxidase conjugate:
0.020g 4-Chloro-1 -naphthol dissolved in 5ml methanol, 20ml TBS buffer 
and lOul Hydrogen peroxide (30%) (Sigma).
Protocol.
The protein gel was blotted onto Hybond-C membrane (Amersham) by 
electrophoretic elution using Biorad trans-plot cell (Bittner et al., 1980; 
Towbin et al., 1979). The membrane was blocked with TBST containing 1 % 
BSA overnight at 4®C or with TBST containing 3% BSA at room
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temperature for 1 hr. The membrane was then placed in a solution 
containing primary antibody diluted in TBST/3% BSA. and agitated at room 
temperature for 1 hr, then washed three times with TBST, 5 min. each. 
Secondary antibody was added diluted with TBS/3% BSA and agitated for 
1 hr at room temperature. Wash four times with TBS, 5 min. each. Develop 
colour with either substrates mentioned above depending upon conjugate 
used.
b. ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA).
Reagents.
1. Coating buffer: 3.18g NagCOg and 5.88g NaHCOg made up to 1 litre. 
Adjust pH to 9.5.
2. Phosphate buffered saline (PBS) 10X: 10.52g NajHPO^, 4.02g
NaH2P042H20 and 85g NaCI made up to 1 litre in deionized distilled 
water. Dilute to 1x upon use.
3. Incubation buffer: PBS containing 1% BSA.
4. Wash buffer (PBST): PBS containing 0.1% Tween 20.
5. Substrate for horse radish peroxidase: 2,2'-Azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid) (ABTS) tablets (Sigma).
Protocol.
Cells were harvested and the pellet was resuspended in 500ul coating 
buffer and sonicated. The debris was spun out full speed In a
microcentrifuge for 10 min.. Flat bottomed Nunc Immunoplates were coated 
with polyclonal serum diluted 1/100 in coating buffer and incubated 
overnight at 4°C. The plate was washed with 300ul/well of PBST 3 times 
and blocked with 50ul/well PBST 3% BSA for 1.5hrs at 37° with shaking. 
Samples were double diluted across the plate 50ul/well and the plate was
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incubated at 37®C for 1 hr. shaking followed by three Washes with 
SOOul/well PBST. 50ul/well polyclonal serum diluted in PBS 1 % BSA was 
added and incubated 1 hr at 37°C. The wells were washed 3 times with 
300ul/well PBST. Add secondary antibody diluted in PBST 1 % BSA was 
added and incubated 1 hr at 37°C. 3 washes with PBST were performed. 
The substrate was prepared and added 50ul/well. The O.D. was read in a 
Dynatech plate reader at 41 Onm.
2.10. SCANNING ELECTRON MICROSCOPY.
Sample preparation.
Cells were harvested and lysed with RIPA buffer (section 1.5). The 
lysate samples were placed on small pieces of cotton tissue. Samples were 
fixed with 3% glutaraldehyde and 0.1M sodium cacodylate for 2-4 hrs, 
followed by two times in sodium cacodylate (5 min. each wash) (Williams 
et al., 1973). Dehydration of samples was carried out for 15 min. in each 
of the following solutions in turn:
1. 30% acetone.
2. 50% acetone.
3. 70% acetone.
4. 90% acetone.
5. 100% acetone (X2).
Critical point drying (E3000 Critical Point Drver. Biorad).
Tissues were placed in baskets taking care not to allow drying: this 
operation should be carried out under the solvent. A transfer boat was filled 
with acetone (transfer liquid) in which the basket was placed. The
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chamber was cooled to 2 0 °C with cold water. After placing the specimen 
boat in the chamber the door was closed and the inlet valve opened. The 
vent valve was opened to avoid back pressure. To maintain the liquid level 
the inlet valve was left fully open with the vent valve slightly open. The 
drain valve was then opened to remove the substitution liquid. This 
"flushing" action was carried out for 4 min. After flushing the bulk of the 
substitution liquid, the chamber was filled with COg and all valves were 
then closed. This was left for 1 hr to allow impregnation. The flushing 
process was repeated a second time. The inlet valve was closed and the 
level of liquid allowed to fall to about the level of the top of the boat. The 
drying run was completed by heating slowly to 36-38°C with all valves 
closed. Carbon dioxide valve was carefully vented, avoiding condensation 
effects. Tissues were removed from the chamber and then specimens 
mounted on microscope stubs.
Microscopy.
After gold casting (El 50 Edwards Sputter Coater) for 2 min. stubs were 
outlined with a colloidal silver suspension (Electrodag 915) in order to 
transport electrons away from the sample and thus prevent specimens from 
charging. The stubs were then placed into a Cambridge Stereoscan 8230  
and titled at 45° before morphological examination proceeded.
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CHAPTER 3
CHAPTER 3 
E2 GLYCOPROTEIN
3.1 SUMMARY
The nucleotide sequence of E2 gene from Rubella strain Thomas was 
determined allowing comparison of sequence variation among RV strains. 
Attempts were made to express the E2 coding sequence as a hybrid gene 
in E. coli. The E2 coding sequence was fused to the 3' end of the lacZ gene, 
which encodes R-galactosidase. The cDNA used contains, at the 5' end of 
the E2 sequence, 32bp from the 3' end of the C coding sequence, the signal 
peptide coding sequence of E2, and at the 3' end 31 bp from the signal 
peptide of E l. Expression of these sequences proved to be lethal to £. coU. 
Deletion of the hydrophobic regions of the gene and expression of a 
subfragment of 100 amino acids allowed the growth of the bacterial cells.
The gene was expressed in vivo in COS-1 cells. The cDNA clone used 
encoded either the entire E2 sequence or was deleted at the 3' end of the 
gene removing part of the transmembrane anchor. Both E2 cDNA constructs 
were expressed efficiently, using the HCMV promoter of vector pUSl OO, in 
transfected COS cells. The E2 protein truncated at its carboxy terminus still 
appeared to be anchored in the cell membrane.
3.2. CDNA CLONING.
The E2 envelope gene was cloned using PCR technology using RNA 
obtained from rubella virus infected Vero cells. The reverse transcribed DNA 
was amplified using two synthetic primers in a PCR reaction. The cDNA was
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then kinased and ligated into the Smal site of pUC13 which was designated 
pE2T3. The E2 cDNA isolated was approximately 1.2 kb in size, Including 
30bp preceding its putative signal peptide coding region at the amino 
terminus and had at its carboxy-terminus 300bp from the amino-terminal of 
El (J. Newcombe, Personal Communication, PC) (Fig. 3.0).
3.3. SEQUENCING.
E2 cDNA envelope gene was excised from pE2T3 with PstI restriction 
enzyme, releasing 1.2 kb insert. The fragment was subcloned into a 
linearized, dephosphorylated M l3 mp19 which was cut with the same 
enzyme. The insert was ligated in both orientation designated clones 7.3 (5' 
to 3') and 7.4 (3' to 51 (Jackson, PC). Other fragments were excised by 
Rsal and Pvull from pE2T3 were also ligated into the Smal M l 3. Sequencing 
was carried out using " Sequenase Version 2.0" protocol for dideoxy- 
sequencing (USB) using random primers.
Sequence data showed that strain Thomas of RV has more than 90%
homology with the published sequence data of strains Therien (Dominguez
et al, 1990; Vidgren et al, 1987), M33 (Clark et al., 1987), HPV-77 (Zheng
et al., 1989) and RA27/3 (Nakhasi et al., 1989). However, the Thomas
amino
strain differs in having two nonconservative,pcids substitutions. The cDNA 
sequence reveals that most nucleotide substitutions occur at the third base 
of the codons. Sequence data is shown in (Fig. 3.1) in comparison with 
other published sequences.
3.4 . SUBCLONING AND EXPRESSION OF E2 in E. CPU.
A large scale plasmid preparation was performed to prepare a working 
stock of recombinant plasmid pE2T3. The plasmid was digested with PstI
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Fig. 3.1. Comparison of E2 cDNA (7306-8228) sequences from RV strains,
Thomas, Therien, M33, HPV77 and RA27/3 (A). (B) Comparison of E2 
glycoprotein amino acid sequences of the same strains.
(CLUSTAL analysis by P. Sanders).
------------------------- ----------- 7306 —E2 Thomas :Saba CCGCTCGGCGCGCCATCCTTGGCGCATCCGCTTCGGTGCCCCCCAGGCCTTCCTTGCCGG 
E2 Therien: Vid CCGCTCGGCGCGCCATCCTTGGCGCATCCGCTTCGGTGCCCCCCAGGCCTTCCTTGCCGG 
E2 Therien: Dorn CCGCTCGGCGCGGCATCCTTGGCGCATCCGCTTCGGTGCCCCCCAGGCCTTCCTTGCCGG 
E2 M33 : Clarke CCGCTCGGCGCGCCATCCTTGGCGCATCCGCTTCGGTGCCCCCCAGGCCTTCCTCGCCGG 
E2 HPV77 : Zheng CCGCTCGGCGCGCCGTCCTTGGCGCATCCGCTTCGGTGCCCCCCAGGCCTTCCTCGCCGG 
E2 RA27/3 :Nakh CCGCTCGGCGCGCCATCCTTCGAGCATCCGCTTCGGTGCCCCCCAGGCCTTCCTTGCCGG 
* * * * * * * * * * * * * *  * * * **  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * *
E2 Thomas :Saba GCTCTTGCTCGCCGCGGTCGCCGTTGGCACCGCGCGCGCCGGGCTCCAGCCCCGCGCTGA 
E2 Therien: Vid GCTCTTGCTCGCCACGGTCGCCGTTGGCACCGCGCGCGCCGGGCTCCAGCCCCGCGCTGA 
E2 Therien: Dom GCTCTTGCTCGCCACGGTCGCCGTTGGCACCGCGCGCGCCGGGCTCCAGCCCCGCGCTGA 
‘E2 M33 : Clarke GCTCTTGCTCGCCGCGGTCGCCGTTGGCACCGCGCCGCCGGGCTCCAGCCCCGCGCTGA 
E2 HPV77 : Zheng GCTCTTGCTCGCCGCGGTCGCCGTTGGCACCGCGCGCGCCGGGCTCCAGCCCCGCGCTGA 
E2 RA27/3 :Nakh GCTCTTGCTCGCCGCGGTCGCCGTTGGCACCGCGCGCGCCGGGCTCCAGCCCCGCGTTGA 
* * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * *
E2 Thomas : Saba TATGGCGGCACCTCCTACGCTGCCGCAGCCCCCCCGTGCGCACGGGCAGCATTACGGCCA 
E2 Therien: Vid TATGGCGGCACCTCCCACGCTGCCGCAGCCCCCCCGTGCGCACGGGCAGCATTACGGCCA 
E2 Therien: Dom TATGGCGGCACCTCCTACGCTGCCGCAGCCCCCCTGTGCGCACGGGCAGCATTACGGCCA 
E2 M33 : Clarke TATGGCGGCACCCCCTATGCCGCCACAGCCCCCCCGTGCGCACGGGCAGCATTATGGTCA 
E2 HPV77 : Zheng TATGGCGGCACCCCCTATGCCGCCACAGCCCCCCCGTGCGCACGGGCAGCATTATGGTCA 
E2 RA27/3 :Nakh TATGGCGGCACCCCCTATGCCGCCGCAGCCCCCCCGTGCGCACGGGCAGCATTACGGCCA 
* * * * * * * * * * * *  * *  *  * *  * * *  * * * * * * * * *  * * * * * * * * * * * * * * * * * * *  * *  * *
E2 Thomas :Saba CCACCACCATCAGCTGCCGTTCCTCGGGCACGACGGCCATCATGGCGGCACCTTGCGCGT 
E2 Therien: Vid CCACCACCATCAGCTGCCGTTCCTCGGGCACGACGGCCATCATGGCGGCACCTTGCGCGT 
E2 Therien: Dom CCACCACCATCAGCTGCCGTTCCTCGGGCACGACGGCCATCATGGCGGCACCTTGCGCGT 
E2 M33 : Clarke CCACCACCATCAGCTGCCGTTCCTCGGGCACGACGGCCATCACGGCGGCACCTTGCGCGT 
E2 HPV77 : Zheng CCACCACCATCAGCTGCCGTTCCTCGGGCACGACGGCCATCACGGCGGCACCTTGCGCGT 
E2 RA27/3 :Nakh CCACCACCATCAGCTGCCGTTCCTCGGGCACGACGGCCATCATGGCGGCACCTTGCGCGT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * *
E2 Thomas :Saba CGGCCAGCATTACCGAAACGCCAGCGACGTGCTGCCCGGCCACTGGCTCCAAGGCGGCTG 
E2 Therien: Vid CGGCCAGCATTACCGAAACGCCAGCGACGTGCTGCCCGGCCACTGGCTCCAAGGCGGCTG 
E2 Therien: Dom CGGCCAGCATTACCGAAACGCCAGCGACGTGCTGCCCGGCCACTGGCTCCAAGGCGGCTG 
E2 M33 : Clarke CGGCCAGCATCACCGAAACGCCAGCGACGTGCTGCCCGGCCACTGGCTCCAAGGCGGCTG 
E2 HPV77 : Zheng CGGCCAGCATCÀCCGAAACGCCAGCGACGTGCTGCCCGGCCACTGGCTCCAAGGCGGCTG 
E2 RA27/3 :Nakh CGGCCAGCATCACCGAAACGCCAGCGACGTGCTGCCCGGCCACTGGCTCCAAGGCGGCTG 
* * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
E2 Thomas : Saba GGGTTGCTACAACCTGAGCGACTGGCACCAGGGCACTCATGTCTGTCACACCAAGCACAT 
E2 Therien: Vid GGGTTGCTACAACCTAAGCGACTGGCACCAGGGCACTCATGTCTGTCACACCAAGCACAT 
E2 Therien: Dom GGGTTGCTACAACCTGAGCGACTGGCACCAGGGCACTCATGTCTGTCATACCAAGCACAT 
E2 M33 : Clarke GGGTTGCTACAACCTGAGCGACTGGCACCAGGGCACTCATGTCTGTCACACCAAGCACAT 
E2 HPV77 : Zheng GGGTTGCTACAACCTGAGCGACTGGCACCAGGGCACTCATGTCTGTCACACCAAGCACAT 
E2 RA27/3 :Nakh GGGTTGCTACAACCTGAGCGACTGGCACCAGGGCACTCATGTCTGTCACACCAAGCACAT 
* * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * * * *
E2 Thomas : Saba GGACTTCTGGTGCGTGGAGCACGACCGACCGCCGCCCGCGACCCCGACGCCTCTCACCAC 
E2 Therien: Vid GGACTTCTGGTGTGTGGAGCACGCCCGACCGCCGCCCGCGACCCCGACGCCTCTCACCAC 
E2 Therien: Dom GGACTTCTGGTGTGTGGAGCACGACCGACCGCCGCCCGCGACCCCGACGCCTCTCACCAC 
E2 M33 : Clarke GGACTTCTGGTGTGTGGAGCACGACCGACCGCCGCCCGCGACCCCGACGTCTCTCACCAC 
E2 HPV77 : Zheng GGACTTCTGGTGTGTGGAGCACGACCGACCGCCGCCCGCGACCCCGACGTCTCTCACCAC 
E2 .RA27/3 tNakh GGACTTTTGGTGTGTGGAGCACGACCGACCGCCGCCCGCGACCCCGACGTCTCTCACCAC 
* ** * * *  * * * * *  * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * * *
E2 Thomas :Saba CCTCAATGACAGCTGCGGCGGCTTCTTGTCTGGGTGCGGGCCGATGCGCTTGCGCCACGG 
E2 Therien:' Vid CCTCAATGACAGCTGCGGCGGCTTCTTGTCTGGGTGCGGGCCGATGCGCCTGCGCCACGG 
E2 Therien: Dom CCTCAATGACAGCTGCGGCGGCTTCTTGTCTGGGTGCGGGCCGATGCGCCTGCGCCACGG 
E2 M33 : Clarke CCTCAATGACAGCTGCGGCGGCTTCTTGTCTGGTGCGGGCCGATGCGCCTGC-CTACGG 
E2 HPV77 : Zheng CCTCAATGACAGCTGCGGCGGCTTCTTGTCTGGGTGCGGGCCGATGCGCCTGCGCCACGG 
E2 RA27/3 :Nakh CCTCAATGACAGCTGCGGCGGCTTCTTGTCTGGGTGCGGGCCGATGCGCCTGCGCCACGG 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * **  * ****
E2 Thomas :Saba CGCTGACACCCGGTGCGGTCGGTTGATCTGCGGGCTGTCCACCACCGCCCAGTACCCGCC 
E2 Therien: Vid CGCTGACACCCGGTGCGGTCGGTTGATCTGCGGGCTGTCCACCACCGCCCAGTACCCGCC 
E2 Therien; Dom CGCTGACACCCGGTGCGGTCGGTTGATCTGCGGGCTGTCCACCACCGCCCAGTACCCGCC 
E2 M33 : Clarke CGCTGACACCCGGTGCGGTCGGT-GATCTGCGGGCTGTCCACCACCGCCCAGTACCCGCC 
E2 HPV77 : Zheng CGCTGACACCCGGTGCGGTCGGTTGATCTGCGGGCTGTCCACCACCGCCCAGTACCCGCC 
E2 RA27/3 :Nakh CGCTGACACCCGGTGCGGTCGGTTGATCTGCGGGCTGTCTACCACCGCCCAGTACCCGCC 
* * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * *
E2 Thomas ;Saba TACCCGGTTTGGCTGCGCTATGCGGTGGGGCCTTCCCCCCTGGGAACTGGTCGTCCTTAC 
E2 Therien: Vid TACCCGGTTTGGCTGCGCTATGCGGTGGGGCCTTCCCCCCTGGGAACTGGTCGTCCTTAC 
E2 Therien: Dom TACCCGGTTTGGCTGCGCTATGCGGTGGGGCCTTCCCCCCTGGGAACTGGTCGTCCTTAC 
E2 M33 : Clarke TACCCGGTTTG-CTGCGCCATGCGGTGGGGCCTCCCCCCCTGGGAACTGGTCATTCTTAC 
E2 HPV77 : Zheng TACCCGGTTTGGCTGCGCCATGCGGTGGGGCCTCCCCCCCTGGGAACTGGTCGTTCTTAC 
E2 RA27/3 : Nakh TACCCGGTTTGGCTATGCTATGCGGTGGGGCCTTCCCCCCTGGGAACTGGTCGTCCTTAC 
*********** ** ** ************** ****************** *  * * * * *
E2 Thomas : Saba CGCCCGCCCCGAAGACGGCTGGACTTGCCGCGGCGTGCCCGCCCACCCAGGTACCCGCTG 
E2 Therien: Vid CGCCCGCCCCGAAGACGGCTGGACTTGCCGCGGCGTGCCCGCCCATCCAGGCGCCCGCTG 
E2 Therien: Dom CGCCCGCCCCGAAGACGGCTGGACTTGCCGCGGCGTGCCCGCCCATCCAGGCGCCCGCTG 
E2 M33 : Clarke CGCCCGCCCCGAAGACGGCTGGACTTGTCGTGGCGTGCCCGCCCATCCAGGTACCCGCTG 
E2 HPV77 : Zheng CGCCCGCCCCGAAGACGGCTGGACTTGTCGTGGCGTGCCCGCCCATCCAGGTACCCGCTG 
E2 RA27/3 :Nakh CGCCCGCCCCGAAGACGGCTGGACTTGTCGTGGCGTGCCCGCCCACCCAGGCACCCGCTG 
* * * * * * * * * * * * * * * * * * * * * * * * * * *  * *  * * * * * * * * * * * * * *  * * * * *  * * * * * * *
E2 Thomas :Saba CCCCGAACTGGTGAGCCCCATGGGACGCGCGACTTGCTCCCCAGCCTCGGCCCTCTGGCT 
E2 Therien: Vid CCCCGAACTGGTGAGCCCCATGGGACGCGCGACTTGCTCCCCAGCCTCGGCCCTCTGGCT 
E2 Therien: Dom CCCCGAACTGGTGAGCCCCATGGGACGCGCGACTTGCTCCCCAGCCTCGGCCCTCTGGCT 
E2 M33 : Clarke CCCCGAACTGGTGAGCCCCATGGGACGTGCGACTTGCTCCCCAGCCTCGGCCCTCTGGCT 
E2 HPV77 : Zheng CCCCGAACTGGTGÀGCCCCATGGGACGTGCGACTTGCTCCCCAGCCTCGGCCCTCTGGCT 
E2 RA27/3 :Nakh CCCCGAACTGGTGAGCCCCATGGGACGCGCGACTTGCTCCCCAGCCTCGGCCCTCTGGCT 
* * * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
E2 Thomas :Saba CGCCACAGCGAATGCGCTGTCTCTTGACCATGCCCTCGCGGCCTTCGTCCTGCTGGTCCC 
E2 Therien: Vid CGCCACAGCGAACGCGCTGTCTCTTGATCACGCCCTCGCGGCCTTCGTCCTGTCGGTCCC 
E2 Therien: Dom CGCCACAGCGAACGCGCTGTCTCTTGATCACGCCCTCGCGGCCTTCGTCCTGCTGGTCCC 
E2 M33 : Clarke CGCCACAGCGAACGCGCTGTCTCTTGACCACGCGTTCGCGGCCTTTGTCCTGTTGGTCCC 
E2 HPV77 : Zheng CGCCACAGCGAACGCGCTGTCTCTTGACCACGCGTTCGCGGCCTTTGTCCTGTTGGTCCC 
E2 RA27/3 :Nakh CGCCACAGCGAACGCGCTGTCTCTTGACCACGCGTTCGCGGCCTTCGTCCTGCTGGTCCC 
* * * * * * * * * * * *  * * * * * * * * * * * * * *  * *  * *  * * * * * * * * * *  * * * * * *  * * * * * *
E2 Thomas :Saba GTGGGTCCTGATATTCATGGTGTGCCGCCGCGCCTGTCGCCGCCGCGGCGCCGCCGCCGC 
E2 Therien: Vid GTGGGTCCTGATATTTATGGTGTGCCGCCGCGCCTGTCGCCGCCGCGGCGCCGCCGCCGC 
E2 Therien: Dom GTGGGTCCTGATATTTATGGTGTGCCGCCGCGCCTGTCGCCGCCGCGGCGCCGCCGCCGC 
E2 M33 : Clarke GTGGGTCCTGATATTTATGGTGTGCCGCCGCGCCTGTCGCCGCC-CGGCGCCGCCGCCGC 
E2 HPV77 : Zheng GTGGGTCCTGATATTTATGGTGTGCCGCCGCGCCTGTCGCCGCCGCGGCGCCGCCGCCGC 
E2 RA27/3 :Nakh GTGGGTCCTGATATTCATGGTGTGCCGCCGCGCCTGTCGCCGCCGCGGCGCCGCCGCCGC 
* * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * < * * * * * * * * * * * * *
8228
E2 Thomas :Saba CCTCACCGCGGTCGTCCTGCAGG 
E2 Therien: Vid CCTCACCGCGGTCGTCCTGCAGG 
E2 Therien: Dora CCTCACCGCGGTCGTCCTGCAGG*
E2 M33 :Clarke CCTCACCGCAGTCGTCCTGCAGG 
E2 HPV77 :Zheng CCTCACCGCAGTCGTCCTGCAGG 
E2 RA27/3 :Nakh CCTCACCGCGGTCGTCCTGCAGG 
* * * * * * * * *  * * * * * * * * * * * * *
B.Comparison of Rubella E2 glycoprotein amino acid sequences.
E2Thomas : Sab ^^ RSARHPWRIRFGAPQAFLAGLLLAAVAVGTARAGLQPRADMAAPPTLPQPPRAHGQHYGH 
E2Therien : Vid • GSARHPWRIRFGAPQAFLAGLLLATVAVGTARAGLQPRADMAAPPTLPQPPRAHGQHYGH 
E2 Therien : Do RSARHPWRIRFGAPQAFLAGLLLATVAVGTARAGLQPRADMAAPPTLPQPPCAHGQHYGH 
E2 M33 : Clarke RSARHPWRIRFGAPQAFLAGLLLAAVAVGTARAGLQPRADMAAPPMPPQPPRAHGQHYGH 
E2 M33 : Cl/Na RSARHPWRIRFGAPQAFLAGLLLAAVAVGTARAGLQPRADMAAPPMPPQPPRAHGQHYGH 
HPV77 : Zheng RSARRPWRIRFGAPQAFLAGLLLAAVAVGTARAGLQPRADMAAPPMPPQPPRAHGQHYGH 
E2RA27/3 :Nakhas RSARHPSRIRFGAPQAFLAGLLLAAVAVGTARAGLQPRVDMAAPPMPPQPPRAHGQHYGH 
* * * , *  * * * * * * * * * * * * * * * * * *^ * * * * * * * * * * * * *^ * * * * *  * * * *  * * * * * ** *
E2Thomas : Sab HHHQLPFLGHDGHHGGTLRVGQHYRNASDVLPGHWLQGGWGCYNLSDWHQGTHVCHTKHM 
E2Therien : Vid HHHQLPFLGHDGHHGGTLAVGQHYRNASDVLPGHWLQGGWGCYNLSDWHQGTHVCHTKHM 
E2 Therien : Do HHHQLPFLGHDGHHGGTLRVGQHYRNASDVLPGHWLQGGWGCYNLSDWHQGTHVCHTKHM 
E2 M33 : Clarke HHHQLPFLGHDGHHGGTLRVGQHHRNASDVLPGHWLQGGWGCYNLSDWHQGTHVCHTKHM 
E2 M33 ; Cl/Na HHHQLPFLGHDGHHGGTLRVGQHHRNASDVLPGHWLQGGWGCYNLSDWHQGTHVCHTKHM 
HPV77 : Zheng HHHQLPFLGHDGHHGGTLRVGQHHRNASDVLPGHWLQGGWGCYNLSDWHQGTHVCHTKHM 
E2RA27/3 : Nakhas HHHQLPFLGHDGHHGGTLRVGQHHRNASDVLPGHWLQGGWGCYNLSDWHQGTHVCHTKHM 
* ** * * * * * * * * * * * * * * *  ****  ^  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
E2Thomas : Sab DFWCVEHDRPPPATPTPLTTAANSTTAATPATAPDPCHAGLNDSCGGFLSGCGPMRLRHG
E2Therien:Vid DFWCVEHARPPPATPTPLTTAANSTTAATPATAPAPCHAGLNDSCGGFLSGCGPMRLAHG 
E2 Therien : Do DFWCVEHDRPPPATPTPLTTAANSTTAATPATAPAPCHAGLNDSCGGFLSGCGPMRLRHG 
E2 M33 : Clarke DFWCVEHDRPPPATPTSLTTAANYTAAATPATAPPPCHAGLNDSCGGFLSGCGPMRLPTA 
E2 M33 : Cl/Na DFWCVEHDRPPPATPTSLTTAANYTAAATPATAPPPCHAGLNDSCGGFLSGCGPMRLRHG 
HPV77 : Zheng DFWCVEHDRPPPATPTSLTTAANYIAAATPATAPPPCHAGLNDSCGGFLSGCGPMRLRHG
E2RA27/3: Nakhas DFWCVEHDRPPPATPTSLTTAANSTTAATPATAPAPCHAGLNDSCGGFLSGCGPMRLRHG 
* * * * * * * *^ * * * * * * * *^ * * * * *   ^* * * * * * * *  * * * * * * * * * * * * * * * * * * * * * *
E2Thomas : Sab ADTRCGRLICGLSTTAQYPPTRFG—CAMRWGLPPWELWLTARPEDGWTCRGVPAHPGT
E2Therien:Vid ADTRCGRLICGLSTTAQYPPTRFG—CAMRWGLPPWELWLTARPEDGWTCRGVPAHPGA 
E2 Therien : Do ADTRCGRLICGLSTTAQYPPTRFG—CAMRWGLPPWELWLTARPEDGWTCRGVPAHPGA
E2 M33 : Clarke LTPG AVGDLRAVHHRPVPAYPVCCAHRWGLPPWELVILTARPEDGWTCRGVPAHPGT
E2 M33 : Cl/Na ADTRCGRLICGLSTTAQYPPTRFG—CAMRWGLPPWELWLTARPEDGWTCRGVPAHPGT 
HPV77 : Zheng ADTRCGRLICGLSTTAQYPPTRFG—CAMRWGLPPWELWLTARPEDGWTCRGVPAHPGT 
E2RA27/3 : Nakhas ADTRCGRLICGLSTTAQYPPTRFG—YAMRWGLPPWELWLTARPEDGWTCRGVPAHPGT
_ * *  *  * * * * * * * * * *  * * * * * * * * * * * * * * * * * * *
E2Thomas : Sab RCPELVSPIGRATCSPASALWLATANALSLDHAHAAFVLLVPWVLIFMVCRRACRRRGAA
E2Therien;Vid RCPELVSPMGRATCSPASALWLATANALSLDHALAAFVLSVPWVLIFMVCRRACRRRGAA 
E2 Therien ; Do RCPELVSPMGRATCSPASALWLATANALSLDHALAAFVLLVPWVLIFMVCRRACRRRGAA 
E2 M33 : Clarke RCPELVSPMGRATCSPASALWLATANALSLDHAFAAFVLLVPWVLIFMVCRRACRRPAPP 
E2 M33 : Cl/Na RCPELVSPMGRATCSPASALWLATANALSLDHAFAAFVLLVPWVLIFMVCRRACRRPAPP 
HPV77 : Zheng RCPELVSPMGRATCSPASALWLATANALSLDHAFAAFVLLVPWVLIFMVCRRACRRRGAA
E2RA27/3 : Nakhas RCPELVSPMGRATCSPASALWLATANALSLDHAFAAFVLLVPWVLIFMVCRRACRRRGAA 
* * * * * * * * *^ * * * * * * * * * * * * * * * * * * * * * * *  * * * * *  * * * * * * * * * * * * * * * * ^^ ^^
E2Thomas:Sab AALTAWLQA^ ^^
E2Therien:Vid AALTAWLQG 
E2 Therien : Do AALTAWLQG 
E2 M33 : Clarke PPSPQSSCRG 
E2 M33 : Cl/Na PPSPQSSCRG 
HPV77 ; Zheng AALTAWLQG
E2RA27/3: Nakhas AALTAWLQG
* :=> match across all seqs.
. :=> conservative substitutions
to excise the E2 cDNA clone from pE2T3. The fragment was ligated in 
frame into the unique PstI site of the expression vector pUEXI and 
transformed into E. coli DH5° . Recombinant clones were analysed and the 
presence and orientation of E2 cDNA determined by Ncoi digestion. All 
inserts obtained were in the reverse orientation, no inserts were obtained in 
the required orientation for expression of E2.
Plasmid pTLE2.
It was decided to use alternative restriction sites for subcloning into the 
expression vector. In order to create more convenient cloning sites, it was 
decided to subclone E2 cDNA into plasmid pMTL24 (Fig. 3.OB). The insert 
was excised from pE2T3 by Hindi digestion, fragments separated using a 
0.8% agarose gel, and purified by Geneclean. The 1.2 kb fragment was 
ligated to plasmid pMTL24. The ligation mixture was transformed into E. coli 
DH5a competent cells. The recombinant plasmid was designated pTLE2.
Plasmids pSXE22, pSEX23 and pSXE24.
The entire E2 coding sequence containing 0.3kb from the 5' end of El 
was excised from pTLEZusing BamHI. The DNA was electrophoresed through 
a 0.8% agarose gel and the fragment was purified using Geneclean. The 
expression vector pUEXI } into which the BamHI fragment could
be inserted in the correct reading frame, was linearized with BamHI and 
dephosphorylated with CIP. The E2 cDNA coding sequence was ligated to 
the linearized vector and transformed into E  coii DH5a. The recombinant 
plasmid was designated pSXE22. As controls the BamHI digested E2 
fragment was also subcloned into the two other reading frames in pUEX2 
to give (pSXE23) and pUEX3 to give (pSXE24) (Fig. 3.0, C, D & E) .
The presence of the required inserts was detected by digesting 0.5ug of 
each DNA with BamHI. Subsequently, the orientation of the insert in the 
vector was determined by PstI digestion which releases a fragment of 288bp
100
plus a vector band of 7.7kb in size when inserted in the required orientation 
for expression.
Forty transformed colonies were screened for E2 and all had the insert 
in the wrong orientation. However, ten transformants of pSXE23 and 
pSXE24 each, were screened for inserts of which half were found in the 
correct orientation.
Plasmid pE2BP.
The E2 coding region was force cloned into pUEXI in the correct reading 
frame using a double digest BamHI/PstI, from pE2T3 which also deleted the 
300bp of El coding sequence from the 3' end. The DNA fragment retained 
half the El signal peptide coding sequence (30bp) attached at the 3' end of 
the E2 coding sequence. E2 was excised from pE2T3 as a 0.93kb, fragment 
was subcloned in frame into similarly digested restriction sites in the 
expression vector pUEXI, the plasmid was designated pE2BP (Fig. 3.2E). 
The ligated mixture was transformed into different strains of E. coli DH5a, 
and strain 866 {recBC) competent cells (obtained from Dr.Willwand, Swiss).
Plasmid pVE2.
pE2T3 (Fig. 3.2) was digested with Pvull to excise a fragment of 0.3Kb 
(aa 332-431 ) in size from the E2 cDNA coding sequence. The fragment does 
not contain any hydrophobic region. The Pvull digested plasmid was 
electrophoresed through a 1 % agarose gel and the fragment was eluted 
using Geneclean. The fragment was ligated in frame into pUEX3 digested 
with Smal. The DNA was transformed into E. coil DH5a. The recombinant 
plasmids were analysed and orientated with Pstl/Nael and Aval/PstI double 
digests. The insert was obtained in the correct reading frame. The 
recombinant plasmid was designated pVE2 (Fig. 3.2C).
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pE2HR.
Plasmid pE2T3 was digested with Hincli/Rsal to release a fragment of 
593bp (7307-7900) in size, and coding for a polypeptide fragment 
containing 198aa residues. This fragment contains lOaa from the C protein, 
The E2 signal peptide and 164aa residues from E2 protein. The fragment 
was purified by Geneclean from a 1 % agarose gel and ligated into pUEXI 
linearized with Smal (Fig. 3.2D). The ligated DNA was transformed into E. 
coli DH5a. The recombinant plasmids were orientated with BamHI digest.
3.4.1. DETECTION OF EXPRESSION.
Production of R-gal-E2 fusion proteins was monitored by SDS/PAGE. 
Recombinant colonies from pSXE23 and pSXE24 were inoculated in 10ml 
L-broth containing 25ug/ml ampicillin and grown overnight at 30°C shaking. 
This was diluted in fresh medium and was grown up to O.D550 equal to 
^ 0 .5 , (3-4 hrs). The cultures were heat induced by placing the samples in 
a 42°C waterbath for 2hrs. An amount equal to O.Ds5o = 1 of culture was 
centrifuged in a bench microfuge full speed for 3 min. The pellet was 
resuspended in 20ul Tris. HCL pH8 and 20ul sample buffer. The samples 
were loaded onto a 7% SDS/PAGE and electrophoresed at 120V until the 
dye was 1cm from the bottom of the gel. The gel was silver stained for high 
sensitivity detection.
Colonies containing recombinant plasmids pSXE23 and pSXE24 
displayed bands of the hybrid R-gal-E2 protein, the R-galactosidase being 
enlarged by the addition of 105 and 39 aa residues respectively (Fig. 5.2 in 
chapter 5). This indicates the expression of the alternative E2 reading frames 
was possible. No protein band was detected for pSXE22. Stable 
recombinants were not obtained for the E2 coding sequence in the correct 
reading frame with R-gal.
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Only one transformed colony was able to grow from £. coH DH5a 
containing pE2BP after 36hr incubation. The recombinant DNA was double 
digested with BamHI/PstI to excise the insert. On a 0.8% agarose gel the 
linearized plasmid digested with the same enzymes appeared smaller than 
the original by more than 3kb (Fig. 3.3B, lane 4) other bands of 0.9, 1.2 and 
0.5kb appeared, none of which resembled the E2 insert size of 0.95kb. 
However, pSXE23 and pSXE24 digested with BamHI/PstI yielded the 
expected bands without any rearrangements, lanes 5 and 6. B). Expression 
of the E2 glycoprotein with a portion of the capsid and El signal peptide 
was therefore lethal. Only clones which contained rearranged plasmids that 
could no longer express the rubella protein, or which had the insert in the 
wrong orientation for expression were obtained.
The cloning difficulty of the E2 in the correct orientation was overcome 
by subcloning of a fragment of the gene coding for lOOaa residues of the 
E2 protein. Expression of the R-gal-E2 fusion protein from pVE2 was 
detected by 7% SDS/PAGE stained with coomassie brilliant blue (Fig. 3.4). 
Subsequently, the hybrid protein was purified in the form of inclusion 
bodies, from pUEX3 and pVE2, and was electrophoresed through a 7%  
SDS/PAGE. The proteins were immobilized on a Hybond-C membrane and 
a western blot was performed. Human anti-RV polyserum was used to 
detect the RV protein, however no protein bands were detected. The lack 
of reactivity of the antiserum with the R-gal-E2 hybrid protein could be due 
to two reasons, the conformation of the fusion protein or the absence of 
antigenic epitopes in this region. This result suggests that the lethality of the 
RV E2 glycoprotein in the bacterial cells could be caused by the presence of 
the hydrophobic regions.
When a subfragment containing the 5' end of the E2 coding sequence 
and 30bp from the 3' end of the C coding sequence was cloned into the 
pUEXI, no colonies were obtained containing the recombinant plasmid
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Fig. 3.3. Rearrangement of prokaryotic expression vector pUEXI. During the 
cloning of RV cDNAs into pUEXI, deletions and rearrangements of the 
plasmid DNA occured. A, BamHI digestion of recombinant and vector DNA. 
(1) release of El insert from pSXEl 1, (2) release of El cDNA from pSM14, 
showing a deletion of approx. 2Kb, and (3) linearized pUEXI. B, 
BamHI/PstI double digest. (4) release of E2 insert from pSXE22, showing 
rearrangement of the of the recombinant vector (text), similar digest of 
pSXE23 and pSXE24 release the required insert (5 & 6).
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Fig. 3.4. Expression of El and E2 subfragments, in E. coli, fused to the 3 ' 
end of lacZ gene. The hybrid proteins from cultures containing recombinant 
plasmid electrophoresed through a 7% SDS/PAGE with sample buffer 
lacking l^-mercaptoethanol to detect native proteins. Lane (a), recombinant 
plasmid pEHI containing a subfragment from E l. lane (b), pVE2 containing 
a subfragment of E2, lane (c), control vector pUEXI.
pE2HR in which the insert would be in the correct orientation, suggesting 
that this fragment of E2 could be lethal to the cells. It was then decided to 
terminate this part of study.
3.5. EXPRESSION IN COS CELLS.
The RV E2 cDNA clone was modified at its both 5' and 3' ends to enable 
the cloning of the envelope gene sequences into the expression vector 
pUSIOOO. Synthetic oligonucleotides were used for the required 
modification via PCR. Oligo E2sp (2062-2077) was used to modify the 5' 
end by adding an in-frame translation initiation codon (ATG) contained 
within an Ncol restriction site, and preceded by an EcoRI site. At the 3' end 
oligo E2an (2932-2947) was used to add an in-frame stop codon (TAG) 
followed by an EcoRI restriction site (Fig. 3.5A). Synthetic oligonucleotides 
are shown, in bold print, as follows:
Oligo E2sp
®'AACGAATTCACCATGGGCCGCTCGGCGCGCCAT^' 
 3'GGCGAGCCGCGCGGTA®'
Oligo E2an
^'CGCGGACAGCGGCGGCGATCCTTAAGCAA®'
■®'GCGCCTGTCGCCGCCGC^'---------------
In the PCR reaction, 2ng from plasmid pE2T3 was used along with 
700ng of both oligonucleotides in a total volume of 50ul. The reaction
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mixture was denatured 1 min at 94°C, annealed at 40°C  for 1 min, and 
extended, 72°C for 5 min, for 30 cycles. The DNA PCR products were 
electrophoresed through a 0.8% agarose gel and the DNA band resembling 
modified E2 gene was cut out and purified using geneclean (Fig. 3.6).
The E2 cDNA PCR product was ligated into the Smal site of 
dephosphorylated pUCI 3 vector. The ligation mixture was incubated 
overnight at 9®C. The DNA from the ligation cocktail was transformed into 
£. coU DH5° competent cells. The recombinant colonies were screened for 
the E2 cDNA insert by EcoRI digestion of plasmid DNA. The recombinant 
plasmid of containing the modified E2 cDNA and pUC13 was designated 
pEUC2.
The E2 cDNA was excised from plasmid pEUC2 by EcoRI digestion to be 
subcloned into the expression vector pUSIOOO and create recombinant 
plasmid pEES2 (Fig. 3.5B).
3.5.1. DEVELOPMENT OF SECRETED E2 PROTEINS
A secreted E2 protein variant would have advantages for production and 
purification of recombinant antigens by animal cell lines. Due to the presence 
of a convenient unique cleavage site for PpuMI, this site was used to place 
a synthetic translation terminator into the E2 3' sequence halfway along the 
transmembrane anchor. The PpuMI restriction site is not present in the 
pUSIOOO vector sequence. Recombinant plasmid pEES2 was cleaved with 
PpuMI restriction enzyme which cuts at the unique site at 2903 in the E2 
sequence, which is 11 amino acids down the middle of the 18aa anchor 
region (Appendix A). Filling in of "sticky end" was carried out by DNA 
polymerase I and followed by dephosphorylation with CIP. The DNA was 
phenol/chloroform extracted and ethanol precipitated. The pellet was dried 
and resuspended with lOul sterile water.
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Fig. 3.6. Modification of E2 sequence using PCR cloned into vector 
pUSIOOO for expression in COS cells. Initiation and stop translation codons 
and EcoRI sites were added to the cDNA (a). Furthermore, the the protein 
was truncated by placing a synthetic termination codon into the anchor 
region (b).
A universal translation terminator {®*d[GCTTAATTAATTAAGC]®’) 
(Pharmacia) was kinased with polynucleotide kinase PNK (Pharmacia) and 
ethanol precipitated. The pellet was resuspended in sterile water and lug of 
the terminator DNA was used to ligate to 0.3ug of PpuMI linearized pEES2. 
The ligation mix was incubated overnight at 9°C. Recombinant plasmid 
pEST2 was detected by digesting with PpuMI restriction enzyme which 
would not cut the required clones due to the loss of the site (Fig. 3.5C). 
Attempts were made to remove the whole anchor region by placing a 
synthetic translation terminator in the unique Kpnl cleavage site, further 
upstream of the PpuMI site. No recombinants were obtained in time for 
inclusion in this work, but clones deleted the whole of the transmembrane 
anchor have now been obtained (Dogan, PC).
3.5.2. TRANSFECTION OF COS-1 CELLS.
Transfection of recombinant plasmids pEES2 and pEST2 into C0S1 cells 
allowed transient expression of these proteins in vivo. The cells were 
transfected with 0.5-1 ug of plasmid DNA per construct per 35mm well 
containing 3x10® cells. After 30 min of incubation with the DNA 
transformation cocktail, the mixture was replaced by 1-2 ml of tissue culture 
medium supplemented with 80uM chloroquine for 3 hrs. The medium was 
replaced with 1ml of medium containing 10% DMSO for 2.5 min. COS cells 
were kept at 37°C post transfection for 72 hrs before labelling with 
[^®S]methionine.
3.5.3. DETECTION OF E2 TRANSCRIPTION.
Total RNA was extracted from COS-1 cells transfected with vector 
pUSIOOO and cells infected with recombinant plasmids pEES2 and pEST2
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using RNazol. The extracted RNA was treated with DNase for 10 min at 
37°C. Samples were electrophoresed through a 1.2% denaturing agarose 
gel, which was subsequently blotted onto N-Hybond membrane 
(Amersham). The blot was hybridized with a DNA fragment, labelled with 
[32p]dCTP, from E2 cDNA excised with Ban!! restriction enzyme (Fig. 3.0). 
The Filter was washed twice with 3X SSC 0.1 %SDS and once with 2X SSC 
0.1 %SDS followed by a 2X SSC rinse. The filter was autoradiographed 
overnight at -70°C.
The northern blot confirmed the transcription of both cDNA constructs 
expressing the entire and truncated E2 genes. Bands of, 0.9Kb andoS4Kb 
respectively, were detected in the corresponding lanes on the 
autoradiograph. No bands appeared in the lane corresponding the RNA 
extracted from cells transfected with pUSIOOO vector (Fig. 3.7).
3.5.4. DETECTION OF E2 PROTEIN IN COS-1 CELLS.
A. IMMUNOPRECIPITATION.
COS cells were harvested and lysed with RIPA lysis buffer. The rubella 
E2 glycoprotein was immunoprecipitated from either cell lysates or the 
growth medium by human polyclonal serum. The antigen antibody complex 
was adsorped to protein A beads (Bioprocessing). The samples were 
analysed on an SDS 12.5% PAGE. The gel was treated with Amplify 
enhancer (Amersham), dried and exposed to film.
B. WESTERN BLOT.
COS-1 cells transfected with pEES2 along with untransfected COS-1 cells 
were harvested, lysed and the proteins were immunoprecipitated with
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Fig. 3.7. Northern blot analysis of RV E2 and El transfected COS cells. 
Total RNAs from uninfected and infected cells were electrophoresed through 
a 1.2% denaturing gel and immobilized on a nylon filter. The RNAs were 
hybridized with E2 and El cDNA probes. (1) pEES2, (2) pESTI, (3) pEMI 
and (4) vector pUSIOOO as a control.
antirubella antibodies from human polyserum. Sample were loaded on SDS 
12% PAGE. The gel was electroblotted on Hybond-C filter paper overnight 
at 4°C. The immobilized proteins were blocked with TBST 3% BSA for 2 hrs 
at RT. The rubella glycoprotein was detected with diluted human polyclonal 
serum preabsorbed with untransfected COS-1 cells.
Preabsorption of the human serum was carried out by incubation of the 
untransfected COS-1 cells with the serum for Ihr shaking at 37®C followed 
by overnight incubation at 4®C. The cells were spun out before using the 
serum.
On the western blot two bands from cells containing pEES2 were 
detected which migrated as diffused duplex. The sizes of the bands were 
41 kD and 39kD. A single band of size 39kD was detected in the control 
pUSIOOO transfected COS-1 cells lane (Fig. 3.8).
Radio-immunoprecipitates of E2 envelope glycoproteins, from pEES2 and 
pEST2 were present in comparable amounts in the transfected cells and of 
molecular weights 41 kD and 39.5kD respectively. This result suggests that 
a deletion of 9 amino acid residues from the carboxy-terminus of the E2 
glycoprotein has no effect either on the translation efficiency and quantity 
of the protein, nor on its retention within the cell membrane by the 
transmembrane anchor region (Fig. 3.9).
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Fig. 3.8. Western blot of the expression of the E2 in COS cells. Transfected 
COS cells with pEES2 and pUSIOOO were lysed with RIPA buffer. The 
lysates were electrophoresed through a 12% SDS/PAGE and blotted on 
nitrocellulose filter. The RV proteins were detected with a human polyserum 
preabsorped with COS cells. (A) showing lysates from pEES2 transfected 
cells showing a band running as a doublet, while lysates from pUSIOOO are 
in shown(B).
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Fig. 3.9. Expression of RV E2 and El envelope genes in COS cells. Analysis 
of proteins from cell lysates and growth media labelled with [^^S]methionine. 
(A) Transfected COS cells lysates, lanes (1 & 5) pEES2-transfected cells and 
lane (2) is pESTI-transfected cell lysate. (3) pEMI, the marked position 
shows the expected size of the El protein. Lane (4) untransfected COS 
cells. (6 & 7) markers. (B) Growth media of the cultures in (A). (8) pEMI, 
(9) pEES2, (10) pESTl and (11 ) untransfected cell medium. Arrows denotes 
the sizes of the proteins.
3.6 DISCUSSION.
DIMA SEQUENCE.
In this study the sequence of E2 from RV strain Thomas is reported. The 
coding sequences of the E2 glycoprotein of the RV strains Therien, M33, 
HPV-77 and RA27/3 have been reported (Frey et al., 1986; Dominguez et 
al., 1990; Clark et al., 1987; Nakhasi et al., 1986; Vidgren et al., 1987; 
Zheng et al., 1989). The nucleotide sequences of all the strains are over 
95% homologous but the variations do lead to differences in the derived 
protein sequences.
The sequences of the two Therein strains are in agreement with the 
exception of a conservative substitution of residue Ala^ ®® (Vidgren et al., 
1987) by residue Asp (Dominguez et al., 1990). Unconservative amino acid 
substitution occur at 3 positions Ala^ ®^^ "^ ®^-»Arg and Ser^^ -^»Leu.
All the sequences are in agreement from the N-terminus through amino 
acid (444). From aa 445 through 471, the sequence of M33 strain (Clark et 
al., 1987) is entirely different. The same strain was resequenced by Nakhasi 
(1989), who reported the sequence of this region was in complete 
agreement with that reported by others of the strain sequences.
Comparison of HPV-77 strain and its w t  strain M33 revealed three aa 
mutations: Ser^” -**Tyr, Thr^^Mle and Thr^^ -^^AIa. The change at position 
412, from Thr to lie in the E2 protein, is of significance because it results 
in the loss of a putative N-linked glycosylation site at Asn^ °^. The loss of the 
glycosylation site leads to a difference of about 3000d in the apparent M, 
of the E2 protein between HPV-77 and M33 strains, 38x10^ for M33 and 
35x10^ for HPV-77. It has been suggested that the altered glycosylation of 
the E2 protein, along with other changes in the viral genome, may lead to
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a change in viral tropism and infectivity of the HPV-77 vaccine strain of the 
RV (Zheng et al., 1989).
RA27/3 vaccine strain (Nakhasi et al., 1989) displays seven amino acid 
mutations, three of which are conservative changes, in comparison with its 
wild type Therien strain (Dominguez et al., 1990). The aa substitutions are: 
Thr®’^-*Met, Leu^^ -^*Pro, Tyr^® -^»His, Pro^° -^*Ser, Cys^^^-*Tyr, Ala®°^-*Thr and 
Leu” ®-*Phe. The RA27/3 has more nucleotide mutations than HPV-77. The 
higher degree of change in RA27/3 vaccine strain could be the reason that 
this strain being a safer and more effective vaccine than HPV-77 strain.
The amino acid sequence of the Thomas strain differs from all the other 
sequences of rubella strains in two residue substitutions. Both mutations are 
nonconservative: Ala (Therien) or Pro (M33) are replaced by Asp at position 
421 and Leu (Therein) or Phe (M33) are replaced by His at position 539. 
Both changes resulted from mutations at the second nucleotide of the 
codon. In general the amino acid sequences of the different RV strains are 
in good agreement, however mutations like the one at position 421, Ala and 
Pro are neutral and hydrophobic while Asp in Thomas strain is negatively 
charged and hydrophillic, the change in the hydrophobicity could affect the 
folding of the protein. It remains to be seen if such mutations have any 
effect on the protein folding which in return could play a role in strain 
specificity, which is found to be associated with the E2 glycoprotein (Gould 
et al., 1980; Dorsette et al., 1985).
EXPRESSION IN BACTERIA.
The coding sequence of the E2 glycoprotein, of RV strain Thomas, has 
been obtained from a cDNA cloned from mRNA derived from an RV-infected 
cell lysate using PCR technology (J. Newcomb, PC). Expression of the E2
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glycoprotein coding sequence has been performed in COS cells (Clark et al, 
1988; Hobman et al., 1989 and 1990; Sanchez et al, 1991) and sf9 insect 
cells (Oker-Blom et al, 1989), yet no reports have been published regarding 
the expression of E2 in prokaryotic cells. In the present study, an attempt 
was made to examine the expression of the E2 glycoprotein coding 
sequence using E. coli as the host.
The C/E2/E1 cDNA, which contained O.Skb from the 5' end of El and 
30bp from the 3' end of C, was subcloned into the BamHI site of vector 
pUEXI causing the coding sequence to be fused in frame to the carboxyl- 
terminus of S-galactosidase. No recombinant plasmids carrying the insert in 
the correct orientation were isolated. The removal of the El portion, 
including half of its signal peptide, from the E2 coding sequence did not 
result in clones with the E2 sequence in the correct orientation for the 
expression. Forced cloning of the same construct, pE2BP, resulted in 
rearrangement of the plasmid and deletions up to 3Kb. The same difficulty 
in cloning E2 was found by another group working on rubella virus in the 
USA (H. Nakhasi, PC).
Plasmid deletions has been reported in the expression of the G-protein, 
a structural protein of vesicular stomitis virus (VSV). The gene was placed 
under the control of the tryptophan operon regulatory region and 
transformed into E. co li. The transformation efficiency was 2 colonies per 
1 ug of DNA, similar to the transformation efficiency of E2 DNA, and the 
plasmids obtained were deleted by more than 500bp (Rose and Shafferman, 
1981).
The E2 cDNA was however cloned in the reverse orientation even when 
different bacterial host strain was used. Forced cloning by double digestion 
to clone the E2 insert had a severe inhibitory effect on growth of the 
bacterial cells and caused plasmid rearrangement. However, the correct
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orientation of E2 cDNA was obtained when the gene was subcloned out of 
frame in the recombinant plasmids pUEX23 and pUEX24. The same result 
was obtained from pVE2 which contained a fragment of the E2 lacking 
hydrophobic regions. On SDS/PAGE, relevant protein bands of the expected 
sizes were detected in cultures harbouring the recombinant plasmids. This 
result indicates that expression of certain hydrophobic sequences within the 
E2 glycoprotein coding sequence are lethal to the bacterial host (see below).
The cDNA fragment in pVE2 which contains a 0.3Kb from the E2 was 
the only fragment to be obtained in frame in the correct orientation. The 
recombinant protein was detected on an SDS/PAGE stained with coomassie 
brilliant blue. This result indicates the lethality of the E2 protein could be due 
to the presence of the hydrophobic regions, the signal peptide of E2 and the 
three regions at the carboxy-terminus of E2 (Appendix A). These regions 
were present in this construct. However, the hybrid protein R-gal-E2 from 
pVE2 did not react with antirubella antiserum on a western blot. Antigenic 
regions which have been identified in E2 are within the 116-residue domain 
at the amino terminus of the E2 glycoprotein (Wolinsky et al., 1991 ), which 
includes most of the Pvull fragment being expressed except 14aa residues 
at the carboxy terminus. This suggests that the hybrid protein did not react 
with the antirubella antiserum because of the conformation of the fusion 
protein.
Expression of a cDNA coding for a subfragment from the E2 containing 
the signal peptide and lOaa residues from the C protein, pE2HR, also 
inhibited cell growth of cells containing the insert in the correct reading 
frame. No colonies were obtained in the correct ORF. This suggests that the 
lethality to the bacterial cells is due to a sequence present at the amino- 
terminus of the E2 within aa 268-332 and could be the hydrophobic region 
of the signal peptide. The signal peptide has a transmembrane spanning 
domain which mediates the translocation of the E2 and could act as an
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anchor to the C protein when cleaved from E2 (Soumalainen et al., 1990;
Hobman et al., 1989; Vidgren et al., 1987; Frey et al, 1988). In a study of
a cell receptor fût
the expression of the lamB gene, which encodes^an integral outer membrane 
protein of the bacteriophage lambda, as a fused protein to the amino- 
terminus of S-galactosidase, it has been reported that the protein had a 
severe effect on cell growth which was suggested to be due to lethal 
jamming of the export machinery of the bacterial membrane due to the 
presence of the signal peptide (Emr et al, 1978 and 1980). Similarly, the 
expression of ma/-R-gal fusions showed that the truncated recombinant 
protein with the m a/signal peptide was inserted into the E. co//membrane 
and found to be lethal to the cell (Ito et al., 1981 ), this again was attributed 
to jamming of the export sites by the enormous S-gal moiety of the fusion 
protein. Accordingly, the R-gal-E2 fusion protein in this study could be acting 
in the same way with the E2 signal peptide mediating the insertion of the 
protein into the membrane.
Expression of several viral glycoproteins has been reported to be lethal 
to the bacterial host (Rose et al., 1981 ; Steinberg et al., 1986). It has been 
reported that the expression of the fusion glycoprotein (F) of the human 
respiratory syncytial virus (RSV) was lethal to E. coli. The role of this protein 
is to fuse the virus and cell membranes during the infection process. After 
heat induction of E. coil harbouring the vector with an insert coding for the 
F protein, the cells did not produce high yields of the protein and there was 
a severe growth inhibition. However, the removal of the hydrophobic region 
of the signal sequence of the expressed F protein restored normal growth 
(Martin-Gallardo et al., 1991). The deletion of the signal peptide sequence 
from (G-protein), a glycoprotein of the vesicular stomatitis virus (VSV), 
overcame the lethality of the product to the cells (Rose et al.,1981).
In contrast, deletion of the signal sequence from human fibroblast 
interferon was not sufficient to eliminate the inhibition of growth upon
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Induction of this protein in E. coli. It has been suggested that the growth 
inhibition may be related to the general hydrophobicity of the interferon 
which causes the protein to adhere to the bacterial membrane (Remaut et 
al., 1983). Similarly, upon the deletion of part of the transmembrane 
sequence and the anchor sequence of glycoprotein D of Herpes Simplex 
virus type 1, eliminated the toxicity of the protein to the bacterial cell 
(Steinberg et al., 1986).
The signal peptide initiates the transfer of the polypeptide through the 
cellular membrane (Blobel et al., 1975). The ultimate positioning of the 
protein chain across the membrane depends on the termination of this 
transfer process. Such a "stop-transfer" event is specified by sequences that 
contain hydrophobic membrane-spanning segments (the anchor) (Boeke et 
al., 1982; Yost et al., 1983; Guan, 1984). It has been demonstrated that, 
for a prokaryotic membrane protein, gene III protein (pill) of the coliphage 
f1 (Ml 3), it is simply the hydrophobicity of this sequence that suffices to 
a "stop transfer". Davis and Model, 1985. have reported that any segment 
of the polypeptide that is sufficiently hydrophobic will act to stop the 
transfer and serve to anchor the protein to the membrane. It was suggested 
that expression of certain hydrophobic regions as the signal peptides or 
anchor, which are uncleaved, might become permanently embedded in the 
E. coii membrane and interfere with the membrane functions (e.g. blockage 
of the export system) (Rose and shafferman, 1981).
The cDNA of the E2 glycoprotein of RV used in the expression study in 
bacteria contains 4 hydrophobic regions. The signal peptide at the N- 
terminus, and three additional regions at the C-terminus of the protein 
including the anchor region of E2 and the signal peptide of El (Vidgren et 
al., 1987; Clark et al., 1987; Frey et al., 1986 and 1988).
Once the protein is overproduced it results in a lethal blockage of the E. coii 
export system through the cell membrane and cause cell lysis (Steinberg et
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al., 1986). This is in agreement with the studies mentioned previously and 
explains the limited growth of recombinant colonies harbouring the E2 gene 
in the required orientation, as any of the three hydrophobic regions at the C- 
terminus could contribute to the jamming of the cell export system and 
lethality of the protein to the bacterial cells.
EXPRESSION IN MAMMALIAN CELLS.
To Study the expression of the E2 coding sequence, in COS-1 cell, a 
construct was made containing the full length E2 with 33aa at its amino 
terminus including its putative signal peptide (23 aa). The construct was 
inserted in the vector pUSIOOO under the control of the human 
cytomegalovirus (HCMV) promoter and transfected into COS-1 cells.
The E2 glycoprotein was expressed efficiently and migrated as a single 
band on SDS/PAGE with a size of 41 kD which is in agreement with other 
published studies (Hobman et al., 1989 and 1990; Oker-Blom et al., 1990, 
Sanchez et al., 1991). So far the manipulation of the E2 protein was geared 
towards the definition of the signal peptide and its effect on the processing 
of the glycoprotein. However, the effects of deletions from the carboxy- 
terminus of the anchor region was not studied (Hobman et al., 1989 and 
1990; Oker-Blom et al., 1990, Sanchez et al., 1991 ). In this study analysis 
of the anchor region and the development of a secreted protein was the 
goal. Deletion of 14 aa from the carboxy terminus region of the E2 
glycoprotein had no effect on the efficiency of the protein translation 
Intracellularly. The protein was present in comparable amount to the full 
length protein and was 0.5kD less in size. This also proves that the 
remaining 11 residues of the anchor region are functional in anchoring the 
protein into the cellular membrane.
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In a study of bacteriophage f1, the successive deletion of the 
hydrophobic carboxy terminus of the gene III protein showed that 11-12 
residues can retain the hydrophobic core of the region and its anchoring 
function . Some proteins with hydrophobic cores of between 10-14 residues 
in length showed degradation of the proteins (Davis et al., 1985).
Expression of the E2 coding sequence of RV was more efficient in 
mammalian cells than in bacterial cells. E2, with 64aa attached to its amino 
terminus from the carboxy terminus from the C protein, from strain M33, 
and a deletion mutant where the putative signal peptide was removed, were 
studied with regard to protein production. In vitro expression studies proved 
that the putative signal peptide was required for the E2 protein to be 
translocated into the microsomal vesicles. The construct yielded a protein 
of 39kD in size, while the deleted construct was 6kD less in size, in vivo 
expression in COS cells indicated that the full length E2 glycoprotein was 
42kD in size (Hobman et al., 1989) and presumed to correspond to the 
41 kD E2 protein found in RV infected cells (Oker-Blom et al., 1983). It was 
reported that the protein lacking the signal peptide failed to translocate into 
the cell membrane and has a rapid turnover (Hobman et al., 1989; Oker- 
Blom et al., 1990; Gething et al., 1982; Hobman et al., 1988). Expression 
of E2 intracellularly in Vero cells using, recombinant vaccinia virus, produced 
the protein of 40kD in size which migrated as a single band on SDS/PAGE 
(Sanchez et al., 1991). The reason of the size difference of the expressed 
E2 glycoprotein in these studies is not clear but may relate to the different 
gel systems used.
in vitro translation of the E2 coding sequence with 50 aa at its amino 
terminus and 21aa of the El signal peptide at the carboxy terminal was 
carried out using pGEM vector. The expressed protein was of 39kD in size 
when microsomal membranes used and 34KD without the membranes. E2
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with only 3aa from its signal peptide and lacking the El signal peptide 
produced a 30kD protein with or without the presence of the membranes 
(Oker-Blom et al., 1990). The study proved that the E2 signal peptide 
mediates the trahslocation of the protein across the ER which cannot be 
translocated upon deletion of the signal peptide from the protein. This study 
is in agreement with the previous study by (Hobman et al., 1989). The 
putative signal peptide of E2 (23 aa) sequence was also expressed in vitro 
with the E2 coding region and proved to be sufficient for signal activity 
(Marr et al., 1991).
A study conducted by Soumalainen, (1990), revealed that the signal 
peptide of the E2 glycoprotein remains attached to the carboxy terminus of 
the C protein. The signal peptide also proved to be long enough to function 
as a membrane-anchoring sequence for the capsid (Adams et al., 1985; 
Davis et al., 1985a and b; MacDonald et al., 1987). This could also 
contribute to the E2 glycoprotein being retained intracellularly along with the 
hydrophobic region of 19aa preceding the anchor region (Frey et al, 1986).
To analyse the transmembrane domain further the effect of progressive 
removal of the hydrophobic regions at the carboxy-terminus of the E2 
glycoprotein on the secretion of E2 from mammalian cells is required. This 
study is currently being continued by the production of recombinant proteins 
lacking the entire carboxy hydrophobic domain (M. Dogan, PC). The results 
produced here show that the 1 laa hydrophobic domain can still act as a 
transmembrane anchor.
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CHAPTER 4
CHAPTER 4 
El CLONING
4.1. SUMMARY.
The El glycoprotein gene, from RV strain Thomas, was cloned and 
characterized with a view to developing a recombinant antigen. This could 
be used in diagnostic kits to detect positive antisera from individuals with 
recent rubella infections or as the bases of recombinant vaccine. Sequence 
data was obtained which allowed comparison of the sequence variation of 
the El sequence with the sequences of other rubella strains.
4.2. CONSTRUCTION OF THE cDPJA LIBRARY.
The cloning of complementary DNA (cDNA) copies of messenger RNA 
is a powerful technique in molecular biology. It facilitates the investigation 
of protein structure and function, allows different parts or fragments of 
genes to be located and provides the means to investigate gene structure 
and control. Biologically important polypeptides can be produced from cDNA 
for medical or commercial use.
4.2.1 CLONING VECTOR.
The method for cloning with the pUEXI vector involves 
unphosphorylated, double stranded oligonucleotide adaptors with one blunt 
end and one cohesive end. These are ligated to a BamHI cleaved pUEXI 
vector and blunt ended cDNA in the same reaction. Only one strand of the
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adaptor forms a covalent bond during this ligation reaction since this 
requires the 5'-phosphate from the cDNA or vector. The other strand of the 
adaptor remains attached only by Watson-Crick base pairing. 
Complementary, single stranded extensions are produced on the vector and 
the cDNA by removing the non-covalently bonded strand of the adaptor 
molecules. This is achieved by a gel exclusion chromatography column 
which also acts to select cDNA inserts larger than 600 base pairs. The ends 
of the adaptorsuare speoialiy’tfesigned so that one end must ligate to the 
cDNA while the other end has to ligate to the vector. When resultant single 
stranded extensions are allowed to anneal onlyrecircuierization between 
vector and cDNA can occur. The recombinant vectors are then ready for 
transformation into host cells. However the resultant nicks left by the 
unphosphorylated ends of the adaptors are first sealed by a combination of 
T4 polynucleotide kinase and T4 DNA ligase (Fig. 4.1).
4.2.2. VIRAL RNA EXTRACTION.
RV genomic RNA was extracted from PEG precipitated virus particles of 
strain Thomas, supplied by JM Best. The RNA pellet was resuspended in 
50ul sterile water and a 5ul aliquot was electrophoresed through a 1.2%  
agarose gel to analyse quality. To minimize contamination with ribosomal 
RNA from dead cells which could be collected with the virus, polyA mRNA 
was isolated from the genomic RNA using Oligo dT paper chromatography.
4.2.3. CDNA SYNTHESIS.
The first cDNA strand was synthesized using Bug RNA from RV as 
recommended in the Amersham cDNA synthesis plus handbook. The cDNA 
was labelled with 20uCi of [a-^^P]dCTP/ug mRNA.
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Fig. 4.1. Summary of the cDNA cloning system-plasmid pUEXI
(Amersham International pic).
The cDNA synthesis was primed with synthetic primers synthesized on 
model 381 A DNA synthesizer from Applied Biosystems. Two primers were 
used with the aim of cloning E2 and C genes. Primer 837A is located at the 
3' end of E2 at position 8167-8181, while primer V535 is located within the 
E2 signal peptide at 7355-7377. Fig, 4.2 shows the location of the primers 
on the rubella sequence. The mentioned nucleotide numbering is according 
to the genomic sequence (Domingues et al., 1990) (Appendix A).
Primer V535
= GAAGGAACGGCCCGAGAACGACG'’ 
— ='CUUCCUUGCCGGGCUCUUGCUGC^-
Primer 837A
'^a c a c g g c g g c g c g g a ' ’
-5'UGUGCCGCCGCGCCU^'
The synthesized cDNA was phenol/chloroform extracted followed by 
ethanol precipitation in the presence of approximately 0.5ug of BamHI 
cleaved vector pUEXI. The pellet was vacuum dried for 5 min. and then 
dissolved in 20ul TE buffer (Fig. 4.3).
4.2.4. LIGATION OF ADAPTORS TO CDNA AND VECTOR.
2ng of the vector was dispensed plus 1 ug cDNA solution into a separate 
microcentrifuge tube containing 5ul TE buffer for use as a " minus adaptors"
120
CO
<
CD
D UNCM
111
O
CD
D<
00
o
CM
CO
m
in
CO
in>
CM
CO
CM
CO
CM <
CO
00
r*
CM
oo
CO
CO
ooo
CO
oo,rs
CM
ooTf"
CM
oor"
CM
oo
00
ooin
o
s
ooO)
oo
CD
oo
CO
X
E
(0m
<
Z
(C
o
Eoc
0)
O)
.o
3
CO
0
mC
co
c0)
II
o
S
O)Ç
*S53
‘350)£
CO
co
0
o
o
"to
ID
c0
1
8
%■
a
H
>
^  0) 
^  .g
CO k . 
<
I
C
as
lO
COto>
CM £
 ^I
M w t Kb
—  23
 9 4— 6* 5 
— 4.3
 2.3
—  2 - 0
—  0.56
Fig. 4.3. RV cDNA synthesis from RNA extracted from the virus. The cDNA 
was synthesized in the presence of [or-^^P]dCTP and shows fragment sizes 
upto more than 4Kb (a), (b) Radiolabelled Hindlll digested lambda DNA.
control. To the rest of the original solution 5ul of adaptors were added. Both 
samples were placed in a 65®C waterbath for 5 min. Samples were 
subsequently allowed to cool for 10 min. T4 DNA ligase was added to the 
"plus adaptors" sample of DNA and ligated overnight at 14°C.
4.2.5. REMOVAL OF ADAPTORS.
Adaptors were removed from the "plus adaptors" sample and the cDNA 
size fractionated through a pre-equilibrated column (supplied) at 65®C using 
IX  TE buffer. Twenty fractions of 200ul were collected and pooled 
according to sizes of the cDNA. Pooled fractions were kinased and ligated 
for 2 hrs at 37°C. The DNA ligation mixture was phenol extracted and 
ethanol precipitated.
4.2.6. TRANSFORMATION.
Competent cells E. coli M C I061 strain were prepared according to the 
recommended protocol. lOOul of competent cells were thawed on ice. 5ul 
of the vector-cDNA ligation and religated vector as a control were 
transformed in E. coii (according to protocol) and plated on L-agar media 
containing 25ug/ml ampicillin. Transformation efficiency was 10  ^
colonies/ug from the ligated cDNA while 10^ colonies were obtained from 
the transformation of religated pUEXI control.
4.2.7. IDENTIFICATION OF RECOMBINANT CLONES.
Transformed colonies were lifted off the plates on replica filters of 
Hybond-N and incubated on fresh agar at 30°C allowing colony growth.
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Colonies were lysed and the nucleic acid was fixed by UV cross linking. 
Colony filters were prehybridized for 4 hr and hybridized in the same way for 
southern blots.
A. PROBE PREPARATION.
The probe used in hybridization was the 5' end of cDNA pKTH345. 
PKTH345 cDNA (obtained from Petterson) consists of a 2kb cDNA rubella 
clone, cloned into the unique Pstl site of pBR322. The cDNA clone was 
double digested with Pstl/Xhol. Since the 0.9 and 1.1 kb fragments from 
Pstl digestion of the El coding region are difficult to separate, it was 
decided to further cleave the 1.1 kb fragment using Xhol to give the 
following fragments: 4.363 (vector), 0.9 (S' probe), 0.49, 0.42, and 0.2 kb. 
The 0.9kb Pstl fragment was isolated using Geneclean according to the 
manufacturer's instructions. The probe was labelled with [a-^^P]dCTP to use 
in the hybridization (Fig. 4.4).
B. LIBRARY SCREENING.
Colony filters were hybridized with the probe 0.9 Pstl fragment and then 
washed down to 1X SSC and autoradiographed overnight at -70®C. Positive 
transformants were picked up and plated onto fresh plates for further colony 
purification and second round screening as above (Fig. 4.5). Transformants 
were inoculated in 3 ml L-broth with 25 ug/ml ampicillin and incubated 
overnight at 30°C. Rapid small scale isolation of positive plasmid DNA from 
transformed colonies was carried out using the alkaline lysis method. For 
insert detection and sizing 0.7ug of the plasmid DNA was digested with 
BamHI.
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Fig. 4.5. A sample plate of RV library screening using colony hybridization 
technique. The bacterial cells were transformed with the ligation mix of 
pUEXI-cDNAs. The transformed colonies were lifted and immobilized on a 
nylon filter. The colonies were denatured and the DNAs were hybridized 
with probe 0.9 Pstl fragment from pKTH345 cDNA clone labelled with [a- 
^^P]dCTP. The figure shows positive colonies containing RV-specific cDNA 
inserts.
DNA digests were analyzed on a 0.8% agarose gel. This showed that all 
RV cDNA clones had an internal BamHI site and gave identical patterns of 
two insert fragments of 1.0 and 0.55 kb on ethidium bromide stained 
agarose gels (Fig. 4.6). The figure also shows that the cloning vector has 
become smaller in size by losing approximately 2Kb from Its original 
sequence (Fig. 3 .3AV
C. SOUTHERN BLOT.
The above mentioned agarose gel was blotted for southern hybridization 
with the 0.9Kb Pstl fragment probe. All 39 DNA samples hybridized to the 
larger fragment. This indicates that the large fragment contains the 5' region 
of the El , or 3' region of the E2 genes (Fig. 4.7).
D. NORTHERN HYBRIDIZATION.
RNA was extracted from infected and uninfected Vero cells using the 
guanidinium thiocyanate method. 5ug of RNA from both extractions was 
electrophoresed through a denaturing 1.2 % agarose gel, and subsequently 
blotted onto Hybond-N membrane. The blot was subsequently hybridized 
with ^^P-labelled 0.9Kb Pstl fragment rubella cDNA clone.
One of the isolated cDNA clones (pSM14) was selected for further 
analysis. To confirm that the clone contained cDNA of rubella virus. It was 
analysed by a northern blot. Both BamHI fragments of pSM14 were used to 
probe total RNA from RV-infected and uninfected vero cells. Fig. 4.8 shows 
that both cDNA fragments hybridized to total RNA extracted from RV- 
infected cell RNA, lane (a), whereas no hybridization occurred with the 
uninfected cell RNA, lane (b). The cDNA clone hybridized to several bands
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Fig. 4.6. Positive cDNA clones from RV library into the cloning vector 
pUEXI. DNAs were extracted from positive colonies by alkaline lysis 
method. The DNAs were treated with RNase, the inserts were excised by 
BamHI digest and electrophoresed through 0.8% agarose gel. Lanes 1, 14,
27 & 40 contain lambda marker digested with Hindlll/EcoRI. Lanes 2, 15,
28 & 41 are pUEXI plasmids linearized with BamHI. The remaining lanes 
display an identical pattern of released inserts with an internal BamHI site 
indicated by arrows.
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Fig. 4 .8 . Northern blot of pSM 14 RV cDNA. Total RNA was extracted from  
RV infected and uninfected vero cells. The RNAs were electrophoresed 
through a 1 .2%  denaturing agarose gel and blotted on a nylon mambrane. 
The filter was hybridized with a BamHI digested fragment of pSM 14  
labelled with [or-^^P]dCTP. Lane (1 ) RV-infected vero cells shows that pSM 14  
is RV specific. (2) uninfected cells.
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in the RNA of sizes 10.2kb and 3.5kb which resemble genomic and 
subgenomic RNA, similar sizes of RNA RV in infected cells RNA have been 
identified (Nakhasi et al., 1986, Oker-Blom et al., 1984, and Hovi et al., 
1970). This hybridization confirmed that pSM14 cDNA clone contained 
rubella virus cDNA.
E. SEQUENCING.
Three randomly selected cDNA clones, pSM 14, pSM9 and pSM2 were 
sequenced using M l3 mpl 8 . BamHI {0.95Kb & 0.5Kb) and Rsal (0.3Kb) 
cleaved fragments (Fig. 4.9) of inserts were subcloned into M l3 into a 
BamHI and Smal sites for sequencing. Sequencing was carried out using 
"Sequenase Version 2.0" protocol for dideoxy-sequencing using universal 
primers.
Sequence data obtained was compared to the El sequence data obtained 
by others in the group for Thomas strain (J. Newcombe, A. Knight and P. 
Sanders, PC) and the consensus sequence (Fig. 4.10.) was compared to 
published RV sequences from other strains. The Thomas sequence is over 
90% homologous to the El envelope gene sequences of Therien wt strain 
(Vidgren et al., 1987; Dominguez et al., 1990), M33 wt strain (Nakhasi et 
al., 1986; Clark et al, 1987), Judith wt strain (Ho-Terry et al., 1988), 
RA27/3 (Nakhasi et al., 1989) and HPV77 (Zheng et al., 1989). The El 
gene was not expected to be isolated in this study as the synthetic primers 
used were aimed to isolate coding sequences for the E2 and C regions. All 
El cDNA clones sequenced contained 32 nucleotides from the signal peptide 
at the 5' end of the gene and extended to the end of the subgenomic 
sequence including the noncoding sequence at the 3' end. The cDNAs did 
not contain poly A tails.
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Fig. 4.I01A) Comparison of RV El cDNA sequences (8193-9757) from RV 
strains. Thomas, Therien, M33, HPV77 and RA27/3 (A). (B) Comparison o 
.-El glycoprotein amino acid sequences of the same strains,f 
(CLUSTAL analysis by P. Sanders).
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RA27/3 1AC11CAACCC1CGCGGCAGC1AC1ACAAGCAGIACCACCC1ACCGCGlGCGACG1IÇAACC1GCC11CGGACACAGCGACGCGGCC1GCIGGGGCTtCCCCACCGACACCG1GA1GAGC
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thomns G1G11CGCCC1IGCtAGCIACGICCAGCACCCtCACAAGACCGCCCGGGICAAGMCCAIACACAGACCAGGACCGtCIGCCAACICICCCIIGCCGGGGIGICGIGCAACGTCACCACI 
Ih e r  V 01ClICGCCCI1GC1AGCIACG1CCAGCACCC1CACAAGACCGICCGGGICAAGIICCA1ACAGAGACCAGGACCGIC1CGCAACIC1CCG11GCCGGCG1G1CGIGCAACG1CACCACT 
Ih c r  0 GIGITCGCCCMGCIAGCIACGICCAGCACCCICACAACACCGICCGGGlCAAGIICCATACACACACCAGGACCGICIGGCAAOICICCGIIGCCCGCGTGtCGIGCAACGICACCACT 
H33: N G1GMCGCCCICGCIAGCIACGICCAGCACCC1CACAAGACCGICCGGGICAAGI11CA1ACAGAGACIAGGACCGtC1GGCAACtC1CCG1AGCCGGCG1G1CG1GCAACG1CACCACt 
H33: C OIGItCGCCCICGCtAGCtACGICCAGCACCCICACAAGACCGICCGGGICAAGIIICAIACAGAGACIAGGACCGtCICGCAACICICCGtAGCCGGCGIGICGICCAACGICACCACT 
Ju d Ith
IIPV77 GÎC1ICGCCCICGCIAGCIACCICCAGCACCCICACAAGACCGICCGGGICAAGIIICAIACACAGACIAGGACCGICIGGCAACICICCGIAGCCGGCGIOICCIOCAACGICACCACI 
RA27/3 G1G11CGCCCICCCtAGC1ACGICCAGCACCC1CACAACACCGtCCGGG1CAAG111CAIACAGAGACIACGAC1G1C1CGCAAC1C1CCG11GC1CGCG1C1CG1GCAACC1CACCAC1
ValPheA loleuA lflScrlyrV BlG liilllsProlllslyslhrA iBA rgV aU ysPhclIlslhrG lulhrA rglhrV flllrpG lnlcuSerV D lA lBG lyV ntSerCysA snV allhrThr
723/161 Vnl
8793 8853
Ihomns CAACACCCG1tC1CCAACACCCCGCACCGACAAC1CGAGG1CCAGC1CCCGCCCGACCCCG0GGACC1CC11GAGtACA11AIGAAI1ACACCGGCAATCAGCAG1CCCGG1GGGGCC1C 
Ih c r  V GAACACCCGIIC1CCAACACGCCCCACGGACAAC1CCAGG1CCAGG1CCCCCCCGACCCCCGGGACC1GGI1GAGIACAI1AICAA11ACACCGGCAAICAGCA01CCCGG1GGGGCC1C 
Ih c r  0 GAACACCCGIIC1GCAACACGCCCCACGGACAAC1CGACG1CCAGGICCCGCCCGACCCCGGGGACC1GGt1GAC1ACA11A1GAA11ACACCGGCAA1CAGCAG1CCCGG1GCGCCC1C 
H33: N GAACACCCCItCtCCAACACGCCGCACGGACAACICGAGGICCAGGtCCCGCCCGACCCIGGCGACCIGGMCAGIACAMAIGAAttACACCGCCAACCAACAGICCCGGICGGGCCIC 
H33; C CAACACCCG11C1GCAACACGCCGCACGGACAAC1CGAGG1CCAGG1CCCGCCCGACCC1GGGGACCIGGICCAGIACA11A1GAA11ACACCGGCAACCAACAG1CCCGG1GCGGCCIC 
Ju d Ith
IIPV77 CAACACCCG11C1GCAACACGCCCCACGGACAAC1CGAGG1CCAGG1CCCGCCCCACCC1GGGGACCIGG1CGAG1ACA11A1GAA11ACACCGGCAACCAACAC1CCCGG1GGGGCC1C 
RA27/3 CAACACCCG11C1GCAACACGCCCCACGGACAAC1CGAGG1CCACG1CÇ1ÇCCIGACCC1CGCCACC1GGI1GAG1ACA11ATGAACÇAÇACCGCCAA1CAGCA01CCCGC1GCCGCC1C
............................ ................................................................................ Z " ' 3 ...........3 ........................3 ............................... .......................... .................................................
ClulllsProPhcCysA snlhrrrolllsG lyG lnlcuG luV alG lnV B lrroProA spProC lyA sptcuV B lG tulyrU cH ctA snlyrlhrG lyA siiG lnG tnScrA rglrpG lyleu
7 6 3 /1 8 1  I w  j i j s
8913 8973
Thomas GGGAGCCCGAATTGCCACGGCCCCGATTGGGCCTCCCCGGTllGCCAACGCCATTCCCCTGACTGCTCGCGGCTTGTGGGGGCCACGCCAGAGCGTCCCCGGCTGCGCCTGGTCGACGCC 
Ther V GGGAGCCCGAATTGCCACGGCCCCGATTGGGCCTCCCCGGÎTTGCCAACGCCATTCCCCTGACTGCICGCGGCTIGIGGGGGCCACGCCAGAGCGCCCCCGGCTGCGCCTGGTCGACGCC 
T her D GGGAGCCCGAATTGCCACGGCCCCGATTGGGCCTCCCCGGTTTGCCAACGCCATTCCCCTGACTGCTCGCGGCTTGTGGGGGCCACGCCAGAGCGCCCCCGGCTGCGCCTGGTCGACGCC 
M33: N GGGAGCCCGAATTGTCATGGCCCCGATTGGGCCTCCCCGGTTTGCCAACGCCACTCCCCTGACTGCTCGCGGCTTGTGGGGGCCACGCCAGAGCGTCCCCGGCTGCGCCTGGTCGACGCC 
H33; C GGGAGCCCGAATTGTCATGGCCCCGATTGGGCCTCCCCGGTTTGCCAACGCCACTCCCCTGACTGCTCGCGGCTTGTGGGGGCCACGCCAGAGCGTCCCCGGCTGCGCCTGGTCGACGCC 
J u d i th
HPV77 GGGAGCCCGAATTGTCATGGCCCCGATTGGGCCTCCCCGGTTTGCCAACGCCATTCCCCTGACTGCTCGCGGCTTGTGGGGGCCACGCCAGAGCGTCCCCGGCTGCGCCTGGTCGACGCC 
RA27/3 GGGAGCCCGAATTGCCATGGCCCCGATTGGGCCTCCCCGGTTTGCCAACGCCATTCCCCTGACTGC1CGCGGCTTGTGGGGGTCACGCCAGAGCGTCCCCGGCTGCGCCTGGTCGACGCC
G lyScrProA snC ysH isG tyProA spTrpA taSerProV alC ysG lnA rgH îsSerProA spC ysSerA rgLeuV alG lyA laThrProG luA rgProA rgL euA rgLeuV alA spA la 
803/221 V al
9033 9093
Thomas GACGACCCCCTGCTGCGCACTGCCCCTGGGCCCGGCGAGGTGICGGTCACGCCTGTCATAGGCTCTCAGGCGCGCAAGTGCGGACTCCACATACGCGCTGGACCCTACGGCCATGCTACC 
Ther V GACGACCCCCTGCTGCGCACTGCCCCTGGACCCGGCGAGGTGTGGGTCACGCCTGTCATAGGCTCTCAGGCCCGCAAGTGCGGACTCCACATACGCGCTGGACCGTACGGCCATGCTACC 
Ther D GACGACCCCCTGCTGCGCACTGCCCCTGGACCCGGCGAGGTG1GGGTCACGCCTGTCATAGGCTCTCAGGCGCGCAAGTGCGGAC1CCACATACGCGCTGGACCGTACGGCCATGCTACC 
M33: N GATGACCCCCTGCTGCGCACTGCCCCCGGGCCCGGCGAGGTGTGGGICACGCCIGTCATAGGCTCTCAGGCGCGCAAGTGCGGACTCCACATACGTGCTGGACCGTACGGCCATGCTACC 
M33: C GATGACCCCCTGCTGCGCACTGCCCCCGGGCCCGGCGACGTCTGGGICACGCCTGTCATAGGCICTCAGGCGCGCAAGTGCGGACTCCACATACGTGCTGGACCGTACGGCCATGCTACC 
J u d i th
IIPV77 GACGACCCCCTGCTGCGCACTGCCCCCGGGCCCGGCGAGGTGTGGGTCACGCCTGTCATAGGCTCTCAGGCGCGCAAGTGCGGACTCCACATACGTGCTGGACCGTACGGCCATGCTACC 
RA27/3 GACGACCCCCTGCTGCGCACTGCCCCTGGGCCCGGCGAGGTGTGGGTCACGCCTGTCATAGGCTCTCAGGCGCGCAAGIGCGGACTCCACATACGCGCTGGACCGTACGGCCATGCTACC
**************************3******************
A spA spP roL euL euA rgT hrA laProG lyProG lyG luV alT rpV alT hrProV alIleG lySerG lnA laA rgL ysC ysG tyL euH isH eA rgA laG lyProT yrG lyH isA laT hr 
843/261
9153 9213
Thomas GTCGAAATGCCCGAGTGGATCCACGCCCACACCACCAGCGACCCCTGGCACCCACCGGGCCCCTTGGGGCTGAAGTTCAAGACAGTTCGCCCGGTGGCCCTGCCACGCGCGTTGGCGCCA 
Ther V GTCGAAATGCCCGAGTGGATCCACGCCCACACCACCAGCGACCCCTGGCATCCACCGGGCCCCTTGGGGCTGAAGTTCAAGACAGTTCGCCCGGTGGCCCTGCCACGCACGTTAGCGCCA 
Ther 0 GTCGAAATGCCCGAGTGGATCCACGCCCACACCACCACCGACCCCTGGCATCCACCGGGCCCCTTCGGGCTCAAGTTCAAGACAGTTCGCCCGGTGGCCCTGCCACGCACGTTAGCGCCA 
M33: N GTCGAAATGCCCGAGTGGATCCACGCCCACACTACCAGCGACCCCTGGCACCCACCGGGCCCCTTGGGGTTGAAGTTCAAGACAGTTCGCCCGGTGGCCCTGCCACGCGCGTTAGCGCCA 
M33: C GTCGAAATGCCCGAGIGGATCCACGCCCACACTACCAGCGACCCCÎGGCACCCACCGGGCCCCTTGGGGCTGAAGÎTCAAGACAGTTCGCCCGGTGGCCCTGCCACGCGCGTTAGCGCCA 
J u d i th  CCGAGTGGATCCACGCCCACACCACCAGCGACCCCTGGCACCCACCGGGCCCCTTGGGGCIGAAGTTCAAGACAGTICGCCCGGTGGCCCTGCCACGCGCGTTAGCGCCA
IIPV77 GTCGAAATGCCCGAGTGGATCCACGCCCACACTACCAGCGACCCCTGGCACCCACCCGGCCCCTTGGGGCTGAAGTTCAAGACAGITCGCCCGGTGGCCCTGCCACGCGCGTTAGCGCCA 
RA27/3 CTCGAAATGCCCGAG1GGATCCACGCCCACTCTACCAGCGACCCC1GGCACCCACCGGGCCCCTTGCGGTTGAAGTTCAAGACAGTTCGCCCGGTGGCCCTGCCACGCGCGTTAGCGCCA
V alG luH etP roG luT rpIleH isA laH isT hrT hrS erA spP roT rpM isP roProG lyP roL euG tyL euL ysPhelysT hrV alA rgP roV alA laL euP roA rgA laL euA laP ro  
833 /301 S e r Arg Thr
9273 9333
Thomas CCCCGCAATGTGCGTGTGACCGGGIGCTACCAGTCCGCTACCCCCGCGCTGGTGGAAGGCCTTGCCCCCGGGGGAGGGAATTGCCATCTCACCGTCAATGGCGAGGACGTCGGCGCCTTC 
Ther V CCCCGCAATGTGCGTGTGACCGGGTGCTACCAGTGCGGTACCCCCGCGCTGGTGGAAGGCCTTGCCCCCGGGGGAGGCAATTGCCATCTCACCGTCAATGGCGAGGACGTCGGCGCCGTÇ 
Ther D CCCCGCAATGTGCGTGTGACCGGGTGCTACCAGTGCGGTACCCCCGCGCTGGTGGAAGGCCTTGCCCCCGGGGGAGGCAATTGCCATCTCACCGTCAATGGCGAGGACCTCGGCGCCGTÇ 
M33: N CCTCGCAATGTGCGTGTGACCGGCTGCTACCAGTGCGGTACCCCCGCGCTGGTGGAAGGCCTTGCCCCAGGGGGAGGGAACTGCCATCTTACCGTCAATGGCGAGGACGTCGGCGCCTTC 
H33: C CCTCGCAATGTGCGTGTGACCGGCTGCTACCAGIGCGGIACCCCCGCGCTGGTGGAAGGCCTTGCCCCAGGGGGAGGGAACTGCCATCTTACCGTCAATGGCGAGGACGTCGGCGCCTTC 
J u d i th  CCTCGCAATGTGCGTGTGACCGGCTGCTACCAGTGCGGTACCCCCGCGC1GGTGGAAGGCCTTGCCCCAGGGGGAGGGAATTGCCATCTCACCGTCAATGGCGAGGACGTCGGCGCCGTÇ 
HPV77 CCTCGCAATGTGCGTGTGACCGGCTGCTACCAGTGCGGIACCCCCGCGCTGGTGGAAGGCCTTGCCCCAGGGGGAGGGAACTGCCATCTTACCGTCAATGGCGAGGACGTCGGCGCCTTC 
RA27/3 CCCCGCAATGTGCGTGTGACCGGGTGCTACCAGTGCGGTACCCCCGCGCTGGTGGAAGGCCTIGCCCCGGGGGGAGGGAATTGCCATCTCACCGTCAATGGCGAGGATGTCGGCGCCTTC
ProArgAsnValArgValThrGlyCysTyrGlnCysGlyThrProAlaLcuValGluGlyLeuAlaProGlyGlyGlyAsnCysHisLeuThrValAsnGlyGluAspValGlyAlaPhe
923/341 t e u  M
9393 9453
Thomas CCCCCTGGGAAGTTCGTCACCGCCGCCCTCCTCAACACCCCCCCGCCCTACCAAGTCAGC1GCGGGGGCGAGAGCGATCGCGCGAGCGCGCGGGTCATTGATCCCGCCGCGCAATCGTTT 
Ther V CCCCCTGGGAAGTTCGTCACCGCCGCCCTCCTCAACACCCCCCCGCCCTACCAAGTCAGC1GCGGGGGCGAGAGCGATCGCGCGAGCGCGCGGGTCATCGACCCCGCCGCGCAATCGTTT 
Ther 0 CCCCCTGGGAAGTTCGTCACCGCCGCCCTCCTCAACACCCCCCCGCCCTACCAAGTCACCTGCGGGGGCGAGAGCGATCGCGCGACCGCGCGGGTCATCGACCCCGCCGCGCAATCGTTT 
M33; N CCCCCTGGGAAGTTCGTCACCGCCGCCCTCCICAACACTCCCCCGCCCIACCAAGICAGCIGCGGGGGTGAGAGCGATCGCGCGAGCGCGCGGGTCATTGACCCCGCCGCGCAATCGTTT 
H33: c CCCCCTGGGAAGTTCGTCACCGCCGCCCTCCTCAACACTCCCCCGCCCTACCAAGICAGCIGCGGGGGTGAGAGCGATCGCGCGAGCgcGCGGGTCATTGAcCCCGCcGCGCAATCGTTT 
J u d i th  CCCCCTGGGAAGTTCGTCACCGCCGCCCTCCTCAACACCCCCCCGCCCTACCAAGTCAGCTGCGGGGGCGAGAGCGATCGCGCGACCGCGCGGGTCATTGACCCCGCCGCGCAATCGTTT. 
HPV77 CCCCCTGGGAAGTTCGTCACCCCCGCCCICCTCAACACICCCCCGCCCTACCAAGICAGCTGCGGGGGTGAGAGCGATCGCGCGAGCGCGCGGGTCATTGACCCCGCCGCGCAATCGTTT 
RA27/3 CCCCCTGGGAAGTÎCGTCACCGCCGCCCTCCTCAACACTCCCCCGCCCTACCAAG1CAGCTGCGGGGGCGAGAGCGATCGCGCGAGCGCGCGGGTCATTGACCCCGCCGCGCAATCGTTT 
************************.
P roP roG tyL ysP heV atlh rA taA ia leuL cuA snT hrP roP roP roT yrG tnV aiS erC ysG lyG tyG luS erA spA rgA laS erA laA rgV atIleA spP roA laA laG lnS erP he  
963 /381  Thr
9513 9573
Thomas ACCGGCGTGGTGTATGGCACACACACCAcrGCIGTGTCGGAGACCCGGCAGACCTGGGCGGAGIGGGCTGCTGCCCATTGGTGGCAGCTCACTCTGGGCGCCATTTGCGCCCTCCTACTC 
Ther V ACCGGCGTGGTGTATGGCACACACACCACIGCTGTGTCGGAGACCCGGCAGACCTGGGCGGAGTGGGCTGCTGCCCATTGGTGGCAGCTCACTCTGGGCGCCACTTGCGCCCTCCCACTC 
Ther D ACCGGCGTGGTGTATGGCACACACACCACTGCTGTGTCGGAGACCCGGCAGACCTGGGCGGAGTGGGCTGCTGCCCATTGGTGGCAGCTCACTCTGGGCGCCATTTGCGCCCTCCCACTC 
M33: N ACCGGCGTGGTGTATGGCACACACACCACTGCTGTGICGGAGACCCGGCAGACCTGGGCGGAGTGGGCTGCTGCICATTGGTGGCAGCTCACrCTGGGCGCCATITGCGCCCTCCTACTC 
M33: C ACCGGCGTGGTGTATGGCACACACACCACTGCrGTGTCGGAGACCCGGCACACCTGGCCCGACTGCGCTCCTGCTCATTGGTGGCAGCTCACTCTGGGCGCCATTTGCGCCCTCCCACTC 
J u d i th  ACCGGCGTGGTGTATGGCACACACACCACIGCTGIGTCGGAGACCCGGCAGACCTGGGCGGAGTGGGCTGCTGCCCATTGGTGGCAGCTCACTCTGGGCGCCGICTGCGCCCTCCTACTC 
HPV77 ACCGGCGTGGTGTATGGCACACACACCACTGCTGIGTCGGAGACCCGGCAGACCTGGGCGGAGTGGGCTGCTGCTCATTGGTGGCAGCTCACTCTGGGCGCCATTTGCGCCCTCCTACTC 
RA27/3 ACCGGCGTGGTGTATGGCACACACACCACTGCTGTGTCGGAGACCCGGCAGACCTGGGCGGAGTGGGCTGCTGCCCAITGGTGGCAGCTCACTCTGGGCGCCATTÎGCGCCCICCTACTT 
**************************************************************************3***************************123**********2***3 
T hrG lyV alV alT yrG lyT hrH isT hrT hrA laV alSerG luT hrA rgG lnlhrT  rpAlaG luT rp A laA laA laü isT rpT rpG lnL euT hrL euG lyA la lleC ysA laL euL euL eu  
1003/421 T hr P ro
9633 9693
Thomas GCCGGCTTACTCGCTTGCTGTGCCAAATGCTTGTACTACTTCCGCCGCGCTATAGCGCCGCGCTAGIGGCCCCCCGCGCGAAACCCGCACTAGCCCACTAGATTCCCGCACCTGTTGCTG 
T her V GCTGGCTTACTCGCTTGCTGTGCCAAATGCTTGTACTACTIGCGCGGCGCTATAGCGCCGCGCTAGIGGGCCCCCGCGCGAAACCCGCACTAGGCCACTAGATTCCCGCACCTGTTGCTG 
T her 0 GCTGGCTTACTCGCTTGCTGTGCCAAAIGCTTGTACTACTTGCGCGGCGCTATAGCGCCTCGCTAGTGGGCCCCCGCGCGAAACCCGCACTAGGCCACTAGATCCCCGCACCTGTTGCTG 
M33: N GCTGGCTTACTCGCITGCTGTGCCAAATGCTTGTACTACTTGCGCGGCGCTATAGCACCGCGCTAGCGGGCCCCCGCGCGAAACCCGCACTAGCCCACTAGATTCCCGCACCTGTTGCTG 
M33: C GCTGGCTTACTCGCTTGCTGTGCCAAATGCTIGÎACTACTTGCGCGGCGCTATAGCACCGCGCTAGCGGGCCCCCGCGCGAAACCCGCACTAGCCCACTAGATTCCCGCACCTGTTGCTG 
J u d i th  GCTGGCTTGCTCGCTTGCTGTGCCAAGTGCTTGTACTACTTGCGCGGCGCTATAGCGCCGCGCTAGTGGGCCCCCGCGTGAAACCCGCACTAGCCCACTAGATTCCCGC-CCTGTTGCTG 
HPV77 GCTGGCTTACTCGCTTGCTGTGCCAAATGCTTGTACTACTTGCGCGGCGCTATAGCACCGCGCTAGCGGGCCCCCGCGCGAAACCCGCACTAGCCCACTAGATTCCCGCACCTGTTGCTG 
RA27/3 GCTGGCTTACTCGCTTGCTGTGCCAAATGCTTGTACTACTTGCGCGGCGCTATAGCGCCGCGCTAGTGGGCCCCCGCGCGAAACCCGCACTAGCCCACTAGATTCCCGCACCTGTTGCTG
* * * * * * * * * * *  * * * * * * * * * * * * * *  * * * * * * * * *  * * * * *  * * * * * * * * * *
A laG ty leuL euA laC ysC ysA lalysC ysL euT yrT yrL euA rgG lyA lalleA laP roA rg 
1043/461 481
9753 
Thomas CATAGpA 
Ther V TATATpA 
Ther D TATAGpA 
H33: N CATAGpA 
H33: C CATAGpA 
J u d i th  TATAGpA 
MPV77 CATAGpA 
RA27/3 CATAGpA
The Com parison  i s  from  20 amino a c id s  u p s tre a m  o f  th e  m a tu re  Ei p r o t e i n .  N u c ic o t id e s  a r e  num bered a c c o rd in g  to  Dom inguez e t  a t. f o r  th e  genom ic RNA. 
Am num bering  s t a r t s  from  th e  s t a r t  o f  th e  s t r u c t u r â t  p o iy p r o t e in  ( b e f o r e  / )  end  from  th e  s t a r t  o f  th e  m atu re  El p r o t e i n  ( a f t e r  / ) .
^  The numbers at the bottom line indicate the position of base change in the 
codon.
(B) Comparison of E l glycoprotein amino acid sequences of the same strains.
so 100
Thomas 
T h e r  V 
T h e r D 
M33 M 
H33 C 
J u d i t h  
HPV77 
RA273
EEAFTYLCTAPGCATQTPVPVRLAGVRFESKlVDGGCFAPVfDLEATGACICElPTDVSCEGLGAVfVPTAPCARlWNGTQRACTFWAVNAYSSGGYAQLAS 692
ISO 200
Thomas YFNPGGSYYKQYHPTACEVEPAFGHSDAACWGFPTDTVMSVFALASYVQHPHKTARVKFHTETRTWQLSVAGVSCNVTTEHPFCNTPHCQLEVQVPPDP 792 
T h e r  V E V P
T h e r D E V P
M33 N E V P
M33 C E V P
J u d i t h  E V P
HPV77 E V P
RA273 Q V L
ep2 ep3 e p l  300
Thomas GDLVEYIMNTtGNQQSRWGI.GSPNCHG?DWASPVCQRHSPDSaU.VGATPERPRLIU:.VDADDPLLRTAPGPGEVWVTPVIGSQARKCGLHIRAG?YGHAT
T h e r 7 Y A
T h e r D Y A
M3 3 N Y A
M3 3 C Y A
J u d i t h Y A
HPV77 Y A
RA273 H V
350 * 400
Thomas VEMPEWIHAHTTSbPWHPPGPLGLKFKTVRPVALPRALAPPRNVRVTGC/QCGTPASLVEGLAPGGGNCHLTVMGEDVGAFPPGKFVTAALOTPPPYQVS
T h e r V T G T. V V
T h e r 0 T G T L  V
M33 N : T G A V F
M3 3 C T G A V F '
J u d i t h T G A V V
HPV77 T G A V F
RA273 S R A V F
450 481
Thomas CGGESDRASARVIDPAAQSFTGWYGTHTTAVSETRQTWAEWAAAHWWQLTI.GAICALriAGLLACCAKCLYYLRGAIAPR 1063 
T h e r V S  T P
T h e r D T I P
M33 N S I  L
M33 C S I P
J u d i t h  T V L
HPV77 S I  L
RA273 S I  L
4.6 . DISCUSSION. 
cDNA CLONING.
The cDNA synthesis initiated in this study using primers V535 and 837A 
was Intended to produce clones containing the E2 and C protein coding 
sequences. However, it would appear that priming with these 
oligonucleotides was unsuccessful, or was much less efficient than the 
mechanism which gave rise to El cDNA clones.
As the cloning of the El gene was not expected it is assumed that the 
cDNA was initiated by self priming. The phenomenonof self priming has been 
reported in the cloning of Pestivirus Bovine Viral Diarrhoea (BVDV). With 
BVDV the reverse transcription step to synthesize cDNA was inefficient and 
low-molecular-weight RNA species <200bp in size were isolated with the 
viral RNA. These low-molecular-weight cellular RNAs were presumed to 
serve as competent random primers on the BVDV RNA (Collett et al., 1988). 
This phenomenoncould explain the cloning of RV El gene in this study. Even 
though the RNA was extracted from virally enriched material this does not 
exclude the presence of small RNA species from the RV infected cells which 
could act as primers. It is also possible that the stem loop structure at the 
3' end of the RV subgenomic RNA (Zheng et al., 1989; Nahkasi et al., 
1990) could be responsible for priming.
The fact that all the cDNA clones are of the same size could be due to 
the high GC content of the virus sequence. This could allow the formation 
of a region of secondary structure which could cause the reverse 
transcriptase to pause and terminate transcription. Sequences, at the 5' end 
of the E l, which could be implicated in pausing are found at position 8189- 
8217 (8189c c g c g g c GCCGCCGCCGCCCTCACCGCGG^^ ^^ ). this sequence 
is able to form a stem loop structure. The El cDNA cloned in this study
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terminates at position 8216 at the 3' end of the secondary structure 
sequence.
SEQUENCE ANALYSIS.
Amino acid sequence analysis of El cDNA clone from rubella virus strain 
Thomas shows that this strain differs from all other strains by one amino 
acid at position 177, where valine (GTC) is replaced by alanine (GCC), which 
are both uncharged, this change appears at the second base of the codon.
The sequences encoding the structural protein El of the Thomas strain, 
wild type strains (Therien, M33 and Judith), and vaccine strains of rubella 
viruses have a total of 74 base substitutions of which 56 are at the third
position, 12 at the first position and 6 at the second position of the codons
in
(Fig. 4.10.). These mutations result in 6-7 aa changes ^ Therien wt strain 
(Vidgren, 1987; Dominguez, 1990), three aa changes from M33 wt strain 
(Nakhasi, 1986; Clark, 1987) and five aa difference from Judith wt strain 
(Ho-Terry et al, 1988). This data (Table, b) shows that the Thomas strain is 
closely related to the wt M33 at least in the aa sequence of the El 
glycoprotein.
The Thomas strain aa sequence of El also differs in eight aa changes 
from RA27/3 (Nakhasi, 1989) and in two a a change from HPV77 vaccine 
strains (Zheng, 1989). Table (a), shows that RA27/3 vaccine strain differ in 
8-11 aa from wt strains while HPV77 differ only in 2-5 aa changes. This 
result might explain the high incidences of vaccine side effects which 
resulted in the removal of HPV77 from the market in 1973. HPV77 had a 
ratio of 49% side effects in vaccinees comparing to 14% from RA27/3 (Polk 
et al., 1988).
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Number of aa changes between rubella virus wt and vaccine
strains.
Strain Thomas Therien M33 Judith
HPV77 2 5 4 3
RA27/3 8 10 9-10 11
Table b: Number of aa chanaes between RV Thomas and wt strains.
Strain Thr.v Thr.d M33n M33c Judith
Thomas 7 6 3 3 5
The comparison shows that the El of strain Thomas shares more than 
90% homology with the other rubella strains. More than 70% of the 
mutations between the strains occur in the third base of the codons which 
imply no change on the amino acid sequence. Sequence mutations do not 
appear in the epitopes so far defined (Terry et al., 1988) nor in the 
glycosylation sites. This suggests that the antigenicity of the virus at these 
epitopes displays no difference among the different RV strains studied. The 
data also shows that Thomas and M33 strains differ in 3aa> however the 
differences between them and Therien strains are 6-7aa. As the M33 and 
Thomas strain are closely related a recombinant vaccine or diagnostic 
reagent from these strains could serve as a better antigen than Therien 
strain.
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CHAPTER 5
CHAPTER 5 
EXPRESSION OF ET GLYCOPROTEIN
5.1 SUMMARY
The El coding sequence was expressed using the bacterial expression 
vector pUEX series. Various subfragments of the El cDNA were expressed 
in £. coH as C-terminal fusions to the R-galactosidase protein expressed 
from the P, promoter derived from bacteriophage lambda. The &-gal-E1 
fusion protein proved to be antigenic when reacted with human polyserum. 
Subfragments of El were also expressed in the same system and resulted 
in similar antigenicity reaction with the fragment containing all epitope 
domains.
A truncated version of the El envelope glycoprotein was constructed 
which lacked the carboxy region transmembrane anchor and had a modified 
truncated signal peptide. This was expressed in eukaryotic cells. The 
truncated protein was detected in the cell culture media, suggesting it was 
no longer anchored in the cell membrane and was now a secreted protein 
variant of E l.
5.2 EXPRESSION OF El IN PROKARYOTIC SYSTEMS.
Expression of eukaryotic viral glycoprotein sequences in bacteria may 
allow synthesis of large quantities of viral antigens that could be useful 
commercially either in immunoassay kits or as vaccines. Several expression
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vectors were studied for the expression of the RV El in which the protein 
was expressed directly, as fusion protein to the alpha fragment of lacZ, or 
as a secreted fusion protein. However the expression was best achieved 
when the protein was fused to the R-galactosidase in plasmid pUEXI.
5.2.1. PRODUCTION OF R-GAL-E1. FUSION PROTEINS.
Rubella cDNA clone pSM14 was selected as a candidate for expression 
of the El gene. Clone pSM14 was digested with PstI to isolate and purify 
a 1.54kb fragment containing the El coding sequence 8216-9757 (Fig. 
4. 9 ) by Geneclean. PstI is a unique site in the El sequence cleaving in the 
middle of the signal peptide at the 5' end of the gene.
Expression vectors pUEXI, pUEX2, and pUEXS were linearized with 
PstI. The vectors were dephosphorylated with CIP prior to ligation with the 
El fragment allowing the insert to be ligated in three reading frames. 
Although the correct reading frame is known from previous studies (Nakhasi 
et al.,1986; Frey et al., 1986) it was decided to express the other reading 
frames to serve as negative controls. Due to the unexpected deletions that 
occurred in the original cloning vector and due to the fact that rec+ E. coH. 
strains are less stable than rec- strains (Smith et al. 1987), it was decided 
to replace MC1061 strain with E. coH DH5a competent cells (BRL) for DNA 
transformation. The transformed cells were plated out onto 25ug/ml 
ampicillin agar plates. The Orientation of the insert was determined by 
BamHI digestion.
Recombinant colonies of El cloned into pUEXI, 2, and 3 were 
designated pSXEII, pSXE12, and pSXE13 respectively (Fig. 5.1). A single 
colony from each was inoculated into 10ml L-broth 25ug/ml ampicillin and 
grown overnight at 30°C with shaking. Fresh medium was inoculated on the
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following day from the overnight culture and grown up to an O.D550 of 0.5. 
The culture was then placed at 4 2 ®C waterbath for 2 hrs to induce 
expression of the fusion protein. Bacterial cultures were pelleted and then 
resuspended in 20ul of sample buffer. Due to the large size of the fusion 
protein (approximately 166kD), the samples were loaded on a 7%  
SDS/PAGE. The gel was run at 120V until the dye was 1cm from the 
bottom and stained with coomassie brilliant blue.
On a 7% SDS/PAGE, coomassie brilliant blue stained, no bands 
resembling the size of recombinant proteins were detected. It was decided 
that a more sensitive method of detection was needed, therefore a second 
gel was silver stained, (Fig. 5.2) shows cell lysates samples of transformed
E. coli, containing recombinant plasmids. Uninduced (b) and induced cultures 
of pSXE11, lanes(c & d), show no fusion protein band at the expected size 
of 166kD, which contains El protein in the correct reading frame to produce 
the R-gal-E1. Fusion protein bands were observed in cultures containing 
pSXE12 and pSXEIS induced cultures, which show the addition to B- 
galactosidase of 49aa and 65aa respectively of the El protein in the 
alternative ORFs (g & j). Uninduced and induced cultures of pUEXI, lane (n) 
and (m), shows the original band of B-galactosidase at 110 kD. Induced 
overnight cultures of all samples were included to check the quantity of 
proteins produced in comparison to 2 hrs of log phase growth, this 
procedure gave poor yields of the fusion proteins.
5.2.2. IMMUNOPRECIPITATION.
Immunoprécipitation of B-galactosidase hybrid proteins was then 
performed using anti-B-galactosidase antibodies to affinity purify the fusion 
protein from 1ml of sonicated cell lysate. The antibody B-gal-E1 was 
precipitated with protein A beads (Bioprocessing) which were subsequently
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Fig. 5.2. Detection of recombinant El and E2 proteins expressed in E. coU. 
The lysates of transformed bacterial cells were electrophoresed through a 
7% SDS/PAGE which was silver stained. Lane (a) Untransformed cell lysate. 
(b,e,h) Uninduced pSXEII and pSXEI2 and pSXEI3. Overnight induced 
cultures of pSXEII (c) pSXEI2 (f) and pSXE13 (i), 2hrs induction of the 
same cultures are shown in lanes (d,g,j). Lane (n) is uninduced pUEXl, while 
lanes (m) 2hr induction of the same culture. The expression of the E2 in 
pUEXI out of frame is shown in lanes k & o uninduced cultures, and I & p 
from the induced cultures containing pSXE23 and pSXE24 respectively. 
Arrows indicate positions of fusion protein bands.
resuspended in sample buffer and loaded onto a 7% SDS/PAGE which was 
western blotted after electrophoresis. The B-gal-E1 fusion proteins were 
detected by anti-B-galactosidase antibodies on the western blot.
Fig. 5.3 shows the Immunoprecipitated fusion proteins produced In all three 
reading frames by the different pUEX vectors. Vector pUEXI expressing B- 
galactosidase on its own is in lane (a), while lanes (c, e and g) shows the B- 
gal-EI fusion proteins from induced cultures containing pSXE11 ,12 , and 13 
respectively. Uninduced culture samples do not appear In lanes b, d, and f 
Indicating the absence of the protein. The level of expression can be 
affected by the size of the protein and therefore 10 times more protein from 
pSXEII expression was loaded than the other samples.
It can be seen that the protein bands are very faint indicating poor 
yields of the fusion proteins, this is due to the fusion protein in the cell 
lysate being less than 4% of total cell protein. Subsequently it is shown that 
the majority of the fusion protein is in inclusion bodies therefore they 
remained in the cell pellet after centrifugation (Stanley et al., 1984).
5.2.3. ANALYSIS OF PUEX TRANSCRIPTION.
Northern blot was carried out to check the transcription from the 
recombinant pUEX vectors, even though it was not recommended by the 
supplier due to RNA degradation after heat induction. lOug of total RNA 
was electrophoresed, northern blotted and probed with a Sail fragment 
(500bp) from the El gene (Fig. 4. 9 ). In spite of the degradation of the 
RNA, the recombinant sample hybridized to the El probe, while no 
hybridization occurred in the negative control and uninduced samples (Fig.
5.4.).
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Fig. 5.3. Western blot of immunoprecipitated of the B-gal-E1 fusion proteins 
from bacterial cell lysates. The El was expressed in the three ORFs in pUEX 
vectors. The cultures were sonicated and the proteins were 
immunoprecipitated with anti-B-gal antibodies. The proteins were 
electrophoresed through 7% SDS/PAGE and blotted on a nitrocellulose filter. 
The hybrid proteins were detected with anti-B-gal antibodies, (a) S-gai 
protein from pUEXI, (c, e & g) B-gal-E1 fusion protein in the three ORFs 
pSXE11, pSXE12 and pSXEI 3. Lanes b, d and f represent the uninduced 
cultures where no protein bands were detected.
1 2 3 4
Fig. 5.4. Northern blot of pSXE11. RNAs were extracted from transformed 
£.co//cells with pUEXI and pSX EII. lOug of the RNAs were DNAsed and 
electrophoresed through 1.2% denaturing gel and blotted on nylon filter. 
Hybridization was carried out using an El fragment digested with Sail and 
labelled with [a-^^P]dCTP. Lane (1&3) RNAs from uninduced pUEXI and 
pS X E Il. Induced cultures are lanes (2) pUEXI and (4) pS X E II. Bands in 
lanes 1, 2 & 3 resemble ribosomal bands.
5.2.4. EXPRESSION OF SUBFRAGMENTS OF El AS FUSIONS PROTEINS.
Based on Terry's El epitope localization (Appendix A) (Terry et al., 
1988), a further; El modification was chosen which could improve the 
quantity of the fusion protein by reducing the size of the fragment (Stanley 
et al., 1984). Plasmid pSM14 was digested with Smal/BamHI restriction 
enzymes to isolate a fragment of 329bp containing all three epitopes ep2, 
ep3, and epl (Fig. 4 .9  ). Epitope ep2 was also isolated on Its own on a 
531 bp Hindi fragment. Both fragments were purified after agarose gel 
electrophoresis by Geneclean and ligated to a Smal linearized pUEX3 
expression vector, in the appropriate reading frames (Fig. 5.5.). The 
recombinant plasmids with all of the epitopes was designated as pSBI, and 
the ep2 recombinant was pEHI.
5.2.5. ISOLATION OF INCLUSION BODIES CONTAINING 
RECOMBINANT PROTEINS.
Inclusion bodies which contained insoluble aggregated fusion proteins 
were isolated from recombinant strains pSXE11, pEHl, and pSBI. The fusion 
proteins were expected of approximately 166,132, and 124kD respectively. 
Pellets containing approximately lug of inclusion bodies were resuspended 
in 30ul of the sample buffer. Samples containing the purified inclusion 
bodies were electrophoresed through a 7.5% SDS/PAGE stained with 
coomassie blue stain (Fig. 5.6.). Similar PAGE was prepared for a western 
blot. The gel included inclusion body samples along with immunoprecipitated 
cell lysates from recombinant cultures, samples were electrophoresed 
through a 7.5% SDS/PAGE. After separation the proteins were 
electroblotted onto Hybond-C filter paper. The filter was blocked with TBST, 
3% BSA for 2.5 hrs at room temperature. An E. coli, containing pUEXI, pre- 
absorped human polyclonal serum, diluted 1:100 was used to determine the 
antigenicity of the B-gal-E1 hybrid protein.
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Fig. 5.6. Expression of the RV El and subfragments in E. coli fusion 
proteins with R-galactosidase. The hybrid proteins were isolated as inclusion 
bodies. The proteins were electrophoresed through a 7% SDS/PAGE stained 
with coomassie brilliant blue, (a) pSXEI 3, (b) pSXEI 2, (c) pSB1, (d) pSXE11 
and (e) pUXEI. Arrows indicate the sizes of the proteins.
Fig. 5.7. shows lysates from PUEXI, p S B I a n d  pEHl containing, 
lanes 1, 2, and 3, did not react with the polyclonal sera. A fusion protein 
band was detected in lane 4 containing the pSXE11 lysate where, the 
protein had been immunoprecipitated from 20ml of lysed culture. Inclusion 
body fusion protein bands were visualized in lanes 5 and 6 from pSXEH  
and pSBI containing cells, but no bands appeared in lanes 7-9 of pEHl, 
pSXEIS, and pUEXI containing cells. Lane 6-9 shows an extra band of 
unknown high molecular weight protein that cross reacted with the human 
polyclonal serum. A similar co precipitating band has been reported by the 
Ho-Terrys (Ho-Terry, PC).
5 .2 .6. ELECTRON MICROSCOPY.
Inclusion bodies are insoluble aggregates of almost pure chimeric 
proteins. The insolubility is conferred on the foreign expressed protein by the 
insoluble cro-R-galactosidase protein (Stanley et al., 1984). Fig. 5.8. shows 
an electron micrograph of bacterial lysate from pS X E II strain before heat 
induction where the lysate appears as a smooth surface compared to the cell 
lysate after heat induction where the inclusion bodies appear as small 
aggregates.
5.3. ASSAYS FOR ANTIBODY SCREENING USING RECOMBINANT E l.
The immune status of individuals to rubella can be ascertained by a 
number of tests previously discussed. One use of recombinant El proteins 
is as an improved source of antigen for use in these assays. The ability of 
the fusion protein to act in immunoassays to detect antirubella antibodies 
IgG and IgM was therefore investigated.
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Fig. 5.7. Western blot of the expression of RV El in prokaryotes. Bacterial 
cultures containing recombinant plasmid DNAs were sonicated and the 
lysates were immunoprecipitated with anti-R-gal antibodies. Complete El 
and subfragments were fused to the 3' end of lacZ. The immunoprecipitates 
along with the isolated inclusion bodies were detected on a western blot by 
anti-rubella human polyclonal. The serum was preabsorped w ith bacterial 
culture containing the vector. Lanes 1, 2, 3 and 4 contain
immunoprecipitated proteins from cell lysates containing pUEXI, pSBI, pEHl 
and pS X E II. Inclusion bodies from pSXEII and pSBI (5 & 6). Lanes 7-9 
inclusion bodies from the induced cultures of pEHl, pSXEI3 and pUEXI 
showing a high molecular weight protein band that dislpayed cross reactivity 
with the polyserum.
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Fig. 5.8. Electron scanning microscopy of inclusion bodies containing 
aggregated fusion protein R-gal-E1. (A) Uninduced E. coli cell lysate 
containing pSXEII. (B) Same culture after heat induction showing 
aggregated proteins in the cell lysate.
5.3.1. ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA).
To determine wether the El chimeric protein could be used as an 
antigen in ELISA assays to detect rubella IgG, sonicated cell lysates in PBS 
and inclusion bodies were used to coat ELISA plates. Proteins used were 
produced by pUEXI, PEG precipitated virus, pS X E II and pSBI. ELISA 
plates were coated with the antigens, double diluted across the plate. £. coH 
pre-absorped human polyclonal human serum was used as the serum and 
secondary antibody was rabbit-antihuman horse radish peroxidase conjugate 
developedwithABTS(2,2'-AZINO-bis(3-Ethylbenzthiozoline-6-SulfonicAcid) 
as the substrate.
The ELISA indicated that there was a difference between the negative 
and the positive samples (1:2) of inclusion bodies coated wells. On the other 
hand there was no significant difference between the lysate samples. The 
ELISA suffered a high background reactivity which could be due to using E. 
coli as host. E. coli is a natural inhabitant in the human body as well as the 
anti-S-gal antibodies are found in the human sera, this was checked by 
Starky, St Thomas Hospital.
Attempts to reduce the non-specific cross reactivity were pursued by 
changing the incubation time with 3% BSA for blocking. No reaction was 
obtained when casein was used as a blocking agent. The plates were coated 
with different antigens or antibodies such as anti-S-gal antibody, human 
polyclonal serum, cell lysates or purified sonicated inclusion bodies. Other 
factors altered were the dilution of primary antibody in 2%  BSA rather than 
1% BSA. However the system still needs optimization to accommodate for 
recombinant antigens.
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5.3.2. M-ANTIBODY CAPTURE RADIOIMMUNOASSAY (MACRIA).
MACRIA is the most sensitive and reliable technique in routine use in 
the UK for detection of rubella-specific IgM. A MACRIA kit is commercially 
available. This technique employs a solid phase coated with antihuman IgM 
which is sequentially incubated with test serum, rubella antigen and a 
monoclonal anti-rubella antibody labelled with iodine-125 (Mortimer et al.,
1981).
The MACRIA technique was used to test B-gal-E1 fusion protein as 
an antigen to detect IgM antibody in three different rubella-infected fetal 
sera. The protein was antigenically active and gave significant results with 
the sera, which were similar to the results obtained when the whole virus 
used as an antigen. Anti-rubella IgM antibody were detected in the positive 
sera of three rubella infected fetus while no reaction occurred with the 
uninfected sera (Starky, St. Thomas hospital) (Fig. 5.9.).
5.4. EXPRESSION OF El IN MAMMALIAN CELLS.
El was expressed in COS-1 cells by truncating the anchor region of 
the gene and deleting 9 amino acids from the signal peptide. The full length 
El coding sequence and a truncated version both using a full length 
heterologous signal peptide is under study (Newcomb, PC).
5 .4 .1 . MODIFICATION OF El CDNA.
The cDNA coding for the El protein was modified at its 5' and 3 ' ends 
using PCR technology. Two synthetic oligonucleotides 5E1 and TrEI were 
made using 381A DNA synthesizer (Applied Biosystems). Oligo 5E1 is
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located at 8110-8128 which leads to the reduction of the signal peptide size 
from 21 amino acids to 11 amino acids. Such a size reduction was chosen 
to determine if the protein can be translocated in the presence of a signal 
peptide containing minimum aa residues required for protein translocation 
through the cell membrane (Perlman and Halvorson, 1983). On the other 
hand oligo TrEI 9586-9599 truncated the gene at the 3 ' end eliminating 
156bp coding for 53 amino acids and including 21 residues of the putative 
transmembrane anchor region. Both oligonucleotides contained an EcoRI 
restriction site (GAATTC) to facilitate cloning in the vector pUSIOOO. 
Furthermore, an in frame translation initiation codon, ATG, was added to the 
5' end of the gene and contained within an Ncol restriction site (CCATGG). 
An in frame stop codon, TAG, was also added to the 3' end. The 
oligonucleotide sequences are shown below:
Primer 5E1
^'AAGAATTCACCATGGTCCTGCAGGGGTACAAC®' 
—^CAGGACGTCCCCATGTTG®’
Primer TrEI
^'GGGTAACCACCGTCATCCTTAAGTAA®'
■—'CCCATTGGTGGCAG^'—
Ing of plasmid pS X E II DNA was used in the PCR reaction at an 
annealing temperature of 37®C with 3min. extension cycles. The El 
fragment of 1380 nucleotides was isolated and purified by Geneclean (Fig. 
5.10.). Subsequently the ends were filled in using the Klenow enzyme and
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Fig. 5.10. The El cDNA modification using PCR. Ing of pSXE11 DNA was 
used in the reaction. The modified cDNA was purified by Geneclean and 
cloned in plasmid pUSIOOO.
the filled in molecules were phosphorylated with T4 pol. kinase. The 
modified DNA fragment was cloned into the unique Smal site of pUCI 3. The 
DNA ligation mix was transformed in E. coli DH5" competent cells.
The El insert was excised from pUC13 by EcoRI digestion, 
electrophoresed through a 0.8%  agarose gel, Genecleaned, and subcloned 
into the unique EcoRI site of plasmid pUSIOOO. The orientation of the insert 
was determined by BamHI digestion. The recombinant plasmid pUSIOOO 
plus El was designated pEMI (Fig. 5.11 ). The plasmid was purified by CsCI 
large scale plasmid preparation for COS-1 cells transfection.
5.4 .2. TRANSFECTION OF COS CELLS.
COS-1 cells were transfected with, 0.5-1 ug DNA of pUSIOOO and 
recombinant plasmid pEMI per 35mm well (Section 2.1.6). Cells were 
incubated with the DNA-DEAE dextran cocktail and tissue culture medium, 
containing 80uM chloroquine for 3hrs at 37°C  5% COg. The medium was 
removed by aspiration and replaced by 1 ml of fresh medium containing 10%  
DMSO for 2.5 min. Cells were washed and incubated in a medium 
containing 10% foetal calf serum for 48-72 hrs. RNA was then harvested 
from cells and transfected cells were also radiolabelled. The growth medium 
was replaced by methionine-free DMEM medium containing 50uCi [^^S]- 
methionine/well for 2-4 hrs.
5.4 .3 . RNA EXTRACTION.
RNA was extracted from cells using the RNAzol method. 2.5ug of each 
RNA sample were electrophoresed through a 1.2% denaturing agarose gel.
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The RNA gel containing samples pUSIOOO and pEMl was blotted 
overnight onto a Hybond-N membrane. A Sail fragment of 740bp from El 
was used as a probe in the hybridization reaction. The membrane was 
hybridized overnight at 42°C , washed twice with 3X SSC 0.1%  SDS, and 
once with 2X SSC 0.1 % SDS followed by a quick rinse with 2X SSC. The 
filter was autoradiographed overnight at -70°C . A band of 1.4kb was 
detected in the RNA from pEMI infected COS-1 cells, which confirms the 
transcription of E l. No band was detected in the RNA from pUSIOOO 
infected cells (Fig. 3.7, See Chapter 3).
5 .4 .4. IMMUNOPRECIPITATION.
Cos-1 cells were harvested and lysed with RIPA lysis buffer. The 
growth media was also collected. Human polyclonal serum was used to 
immunoprecipitate the El antigen from cell lysates and growth medium. The 
antibody antigen complex was adsorped onto protein A beads. Samples 
were analysed on an SDS 12.5%  PAGE system by loading the beads in 
sample buffer after boiling for 5 min. The gel was treated with an 
autoradiography enhancer. Amplify, dried and autoradiographed.
A band of 50Kd was detected only in the growth medium of sample 
pEM I, while no extra band appeared neither in the cell lysate of pEMI nor 
in the lanes correspond to the control plasmid which lacks the El coding 
sequence, pUSIOOO. It was concluded that this band corresponds to the 
truncated El protein which is being secreted into the growth medium (Fig. 
3.9, See Chapter 3).
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5. DISCUSSION.
EXPRESSION OF El IN £. COU
E l, one of the two glycoproteins in the rubella virus envelope, represents 
the major viral antigen to which most human rubella specific antibodies are 
directed (Ho, 1983; Mazancourt et al., 1986) and carries at least three major 
epitopes which react with antibodies produced during infection or after 
vaccination (Terry et al., 1988)
RV El coding sequence has been expressed in bacteria as a fusion 
protein fused to the carboxy-terminus of 8-galactosidase. This approach 
provides a simple, efficient and a cost effective method for antigen 
production.
The R-gal-E1 hybrid protein was expressed at high levels (more than 
20%  of total cell proteins) and aggregated in inclusion bodies. Although the 
expression of proteins in inclusion bodies is associated with the fusion of 
foreign genes to the carboxy-terminus of cro-lacZ (Stanley et al., 1984) 
other proteins expressed in different systems has been reported to be 
insoluble. Calf prochymosin, zymogen of the milk clotting enzyme chymosin, 
was expressed in a plasmid containing the E. co//tryptophan promoter, 
operator and ribosome binding site. The prochymosin was expressed at high 
levels in inclusion bodies. It was reported that the insolubility of the 
recombinant protein was partially due to the presence of disulfide linkages 
formed by the cysteine residues in the protein (Schoemaker et al., 1985). 
In this respect the El protein of RV is rich in cysteine residues (5%) which 
could affect the solubility of the protein even If it was directly expressed in 
E. coli.
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Subfragments of the El gene were found to produce a similar result 
when the previously identified epitope domains (Terry et al., 1988) were 
expressed as fusion proteins. However the expression of a fragment 
containing only epitope ep2 (Fig. 5.7.) fused to B-gal was not antigenic. The 
lack of antigenicity of ep2 could be due to the conformation of the protein 
as the epitope lies at the end of the carboxy-terminus of the fusion protein. 
The effect of the conformation of the protein was also reported in a similar 
study when a weak reaction, in ELISA test, was obtained from the El epi 
fused to protein A (Terry et al., 1988). It was suggested that the correct 
formation of disulphide bonds were not formed, therefore the epitope might 
not be accessible to react with the antibody.
Although the El expressed in £. co// is unglycosylated (Harris and 
Emtage, 1986; Martson, 1986), the protein retained its antigenicity when 
detected by human antisera on a western blot. It is evident that the inability 
of E.coH to glycosylate the expressed protein does not diminish its 
immunogenicity. This result is in agreement with published reports which 
suggested that the protein antigenicity does not depend on its glycosylation 
when the RV treated with glycosidase (Ho-Terry et al., 1984). This was 
confirmed when El was expressed in £. coli, fused to the coding region of 
protein A, however the system was not very practical due to the presence 
of IgG binding region. The IgG binding domain caused a high background 
reactivity yet the antigen was recognised by monoclonal antibodies raised 
against the whole virus (Terry et al., 1989). Similarly, the lack of 
glycosylation had no effect on antigenicity of recombinant protein expressed 
in bacteria such as IFN-B (Simons et al., 1985) and Bovine viral diarrhoea 
virus (BVDV) (Collett et al., 1988). However, it was reported recently that 
a mutant lacking all glycosylation sites, precipitated by human anti-RV 
sera, was not recognized by HI antibodies. It was proposed that 
glycosylation may be required for the folding of El protein such that the HA 
epitopes are exposed (Hobman et al., 1991).
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CLEAVAGE OF FUSION PROTEINS.
If the El protein is required in isolation from the fusion protein a 
cleavage site for a protease could be placed between the C-terminus of the 
B-galactosidase sequence and the N-terminus of El coding sequence. 
Typical examples of protease cleavage sites are listed in the table below 
(Marston, 1986) with the frequency of their appearance in the El protein. 
The data indicates that the best cleavage site which does not exist in the El 
aa sequence is factor X , or collagenase. If desired these sites should be 
engineered within the fusion protein sequence.
Table c: Cleavage sites & frequency appearance In El of RV.
Cleavage effector Sequence recognized No. in El
Acid pH -Asp^Pro- 6
CNBr “Met Xaa- 27
Trypsin -Arg^Xaa- or Lys^Xaa- > 3 0
Factor X, -lle-Glu-Gly-Arg'^Xaa-
Collagenase -Pro-Xaa^Gly-Pro-Yaa^
Clostripain -Arg^Xaa > 3 0
cleavage site.
The protein could be then purified by Ion-exchange chromatography. 
This way one can exclude false positive results, when using the El protein 
as an antigen in diagnostic immunoassays, due to antibody reactions with 
the bacterial proteins. The chimeric protein could be used for IgG detection 
if the viral antigen is separated from the B-gal protein by proteolytic cleavage 
before use (Steger et al., 1990).
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RECOMBINANT PROTEINS FOR USE IN DIAGNOSTIC IMMUNOASSAYS.
The use of the B-gal-E1 chimeric protein as an antigen in ELISA to 
detect anti-RV IgG was partially successful when sonicated inclusion bodies 
were used in the assay. The ratio between the positive and negative sera 
was 2:1. The ELISA gave a high cross reactivity of antisera which could be 
due to the cross reactivity of the presence of bacterial proteins in the 
samples. Several modification to the system were performed such as 
alterating the incubation time, antibody dilution and coating material, 
however the system needs further optimization for use with recombinant 
antigens. A similar study by Terry et al. (1988) reported cross reactivity in 
ELIS As when the EI-protA hybrid protein was used as an antigen. This cross 
reactivity was suggested as being due to the appearance of an unidentified 
protein in all protein samples. Similar result was obtained in this study, a 
cross reacting protein can be seen in the western blot in (Fig. 5.7 .). This 
could be solved by cleavage of the El from the B-gal by placing a cleavage 
site at the amino terminus of El to yield a pure El protein as mentioned 
previously. Thus false-positive results due to antibody reactions with 
bacterial proteins would be excluded. This strategy was reported to be 
successful in the expression of the structural proteins as fusion proteins to 
B-gal of the Human Papillomavirus type 8 (HPV-8) (Steger et al., 1990).
When the B-gal-E1 protein from sonicated cell lysates was used as an 
antigen in an IgM antibody-capture radioimmunoassay (MACRIA), it gave 
results similar to those obtained in tests employing viral antigens. Sera were 
obtained from three infected fetuses. The antigen proved that it could be 
used in the detection of rubella-specific IgM which is most significant for the 
diagnosis of recent infection. Crude antigen such as cell lysates are of 
preference to use for practical and economic purposes. They have been used 
successfully in assays for IgM antibodies to measles virus (Forghani and 
Schmidt, 1979) and herpes viruses (Knez et al., 1976; Arvin and Koropchak,
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1980; Kalimo et al., 1978). Antigen preparation of low purity, for example 
faecal extracts, were also used in assays for IgM antibody to hepatitis A 
virus (Tedder et al., 1982).
The presence of IgM during the first months of life is an evidence of 
congenital infection. The risk of fetal infection is greatest when a woman 
with vaccine-induced immunity is reinfected with wild virus; therefore. The 
distinction between primary infection and reinfection is essential. Primary 
infection is accompanied by IgG seroconversion with a strong IgM response; 
reinfection is characterized by a rise in the titre of pre-existing IgG antibody 
with an IgM response which is usually weak (Cradock-Watson, 1991 ). It has 
also been reported that IgM and IgA antibodies, unlike IgG, showed selective 
reactivity with individual viral proteins. IgM reacted mainly with El of RV, 
while IgG antibodies reacted with all three structural proteins. The selective 
reactivity of IgM antibodies suggests that the El glycoprotein of RV could 
be used in IgM antibody assays (Partanen et al., 1985).
EXPRESSION IN MAMMALIAN CELLS.
The translocation of the El protein into the endoplasmic reticulum 
(ER) is mediated by a hydrophobic signal peptide which lies at the N- 
terminus of the protein (Clark et al., 1987; Vidgren et al., 1987). El also 
contains a hydrophobic sequence of 27 amino acids which functions as an 
anchor domain at the carboxy-terminus (Clark et al., 1987; Hobman et al., 
1988). So far El has been expressed containing the putative signal peptide 
and the anchor region in COS cells and Vero cells (Nakhasi et al., 1986; 
Mazancourt, 1989; Hobman et al., 1988).
In this study a construct was made where the transmembrane anchor 
El was truncated and 8 residues were removed from the putative signal
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peptide. The putative signal peptide of the El glycoprotein is 
j only defined on the basis of published sequence data : (Frey
et al., 1986; Nakhasi et al., 1986; Vidgrin et al., 1987). In an attempt to 
define a minimal functional signal peptide of 1 laa  residues were used in the 
expression of the El glycoprotein. This signal peptide included half of the 
hydrophobic core, retaining 8aa residues, the minimum length required for 
a functional signal peptide (Perlman and Halvorson, 1983) with a methionine 
codon added upstream to initiate translation and the signal peptidase 
recognition site at aa 619-621 (cleavage site) (von Heijne, 1983 and 1984). 
The expressed protein of the construct pEMI in COS-1 cells was not 
detected in the cell lysate. However a small amount was detected in 
immunoprecipitate from the growth medium. Large amounts of El-specific 
RNA were produced which indicated that the inefficiency of protein 
production by this recombinant is not due to presence of low levels of 
mRNA, but may be due to poor translation and/or processing.
It has been reported that the loss of 1 laa from the 16aa signal 
peptide of the haemagglutinin, of influenza virus, did not affect the 
expression of the protein as it accumulated in the cytoplasm of the AGMK 
cells but it fail to translocate (Sekikawa and Lai, 1983). The deletion of the 
signal peptide of the human transferrin receptor failed to translocate the 
protein into the membranes in vitro experiments (Zerial et al., 1986).
The removal of the hydrophobic region at the carboxy-terminus has 
failed to anchor the pill coat protein of bacteriophage f1 and the protein was 
secreted in the periplasm of £. coli (Davis et al., 1985). The haemagglutinin 
of influenza virus lacking the anchor region was also secreted (Sveda et al., 
1982). Similarly the anchor region of the E2 protein of SFV proved not to 
be important for the protein transport to the cell surface when expressed on 
COS-1 cells (Garroff et al., 1983).
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It has been reported that El glycoprotein of RV was not detected in 
transfected COS cells when the putative signal peptide was deleted, 69aa 
from the carboxy-terminus of the E2, it was suggested that this could be 
due to the rapid proteolysis of the untranslocated protein in the RER 
(Hobman et al., 1988). However, it does seem that in the absence of the 
anchor region and with only 11 amino acids in the signal peptide some 
translocation of the El protein to the ER and out of the cell is possible. 
Therefore, the most likely reason for not detecting the E1 protein in the 
COS-1 cells transfected with pEM1 is rapid proteolysis of the untranslocated 
protein. The expression and the secretion of the truncated El glycoprotein 
of RV suggested that at least the last 50aa residues are dispensable. 
Similarly, deletion experiment on the pill of bacteriophage f 1, which consists 
of 405aa, proved that 200-300aa from the carboxy terminus are not 
required for the protein's translocation (Davis et al., 1985 .).
Expression of the El protein of the Thomas strain of El in 
mammalian cells has been very poor (P. Sanders and J Newcomb, PC) and 
the El expressed in this study is the first expression of the El protein of this 
strain. The signal peptide used may not be optimal for expression, other 
parallel studies are in progress to use heterologous signal peptides and to 
define constructs more efficient for the production of a secreted E l. The 
development of continuous mammalian cell lines producing a secreted El 
antigen will be of considerable value for the production of a defined protein 
for use as a diagnostic reagent or vaccine.
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CONCLUSION
In the United Kingdom over 600,000 tests are performed each year 
to assess the level of antibody to rubella virus. Propagation of RV in tissue 
culture has been invaluable in providing viral antigens for diagnostic or 
immunization purposes. However RV antigen production is inefficient due to 
the poor growth of the virus as well as being costly and labour intensive. In 
addition, antigenic differences have been demonstrated between RV wild 
type and vaccine virus strains (Gould and Butler, 1980; Ho-Terry et al., 
1982; Oxford, 1969) which may be responsible for the high rate of 
reinfection in individuals with vaccine-induced rather than natural immunity 
to rubella (Meyer et al., 1969; Plotkin et al., 1969; Portnay et al., 1969). 
Production of an antigen also suffers batch to batch variation, therefore 
there is a clear requirement for production of non-infective rubella antigen 
using recombinant DNA technology.
RV virions contain two glycosylated envelope proteins, El and E2 
located on the virion surface (Oker-Blom et al., 1983). They are thought to 
exist as heterodimers that comprise the viral spike complexes (Waxham and 
Wolinsky, 1983). At least six spatially independent epitopes are present on 
the El including domains that are important for viral infectivity and 
haemagglutination (HA) activity (Waxham and Wolinsky, 1985; Green and 
Dorsett, 1986). Epitopes on E2 have not been characterised yet.
cDNA that encodes the El and the E2 glycoproteins from the RV 
strain Thomas has been obtained and sequenced (S. Almumin, J. Newcomb, 
A. Knight). The structural coding sequences from other isolates from the US,
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Japan and Australia have been reported (Nakhasi et al., 1986 and 1989; 
Zheng et al., 1989; Clarke et al., 1987; Vidgren et al., 1987; Hobman et al., 
1988; Marrand Frey, 1991). The sequence derived from the Thomas strain 
allowed comparison of the sequences with other strains. Although the 
sequences share more than 90%  homology several mutations did occur 
which are discussed in this study.
Expression of foreign proteins in E. coli has been applied extensively 
in the production of large amounts of recombinant proteins that are used in 
vaccine development (Pilancinski et al., 1984) or in development of 
diagnostic kits (Cabradila et al., 1986). In most of the cases expression of 
hybrids of prokaryotic and eukaryotic sequences results in the formation of 
cytoplasmic inclusion bodies in the cell (Shine et al., 1980; Williams et al., 
1982; Marston et al., 1984; Schoner et al., 1985). Inclusion bodies are 
formed when intracellular proteins are produced at high levels, inclusion 
bodies have an advantage in that the protein can be isolated in a pure form 
with minimum effort.
Unfortunately, expression of certain portions of eukaryotic proteins 
may not be favourably tolerated by the bacterial host. Typically these toxic 
proteins include very hydrophobic amino acid sequences (Amann et al., 
1984a; Rose and Shafferman, 1981;Remaut et al., 1983; Brosius, 1984). 
Attempts to express E2 with parts from El and C coding sequences in E. 
coli, as a fused protein to B-galactosidase proved to have a severe effect on 
cell growth, however there was no effect on cell growth when a 
subfragment of E2 lacking the hydrophobic regions of the signal peptide and 
the anchor was expressed. Expression of a subfragment lacking the anchor 
region but attached to the signal peptide of E2 has also inhibited cell 
growth. This has been attributed to "jamming" of the export machinery due 
to the accumulation of the fusion proteins. Therefore blocking the export 
could be due to the presence of the signal peptide of E2. Removal of the
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signal peptide has been reported to restore cell growth (Boeke and Model,
1982).
The expression of El glycoprotein with subfragments as fusion 
proteins to B-gal has been achieved and the protein was produced in 
inclusion bodies in E. co/i. The hybrid proteins proved to be antigenic and 
could, in future, be used to diagnose primary infections with rubella by 
detecting the presence of anti-rubella IgM antibodies. This expression 
strategy has the benefit among other systems in that the fusion protein can 
be easily purified by affinity chromatography using anti-B-gal antibodies, 
especially in the case of the lack of a specific antibody to the antigen.
Using the recombinant B-gal-E1 protein as an antigen in detecting IgM 
antibodies proved to be successful, however high background cross 
reactivity was obtained when the protein was used in ELISA to detect IgG 
antibodies. Optimisation of the ELISA test to accommodate the use of 
recombinant protein as an antigen should be studied. Future work could also 
include using the recombinant antigen to induce immunity in laboratory 
animals and compare its efficiency with the viral antigen.
Production of the El and E2 glycoproteins has been obtained in COS 
cells. The El glycoprotein lacking the anchor region and half of the signal 
peptide has been secreted in the media. Previous El constructs of the 
Thomas strain which contain the complete putative signal peptide have not 
produced detectable amounts of protein when expressed in COS cells (P. 
Sanders, J Newcomb and A. Knight). The E2 glycoprotein can be detected 
in abundance intracellularly. The absence of detectable protein of El in the 
cytoplasmic fraction compared to the supernatant argues for this being true 
secretion rather than leakage from dead cells, particularly when the El 
protein levels are compared to the more highly produced E2. Presumably any 
El which does not enter the secretory pathway is degraded intracellularly.
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It is of interest to develop animal cell lines expressing secreted 
proteins which can be used as detection antigens or vaccines. Progressive 
deletions from the signal peptide and the anchor facilitate the definition of 
the functional sequences from these regions. Further studies should include 
production of recombinant antigen in different cell lines to optimize 
maximum production and determination of the role of the capsid protein as 
an antigen. Experiment on the induction of immunity in laboratory animals 
with C, E2 and El protein individually in comparison to the immunity 
induced by all the structural protein together. It is also of interest to study 
the role of the nonstructural proteins in the virus replication and processing.
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a
1 NNAUCCAACCUAUCCCACCUCGaJOACGACUCCCAUUCCCAüCCASAAACUCCÜACAÜCACCüUrJUCCCCCCCCUCCCCCÜUAUAACUUAACCCJCSGCACUUCCCUAACAGACCACC’J l)o
M E R  L L O E V L A  P C  C P  Y S  t T V S S W V R D H V
121 CCCAUCAAUUCUCCACCCCCCCUCCCAACUCCCCCAUCUUCUUACCSC'JCCCCAAAACCCCCCCAUCCGACCCCUCAUACCCACACCUCUCJUCACSCAGAUCCACCUCACJCAUCACCC 240 
28 R S I V E G A W C V R  O V V T A A  O R A A I V A V Z P  R P V F  T G M O V S  a H P
241 ACCACUCCACGCAAUUUCGCGCUAUACCCGCCCCCAUUCGAUCGACJGCCCCCCUAAACAAGCCCUACACCUCCUCAUCGACCCAACCCCCCGCCUGCUCCGCCACCUCCrjCCCGUUCA 3«c 
68 A L N A 1 5 R Y  T R  R H H I E M C P K E A L H V 1 . 1 0 P S P C 1 L R E V A R V E  107
361 CCCCCCCUCCCUCCCACUGUeCCUCCACACCACCCCACCCAAACSCCCCACCCCCCOCCCCCAeACCeCCACCCACCCCUCCCACSCTCACUACCGCUGCeCCCUCCCgCCCCCACCCAC 480 
108 R R N V A X . C L H  R T A t l R  L A T  A L A E T A  S E A H H A  O Y V C A L R C A P S  147
481 CCCCCCCOUCOACCüCCACCCÜGACCACcÔcCCCCACCGCCC-JCCCCCCCWCCCCCACACAaCCWUCCÜCüACTACACACCeAUCCACAOCUCCGAGCUGAOCCCOACCAÜUCACCCCAC 600 
148 C P F Y V H P  E O V P H C G R A V A O R C L L T Y T P M  Q M C E i M R T I D A T  187
601 CCUGCOCeOCCCCCOUCACOOCOCCCCCCOCCCCaiDCCGCCCCACGOCCCCCACGACOGGCACCACCOCGCCADDCCCUGCCAOCOCCACCAUCACCCCGCOUCCCCCCCCCAUUCCCG 120 
188 L I V A V D L W P V A I A A H  V G D D W D D L G I  A W H L D M D C C C  P A D C R 227
721 CCGAGCCGCCCCOGGGCCCACCCCCGGCyACACCCCCCCCOGCACCACACCCAOaJACCAACOCaiCCCCGACACCGCCCACCCCCGGCCCCOCUACCGGOCCCGGCCCCCCCUGUGCAC 840 
228 G A C A G P T P G Y T R P C T T R I Y O V t P D T A H P G R L  Y R C C P R I . W T  267
841 CCGCCAUUCCCCCGUCGCCCAACOCUCAaCGCAGCOUCCCCAACACUCCCGGCACCACGCCCCCCUCCGCGCCGUCCCAUGCACCCUCCCUAUCCGCCACCUCCCCAGCCUCCAACCCAG 960 
268 R D C A V  A E L S  W E V A O H C  C H O  A R  V H A V R C T I . P I R H V R S L O P S  307
961 CCCCCCCCUCCGACUCCCCCACCUCCUCCAUCUCCCCGAGGUGGCCCGGUCGCGGUGCUOCAGCCUCCCCCGCCCCCUCUUCCAGCCCAUGCUGUCCUACUGCAAGACCCUGAGCCCCCA 1080 
308 A R V  R L P D L V H L A  E V G R W R W F S L P R P V F Q R M I S Y C  K T L S P D  347
1081 CCCGUACUACACCCACCGCCUCUOCAACUUCAAGAACCCCrjCJGCCACAGCAUCACCCUCGCGGCCAAUCUCCUCCAAGACGCCUCGAAGCCCACCUGCCCCCACCAACACCCGCUGUG 1200 
348 A Y Y S E R  V r K F K N A I , C H  5 1 T L A G N V L Q E C H X G T C A  E £ D A L C  387
1201 CCCAOACCUACCCUUCCCCCCCDCCCACUCUAACCCCACGOUGGCSCS&AOUAUCAAACCCCCCAACUCCSCCCCCCACOCVtniCAGCCUCCCCSCCUCCCUCCACACCAUUUGCCACCC 1320 
388 A Y V A F R A H Q S N A R L A G I M K C A K C A  A D  S L S V A C H I . D T I M D A  427
1321 CAUOAACCCCmiCCUCCCUAGCCUCCCCCUCCCCCACCCCAUCGAGCACUGCCAACACCACGCCCCCGUCCCCGCCUUCCACCCCGCCCCCCUCCAGGACCCCSCGCCCCACmiCGACAC 1440 
428 I K R F L G S V P L A E R M E E M E Q D A A V A A F D R C  P L E O G G  R H L D  T 467
1441 CGOGCAACCCCCAAAAOCGCCGCCCCCCCrJGAGAUCGCCGCGACrvGGAUCGUCCACGCAGCCACCCAACACCCCCAOUGCGCG'JCCCCUCCCCGCJGCGACGOCCCGCGCCAACCUCC 1560 
468 V Q P P K S P P R P E I A A r w i V H A A S E O R H C A C A P R C O V P R E R P  5:7
1561 UUCCCCCCCCGCCCGCCACCCCGAUGACCACCCGCUCAUCCCGCGGGCGC'w’GOUCGCCCACCCCCGUGCCajCCGCUCCCCCCACUCGGAUUUCGAGCCUCUCCGCGCCCCCGCCGAUAC 1680 
508 S A P .  A G O P O O E A i l P P  W t F A E R R A L R C R E H D F E A L R A R A D T  547
1681 GGCGGCCGCGCCCCCCCCCCCGGCUCCACCCCCCGCGCGGt;ACCCCACCGUGCOCUACCGCCACCCCCCCCACCACCCCCCCUGCCOCAC(;pUUGACGAGCCGGGCGAGGaJCACGCGGC 1800 
548 A A A P A P P A P R P A  R Y P T V L Y R H P A H H C P W L T t O E P  G E  A O A A  587
1801 CCOCCUCmjAUGCCACCCACOUGCCCACCCCCOCCGCCGCCCGCAACGCCACUaCCCCCCCCCCGCCCAOAUCUGCCCCCAGCCGCCCGGGCOCCAGCCUOUUCUCCCUCUCGUCCCUCC 1920 
588 L V L C D P  L G Q P L R G P E R H F A A G  A H M C  A Q . A R  G L Q A F V R V V P P  627
1921 ACCCGACCCCCCCOGCGCCCACGCCGGCCCCAGACCGUGCCCCAACGUCUUCCGCSCCUCCCCCOCGSCCCACCCCOOCCOCCCCCACCCACCACUOAUCCACCUCCCAOACACCCAUCC 2040 
628 P E R P H A D C  G A R .  A N  A K F F R G C A M A O  R L  L G E P A V M H I , P y T D C  667
2041 CCACCOCCCACACCnCADCCCACUGCCUUUCCCCACCCOCGCCCAACAGGGCCCCCCCUOCCCACOCDCCCOGCCUCACCUGCCCCGCCCUGCACCCUUCCACGCAAACGCGCJCACCGC 2160 
668 D V P  O L I A L A  I R T L A O  Q G A A  L A L S V R D L  P G  G A A F D A N A V T A  707
2161 CCCCGOGCCCGCUGCCCCCCCCCACDCCCCGCCCGCCOCACCSCCACCCCGCCACCCCCCGCCCCCGCGCCCCGCACCCCaAOCCCAACCGCACUCGGACCCtJCCCCCCACUCCGCCCCC 2280 
708 A V R A C P  R Q S A A A S P P  P G O P P P P R R A R R S Q R H S O A R G T P P  P 747
2281 CGCCCCUGCCCCCCACCCCCCCCCCCCCCCCCCCACCCCGCCCGCSCCACCCCCCCCOCGOCACCCCCUCCCOCCCAOUCCCCCGGCGCCCCCCSAUCGCCCGCCUCACGCCCAGCUGSA 2400 
748 A P A R D P P P P A P  S P P A P P R A G  D P V P P I P A C P A D  R A R O A E L E  787
2401 GGOCCCCUCCCAGCCCACCCCCCCCCCCACCOCAACCACCGCACACCCACACACCCACADCCOUCAAACOUACCCCCCCCCCCCCGCACCCCOGCACCOCCCACUCCGCCACAUCAUCGA 2520 
788 V A C E P S C P P T S T R  A O P D S O I V E S Y A R A A C P V  H L R V R D 1 H D 827
Appendix 1. Nucleotide sequence of the RV genome. The identity of the two 
5' nucleotides has not been determined. The deduced amino acid sequence 
of the nonstructural protein ORF (S' proximal) and structural protein ORF (3' 
proximal) is given. The S' end of the subgenomic RNA and the amino termini 
of the structural proteins are indicated. Inverted traingles denote 
glycosylation sites. Hydrophobic regions are underlined and epitopes 
domains are double underlined. The loop region at the 3' end is denoted with 
inverted arrows*
RUBELLA VIRUS GENOME SEQUENCE
CCCACCGCCCGCCUCCAACCÜCCUCCUCAACCCCCCCXACCACCCCCUACÜCCCCCCCUCUCCCCUCUCCCCÜCCCAÜCUüUGCCAACCCCACCSCCCCCOJCCCaCCAAACUGCCCCCC 2640 
P P P C C R V V V N A A N E G L L A G S G V C C  A I F A N A T A A L A A N C R  R 867
CCOCGCCCCAOGCCCCACeGGCCACGCAGOCCCCACACCCGCCCACCGaJGCGGGOACACCCACAUCAUCCACGCCGUCCCCCCGCCCCCUCCOCGGCACCCCGCCGCCCUCGAGCAGGC 2760 
L A P C P T  G E A V A  T P G H G C  G Y T  H I I  H A V A  P R R P  R O P A A L E E G  907
CCAAGCCCUGCaCCAGCGCCCCUACCCCACCAUCGUCCCCCOACCCOCCCCSCCOCCCTKGCCCOCQCUCeCCOGCCCCCOCCOCCOCCCGGCCCSCUACCCCOCCUCUCCUCCCCACUC 2180 
E A L I . E R A Y R S  I V A L A A A R R N A C V A C P l L C A G V r G N S A A E S  947
CCOCCCAGCCCCGCOCCCCGCUACCCCCACCCAGCCCCUCCAGCCCGGGACCCUGCACAUCOCCCACCCCCACCGCGCCACCCUCACCCACCCCGCCCUCCUCCUCGCCGCCGGCCUCCC 3000 
I R A A t A A T R T E P V E R V S l H I C H P O R A T L T H A S V L V G A C t A  987
UGCCACGCGCGOCACOCCOCCUCCCACCGACCCCCOCGCAOCnUGCCCCGCCGCOCACCCCCGCCGACCCGCnCAGCGCAOCCCGOCCCCCCCAGCCACCCCCCOOGGGCAOCCCACCGC 3120 
A R R V S P P P T E P L A S C P A C D P G R P A O R S A S P P A T P L G O A T A  1027
CCCCCACCCCCCCCCAUCCCAGCCGUCCCAACUCUCCCCCDACACCCCCGUCACCAAOCACCCCCCCOAUCOaUCCUCOCGCDCCACCGCCACCCCCGCGCCACCACCUGCCCCAUCCC 3240
P E P R G C Q G C E L C R Y T R V T N D R A Y V M L W L E R D R C A  T S W A M R  1067
CAUUCCCGACGOGCUUCUCTACCGGCCGGAGCACCOCCCCACCCAOOOTJCCAOTAAACCACnACACUGtJCCOCAACCCCCCGCACCOCACCCCCCCCCGACGCAOGOCCCGCACUCACAU 3360
I  P E V V V Y 6  P E H L A T H F P  L K H Y S V I K P A E V R P  P R 6  M C G  S 0 M  1107
GOGGCCCUGCCGCCCCUCGCAÜGCCAOCCCGCACCUCCGCUGCACCCCaJCCAACCCUCACGCCGCCCnGOGCCCCACACGCGOCCCCCaJCGGCCGACCACGCCAGGCGOCCACCÜACA 3480
W R C R G M H G M P Q V R C T P S  K A H A A L C R T G V P P R A S T R C C E L O  1147
CCCAAACACCUGCUCCCUCCGCCCCGCCCCCAACCOUCCGCACCCUGCCCGCCCCtJCCCCCGCCUACACCACUGCCCGGUGCCCCAACUCCCCCUACCCCCGCCCCCUCACCCAASCCCC 3600
P N T C M L R  A A A H  V A O A A R A C G A Y T S A C C P K C A Y G  R A I S E A R  1187
CACOCAÜGAGCACnOCGCCCCGCOGACCCACCGGUOGACCGCGAGCCACCCCCAOGCCOCCCaJGACGCCACCGGACAüCCCaJCGACCCCCOCAOGCACACCGUCOCAüGCCCCUCUUC 3720
T K E O F A A L S Q R H S A S H A D A S P O C T  G O P I D  P L M E T V G C A  C S  1227
GCCCCOGUCCCUCCCCUCCCACCAUCACCCCCCGCCCCACCACCUCCUGCUCOCCCQUCACCGOCCCCCAAAOCCUCCCOGCGCCCOAcÔgCUCCACGUCCGGGCCCCCCCCCACCCCCC 3840
R V H V C S E H E A P P D H I . I . V S L H R A P H G P W C V V L E V R A R P E C G  1267
CAACCCCACCCCCCACOUCGUCOGCGCGGUCGGCGCCCGCCCACCCCGCCUCUCCGACCCCCCCCACCOCUOGCUOCCCGOCCCCCOGOCOCGOGCCCgÔgGCACCOGÜGCCOCGACCcÂ 3960
N P T G H F V C A V G G G P R R V S D R P H L H I . A V P I , S R C C C T C A A 7  & 1307
CGACGGCCUGCCCCAGGCCJACGACCACCACCCCCAGCUGCCCCCCCaCCGCCAUGACCCCAOCCCCCCCGCGGCCaiCCCAaCACUCCAACCCCCUCGCAAACCCCCWACAAUAUCAC 4080
E G L A O A Y Y D  D L E V R R L G D D A M A R A A L A 3 V Q R P  R X G P Y N I  R 1347
GGUAUCSAACAOCCCCGCACGCCCVCGCAACACOACCCCCAUCCUCGCUGCCUUCACCCSCCAAGACCUUOACGUCUCCCCCACCAAUCCCCUCCaCCACGAGAOCCAGGCCAAACUCCS 4200
V W N M A A G A G K T T R I L A A F T R E D L Y V C ,  P T N A I ^ I H E I Q A K I R  1387
CCCCCCCSAUADCCACAOCAACAACCCCCCCACCOACSAGCCCCCGCOCACCAAACCCCDCCCCGCCOACCCCCGCAUCaACAUCCAGGACCCCUOCACUCUCCCCGCCCACUACUCCCC 4320
A R D I D I K N A A T Y E R R I T K P I A A Y R R  I Y I  D E A F T L  G G E Y C A  1427
COUCCUUCCCACCCAAACcÂcCCCGCAGCGGAUCUGCCUCGCUCAOCGCGACCACOGCGCCCCACACOACCCCAAOAAcÔgCCCCACCCCCCUCCCU&ACCCCOCGCCu ÀcCGAGCGCOC 4440
r V A S Q  T T A E V I C V C D R D Q C G P H  Y A l l N C  R T P V P O R N P T E R S  1467
CCGCCACACOOaCCGCUOCCCCCACOCCOCCGCCGCCCCCCOCCCCCCCCCCCOCCAUUAOGACAOCCAGGGCCAGCCCACCCCCACCUGCCCCtlGCAACanniGCCACCGCCCCCACGG 45 60
R H T N R r P O C W A A R L R A G  L D Y D I E G E R T G T P A C N L M D G R Q V  1507
CCACCCOCACCOC&CCUUCaCGCGCGAAACC&aGCGCCGCCUGCACGAGCCaGGCADACSCCCAaACACCGOGCCCGAGCCCCACGCOADCACCCaCCCCACCCCCOGCAOCCACCUAGC 4680 
O L K I . A r S R E T V R R I H E A C l R A r T V R E A Q G M S V G T A C I H V G  1547
CAGACACCCCACCGACGOUCCCCOGGCCaiGACACGCSACCOCCCCADCCOCAGCaiCACCCCGGCCOCCCACCCACOCDACCOCCACGAGCOCCACCACGGCaCACUGCCCCCOCCCGG 4800
R 0 6 T 0 V A L A 1. T R 0 L A I V S I . t r  A  S 0 A L Y L K E 1. E D G S L R A  A G  1587
CCUCAGCCCGUOCCUCCACCCCGGGCCACOGCCCCAGCOCAAGGACGOOCCCCCOCCCAOOCACCCCCaOGOCGCCGOCCACCAGCCACCACCACCCOOCCCCCCCCCCCACGCCADCCC 4920
L S A r L O A C A L A E L K E V P A G I O R V V A V E Q A  P P P L P P A O G I P  162?
CCAGGCCCAACACCOGCCCCCCnOCOCCCCCCGCACOCOGGACCAGCOCCOCUOCCCCCCOGCCCGCCACCCCCAUaACCCCGACCOCAACCOCGOCACOGACGCCCAACGACAAGOGCC 5040
E A Q O V P P r C P R T L E E L V  R A C  H P H Y A O L M R V T E G E R E V R  1667
5041 eDACAOGCCCAOCOCCCSOCACCPCCOCAACAASAAOCACACCCACAOCCCeCGAACCCAACCCCOOCOCACOGCCCOOUGCGCCCOGCGGCCeCACeGCGCCCGCGAGCAOGCCOCGAC 5160 
Y N R I S R H L L K K K H T E M P G T C R V L S A V C A V R R Y R A G E  D C S T  1707
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SI 6 :  rcucCCCArVGC'JCaCSCCCGCGAGCACCCCCCCCC'JUOUCCCCACAOCCCACCCCCCCCCSUCACUCCTCCCCOCSCCCACCACUCCCCCAUCACCUACUUCCCCCAACGGAl'CCACrJ 5 2 4 ; 
'.7CA R T A V A » 5  H P *  f f  R 0  I P P P R V T  A G V  A  5  E W  R M T Y L  R E R 0  » '. '« 7
*■7 8 ’. 'ACU'’.Ai;C'JC';A':AC0CACAüCCCCCUCCCCCCGCGCGACCUCACeCACCSCi'ACSC0CGCCCCUAÜCa;CASAt;CG*w'C2CCCGCAUC’JC'JACCGCCCACACCCyCACCCVC:CCCCCUU S4Î3
:  MB T :? V Y T 0 M G V A A R E I . T  D R Y A R R Y P E : F A G M G T A 0 S 1 . S V P A F  M7
’ 5 * 0 ) •TCl'CAAAGCCACC’jyCAACJKCC’JACACCCCCCCCUCCCCCCCACGGACACCGAOGACaGCCACCCCSCOCACCOCAAACCCCGCeOUGACAUCCSCCCCyCCCCCAAGCAGUCCCU’JCA b i 7î
:TBB !. K A T L K C V D  A A  L C P R D T E D C H  A A O S K  A C L E I R A H A K E  H V O  1877
552 ) GG’JUAUG’JCCCCGCAOUUCCGCCCCAOCCACAAGAOCAOCAÜCCCCCCCtIUCCCCCCCCAAÜtICCOOCÜGGCCCCVGGCCAOACCGACCCCCAGGUCCAÜGCCOGCOCCCACGCCCAUUA 5 t« î
; i 2s v m s p h f r a : o r i i m b a i , r ? o f i . v a a c h t e p e v o a w w q a h y  : 8«7
5641 CACCACCAACGCCAOCCACCUCGACUOCACUCACUOCCACAOCAACCACACCCyCCCUACaCOGCACCOCCAGCUCGACAOOACCCCCGCUCUCOOGGGCCUCCCUOGCCrCGAACACUA 5? 6Î
1668 T T H A I  E V D F T E r O M K  O T L A T R D V E i E l S A A L  L C L  P C A E D Y  1957
5761 CCCCGCCCUCCCCCCCGCCACC’JACOGCACCCUGCGCCAAaJGGCCacCACUGACACCCCCUCCCAOCGCACAAGCGCCGAGCCCCCCACCCWGCUGCACAACACCACCCaCGCCAUCUC 5880
1908 R A L R A C S  Y C T  l  R £  i C S T E T  C C E R T S  G E  P A  T 1  L H  N T T V A M C  1947
5881 CAUCCCCAUCCGCAOCCUCCCCAAAGCCCOCCGCyGCGCCGGGAUOOVCCACCCOCACCAOAOGGWCAOC'JUCCUCCCCGACCGCCCGCGCACCGCCGCACUCAAGUGSACCCCCGCCGA 6000
1948 M A M R K V P K G V R M A C I F Q  G O D M V I F L P E C A R S A A  L K W T  P A E  1987
6 00 ) GOUGGCCt/'JCirJUGCCU’JCCACAUCCCCGUCAACCACCUCAGCACCCCÎ/ACCCCCAGCUycyCCCCGCACCyCGGCACCGCCCCCGGCCÜCÜt.’CCAyCAt/CO'CAÜGCACCAGCCGAO'CAA 6 :2 0
1988 V G i  F G F H I P V K H V S T P T P S  F C C H  V C T A A  C L F H D V M H C A I X  2027
6121 GG’JGajUUCCCGCCWJUCCACCCAGACGUCCUUGAAGAACACCAGGUCGCCrJCCOCCACCOCCUCCCGSGGG’JCUACCCGCCUCUGCCOCACACCGUUOCCGCCAAUCCw’GCS’JACyA 6240
2028 V L C R R F D P D V L E E 0 0 V A L L 5 R L R C V  Y A A 1 . P D T V A A N A A Y Y  2067
6241 CCAC'JACAGCGCCGAGCGCGUCCJCGCJAÜCGüCCSCCAAC’JUACCCCGyACGCGGGCGCGCGCCCOCCACCACCCSCCCACCAüCGCCCCCCUCGAGCAGAÜUCACACCCCrwACGCCC 6360 
2068 O Y S A E R V t A I V R E L T A Y A G A R P R P P G H H R R A R C D S D P L R A  2107
I — »S Lbgenom lc RNA b e g in s  . . .
6361 GCOCCAAUCJCCACCACGCCCACUAACGCCCCOGUACGOC5GGCCUUUAAOCO*JACCOACOCUAACCACGOCAUCACCCACCCUOCUUUCGCCCCAUCOGCaGCGUACCCAAClJOTUGCC 6480 
2108 R Q S P R R I ' I T F I ' T V S P L I I . P T I T R S S P T V V S P H I V G T Q I . I . P  2147
6481 A’JUCCCGACAGCCCCACGGUGCCCCAAUCGCU'JCUACUACCCCCAUCACCAUGCACCACCUCCAGAAGGCCCGCGAGGCACAAOCCCGCGCCCwGCGCCCCGAACUCGCCGCCGSCCCrJ 6600 
2 :4 8  F C R A P G C P N G F Y  Y P H H H G G P P E G P R G T I P R P A R G T R R R R l .  2187
:  ” * _ S - ^ ? I * “ î ; 2 L 0 K A L E A Q S R A L R A E L A A G  A S  32
6601 CGCACUCGCSCCGGCCGCGCCCCCCCCSACACCGCSACUCCAGCACCO’CCSGAGAGGACaCCGCCCGGGACyCCSGAGGGCCCCCCCCCCGCCSCGCCAACCGGGGCCG'.'GGCCAGCGCA 672:
2188 A V A P A A A A A T A R L O  H L R R *  .
33 C S R R P R P P R  O R O S  S T S C D O  S G R 3 S G G P R R R  R G N  R G R 3  C R R  ' 2
6 X 1  SSGACUSGyCCAGGGCCCCGCCCCCCCCSGACGACCCCCAAGAAACyCGCVCCCACAC’JCCSGCCCCGAAGCCAl-CGCGGGCCCCGCCACAACACSrJCAACCCCCGCGCATGCAAACCG 6840 
•>3 3 W S R A P P P P E E R Q E T R S C T P A P K P S R A P P Q ,  0 _ P  Q ? P R M 5 7 C  112
6841 33CS’w’GGGGGCUC0 GCCCCCCGCCCCCAGC-J0 CGGCCACCGACCAACCCSUi;CCAACCAGCCSUGGCCCG’v-GGCr--5CGCCCCCClICUCCAC=ACCaJCACACCGAGGCACCCACCGAGG 6960 
: : 3  R S G S A P R P E L C P P T N P F O A A V A R G L R P P L H D P O  T E A P T E A  152
6961 CCVGCSyCACrjCSOCCCaOUCGACCGAGGGCGAAGGCOCGGOCOyW;ACCGCCOC5ACCUCCAroi;CACCAACr.*GGCCACCCCCCCACaCGACCAGGACGGCCGCSC3GACCC’JGCCC 708:  
153 C V T S W L W  S E G  E C  A V F Y R V D L N F T N L C T P P L D E D G R W D P A L  192
7081 •-•CAOGyACAACCCaOCCCGGCCCGAGCCGCCCGCGCACGCCGyCCSCGCSl’ACAAyC.AACCVCCCCCCGACCO’CAGCGGCSOOVCGCG'JAAAGGCCAGCGCACCOACCCCCACCAGGAC’w’ 7200 
193 M Y N P C G P E P P A W V V R A Y  N 0 P A C D V R G V W G K G E  R T Y A E 0 3 F  232
7201 3CCSCG-v;CCGC5GCACCCCC0CCCACCaAaiCCaGCGCAtfCCCAOTGCCCGGCCSCSACCGCCACASCCCCCCCCr«CCCCCCCACACCACCGACCSCATOCACACCC5ClJCC3CCC5CC 7320 
233 R V G G T R H H R I I . R M P V R C  I . D C D S A  P 1 . P P H T T E R 1 E T  R S A R  H 272
7321 A3CC30CGCGCA0CCSCW)CCÇ0CCCCCCCACCCCaaCC00GCCGSGCUC3nGCnCGCcÂcGG3CCCCGi’GCGCACCGCGCCCCCCGCGCi;CCACCCCcÔcCC0CAUAÏGCCCGCACC’JC 7440 
273 P W R I R F G A P Q A F I A G L L L A T V A V G  T A R A G L Q P R A D M A A P P  312
. I— > E2
7441 CUACGCOGCCCCACCCCCCCÜCCGCCCACGGGCAGCAüCACGCCCACCACCACCAOCACCOGCCGySCCCCGGGCACCACGCeCAÜCAUGGCGGCACCoÛGCCCCCCGGCCACCAnUACC 7560 
313 T L P Q P P C A H C 8 H Y G H  H _H g . B l P F L G H D G H H G G T L R V G Q H Y R  352
V • ' 9 « .
7561 SAAACCCCACCCACCOCCUGCCCCGCCACVGCaJCCAACGCGCCUCGGCUOCCOACAACCÜCACCCACUGGCACCAGGCCACVCAOCVCVGUCAÜACCAAGCACAUCSACUÜCUCGÜCUG 7680 
353 N A S . D V  L P C N W 1 0 G C W C C T N 1 S . D W N C C T H V C N T K H M D F W C V  392
—Continuée
RUBELLA VIRUS GENOME SEQUENCE
UCCACCACCACCGACCCCCSCCCSCCACCCCCACCCCUCUCACCACCCCCSCCAACaCCACCACCSCCGCCACCCCCCCCACaGCCCCCCCCCCCJCCCACCCCCCCCOCAAUCACACaJ 7800 
E H D R P P P A T P T P L T T A A M S T T A A T  P A T A P A P C H A C L K O ' S C O Z
CCGCCCCCOUCUÜCUCUCGCaGCGGCCCCAÜGCGCCUGCGCCACGCCOCOGACACCCCCOCCGCUCGCOUCAOCJGCCGCCUCUCCACcÂcCCCCCACOÂcCCCCCOACCCCCUUUGCcÙ 7 920 
C C F L S C C G P M R I R  H G A D  T R C  C R L  I C G L S T T A O Y P P T  R F  G C  472
CCCCUAUCCCCyCCCSCCGOCCCCCCOCCCAACOCCgCCOCCOOACCSCCCCCCCCSAACACCCCUeSACOOCCCCCSCCCOSCCCSCCCAOCCACCCCCCCeCUGCCCCSAACUCCUCA 8040 
A M  R M C  L  P P *  E L V V L T  A R P  E D G M T C R G V P A H  P C A  R C P E L  V  S 512
GCCCCAOGGCACGCCCGACUCCryCCCCACCCOCGGCCCTOTGGCOCCCCACAGCGAACGCCajGOCOCOTGAOCACGCCCOCCCGCCCTOCGOCCOGCOGGOCCCCUGCCOCCOCAUAO 8160 
P H  C R A T C  S P A S A L M L A T A N A L S L D  H A L A A F V L L V P W V t i r  552
OUAOGCOCOCCCCCCOCGCCOCCCGCCCCCGCGCCCCCCCCCCCCCCaJCACCCCGCOCGHCCUGCAGCCCOAakACCCCCCCGCaJAOCGCGAGGAGGCBUOCACCUACCOCTGCACuÔ 8280 
M V C R R A C R R R  G A A  A A L T A V V I .  Q G Y N P P A Y G E E A r T T l . C T A  592
I — > E l
CACCCGCCÜCCGCCACUCAACCACCUGOCCCCCOCCGCCOCCCUGOCCOCCCUUUUGACOCCAAGAWJcÔgGACCGCCGCOGCOTOGCCCCAOGGGACcÔccAGGCCAcÛoCAGCCUCcÂ 8400
p c c a t q a p v p v r l a g v r f e s k i v d g g c f a p n d l e a t g a c i  632
OUOCCGAOAüCCCCACOCAÔcOCOCGOCCCACCCCUOGGCGCCCUCGCuÂcCCCCAGCCCaroCCCCCCCCAOCOCGAAÛcGCACACACCCCOCGUGCACCUUCOCCCaicOCAACCCcÛ 8520 
C E I P T D V S C E C L C A N V P  A A  P C A R I W H G T Q R A C T F W A V H A Y  672
ACOCCUCOGGCGCCOACGCCCACrjGGCCUCUUAaroCAACCCOCGCGGCACCUACnACAACCAGUACCACCajACCCCCTCCCACGtIOGAACCUCCCuÙcGGACACAGCCACCCCGCcÛ 8640 
S S G C Y A Q  L A S  Y F N P C G  S Y Y K Q Y  H P T A C E V E P A F C H S D A A C  712
GCUGGGCCUUCCCCACCGACACCGUCAUGAGCGOCaUCCCCCOOCCUACCtZACCUCCAGCACCCOCACAAGACCGUCCGCCHCAACOOCCAOACACACACCACGACCCUCTCCCAACOCU 8760 
N C F P T D T V M S V F A  L A S Y V Q  H P H K T V R V K F H  T E  T R  T y W Q L S  752
.  V  .  • • • • .  ; ,  ,  V
CCCUOCCCCGCCUCOCCOCCAACGVCACCACOCAACACCCCaUCOCCAACACGCCCCACGGACAACOCCAGCOCCACGOCCCCCCCGACCCCCGGCACCOCGiroCACUACAUnAUGAAUU 8 880  
V A G V S C N V T T E H P F C K T P H C Q L E V Q V P P O P G O L V E Y I M N Y  792
. . • • • • • • • , . aP2 ,
ACACCCGCAAUCACCACUCCCCGGGCCCCCOCGGCAGCCCCAAtniCCCACCCCCCCCAUUCGGCCOCCCCGCUOOOCCAACCCCATOCCCCUCACOCCOCCCGCCUOCOCCCGCCCACCC 9000 
T 6 M 0 Q S R N C L 6 S P N C H C P D N A S P V C Q R H S P D C S R L V C A T P  832
. . • CP3 . . . . .  Cpi . . .
CAGAGCGCCCCCGGaJGCCCCaGCrCGACCCCGACCACCCCCOCCUCCGCACOGCCCCOCGACCCOGCCACCOGUCGGOCACGCCaCOCAUAGGCUaJCAGGCGCCCAAGaGCCGACJCC 9120 
E R P R L R L  V 0 A D D ? L  L R T A P G P C E V H  V T P V I G S Q A  R K C C L H 872
ACAUACGCSCUCGACCC'JACGGCCAUGCJACCCUCCAAAUGCCCGAG'JGGAUCCACCCCCACACCACCACCGACCCCOGGCAOCCACCaGGCCCCUOCCGGCUCAAGOTCAAGACAC'J’JC 9240 
I R A G P Y C H A T V E M P E H I H A H T  T S O P N H P P G P L G L K  F K T V R  912
GCCCOCUGCCCCUGCCACGCACC-.-GAGCCCCACCCCGCAAOGOGCGUCnGACCGGGaGCOACCAGOGCGGUACCCCCGCGCDGCOGCAACGCCUUGCCCCCGGaGGACCCAAUUGCCAUC 9360 
P V A L P R T L A P P R N V R V T C C Y Q C C T P A L V E G L A P G C G N C H L  952
OCACCCOCAAOGCCCAGGACCOCGCCCCCCUCCCCCCOGGGAACOOCGUCACCGCCpCCCGCaJCAACACCCCCCCOCCCCACCAACaCAGCliGCG’cGCGCGAGAGCCAOCGCGCCACCG 9480 
T V N C E O L O A V P P C K F V T A  A L L M T P P  P Y Q V S C  C G E S D R A T A  992
CCCGGCaCAUCGACCCCGCCCCGCAAUCCQUUACCCGCGUCGUGUAUGGCACACACACCACUGCOGUGUCCGACACCCCCCACACCJCGCCGGACUCCGCacCUGCCCAUUCCUCGCACC 9600 
R V I O P A A Q S F T G V V Y C T H T  T A V S E T R Q T M  A E W A  A A H W W Q L  1032
OCACUCOCCCCCCCAUUUGCCCCCSCCCACUCGCOGCCVOACOCCCQnGCCGUCCCAAAOCaSGOACQACOUCCCCCCCCCUAOACCCCCUCCCOACUCCCCCCCCCCCCGAAACCCGC 9720 
T L G A I C A L  P L A C L L A C C A  K C L Y Y L R  G A I A P R *  1063
ACÜAGGCCACÜAGAnCCCCGCACC3GUUCCUG0AUAG p o ly A  . 9757
—Continued '
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